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Abstract 
Dietary restriction (DR) increases lifespan robustly in diverse species.  Effects of the dietary 
polyphenol resveratrol consistent with delayed ageing and/or extension of lifespan have been reported.  
The involvement in the longevity response to DR of the protein Sirt1, which may be activated by 
resveratrol and deacetylates a range of cellular substrates that includes histone proteins, identifies 
epigenetic processes as a pathway that may mediate effects of both DR and dietary resveratrol in 
delaying ageing and/or extending lifespan. 
Based on a preliminary observation, the hypothesis underlying the study is that some of the 
beneficial effects of resveratrol on lifespan/aging are mediated through effects on histone expression 
that oppose changes observed in ageing. A secondary hypothesis, based on a degree of structural 
similarity between resveratrol and 17β-oestradiol, was that epigenetic effects of resveratrol are 
mediated through the estrogen receptor (ER). 
The effect of resveratrol on histone protein expression was investigated in human intestinal 
Caco-2 cells and human MCF-7 breast cancer cells. Histone H2a, H2b, H3 and H4 expression was 
decreased in response to resveratrol treatment in both cell lines. In support of our hypothesis that 
resveratrol affects ageing through reversing ageing-associated changes in histone proteins, higher 
levels of H2A, H2B, and H4 expression were detected by western blotting in the small intestine of old 
(38 months) mice than in younger (12 months) mice. To investigate possible consequences of effects 
of resveratrol, including effects resulting from altered histone expression, we studied the effect of 
resveratrol on global gene expression in Caco-2 and MCF-7 cells to address several objectives 
including: (1) investigating if resveratrol has an effect similar to that of DR at the level of gene 
expression; (2) identifying if genes or pathways affected by resveratrol were also affected by 
manipulation of the expression level of Sirt1. For both cell types, the number of genes in the 
intersection between those affected by resveratrol and a compiled list of genes reported in other studies 
to respond to DR was greater than expected by chance, supporting the view that responses to 
resveratrol and to dietary restriction have some commonality and that resveratrol may mimic some 
effects of dietary restriction. We also found that there was very little overlap between genes affected 
by resveratrol treatment and by knockdown of Sirt1 expression in Caco-2 cells, which adds to 
accumulating evidence that resveratrol does not act through effects on Sirt1.  
To investigate if effects of resveratrol - in particular the reduction in histone protein expression 
- are mediated through the estrogen receptor (ER), Caco-2 and MCF-7 cells were treated with 
resveratrol in the presence or absence of the ER antagonist fulvestrant, then total cell lysate was 
analysed by western blotting.  The reduction in histone protein (H2a, H2b, H3 and H4) expression was 
attenuated by fulvestrant, indicating that resveratrol reduced histone expression via an ER-dependent 
mechanism.  For further investigation of effects of resveratrol on histone expression, Caco-2 cells were 
transfected with a promoter reporter construct comprising the histone H3 promoter upstream of the β-
galactosidase reporter gene, and the effect on reporter gene expression of treatment with resveratrol in 
the presence and absence of the fulvestrant was measured. Resveratrol reduced reporter gene 
expression and this effect was attenuated by fulvestrant, demonstrating that resveratrol acts to reduce 
histone H3 expression at the level of transcription through an ER-mediated mechanism. To investigate 
if the response to resveratrol treatment is through interaction with estrogen response elements (EREs) 
in the histone H3 promoter we replaced three potential EREs within the histone H3 promoter region 
included in the promoter-reporter construct with random sequence. Caco-2 cells were then transfected 
with either original or mutated promoter-reporter construct and treated with resveratrol or the 
endogenous ER ligand 17-β estradiol in the presence and absence of fulvestrant. Resveratrol and 17-β 
estradiol both reduced reporter gene expression from both promoter reporter constructs and in all cases 
responses were attenuated by fulvestrant, indicating that effects of neither compound, although 
mediated through the ER, are on the specific sequences region we identified and replaced. 
In conclusion, these data indicate that resveratrol reduces histone expression in both intestinal 
and breast cancer cells through an ER-mediated mechanism acting at the level of transcription and that 
this effect may oppose an accumulation of histone proteins (observed in mouse small intestine) that 
accompanies ageing.  With respect to effects on gene expression, resveratrol was found to mimic some 
effects of dietary restriction but appeared to act through a mechanism independent of Sirt1.  
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 1 
 
1. Introduction 
The thesis is concerned with the activity of the compound resveratrol, particularly 
with respect to its potential epigenetic effects relating to its ability mimic aspects of 
the beneficial effect of dietary restriction on lifespan. The properties of resveratrol 
will be considered in detail then the concept of longevity in response to dietary 
restriction will be introduced and a summary of epigenetic modification will be 
presented before outlining the specific aims of the thesis.      
 
1.1  Resveratrol  
Resveratrol (trans 3, 5, 4-trihydroxy-stilbene), a polyphenol that is present in red 
grapes and their product red wine, has been demonstrated to have a wide variety of 
potential health benefits. Several studies have documented its role as an anti-
inflammatory (Gentilli et al., 2001, Donnelly et al., 2004), anti-coaggulative (Pace-
Aseiak, 1995, Kirk et al., 2000) and anti-oxidative (Miller et al., 1995, de la Lastra 
and Villegas, 2007) agent. As an anti-cancer agent, resveratrol has been shown to 
inhibit tumour cell proliferation during three stages of cancer: initiation, promotion 
and progression. Moreover, it appears to induce the apoptotic death pathway in 
several types of tumour (Chang et al., 2000; Fulda and Debatin, 2004, Rayalam et al., 
2008). Recently, resveratrol has received particular interest as a result of its ability to 
promote longevity in mammals and in lower organisms, which may be by stimulating 
the NAD (+) dependent deacytlases Sirt1 and Sir2 respectively, although this view is 
the subject of recent vigorous challenge (Pacholec et al., 2010). These proteins 
deacetylate a large number of substrates including histones, and have an important 
role in the regulation of gene expression, fatty acid metabolism (Picard et al., 2005) 
cell cycle progression, and lifespan extension (Cohen et al., 2004). 
  2 
The mechanisms by which resveratrol induces these biological effects are not 
understood fully. Resveratrol has a structure similar to that of known phytoestrogens 
so may mediate some of its action through its interaction with estrogen receptors ERα 
and/or ERβ. Some studies have reported that resveratrol may act as an ER agonist in 
the MCF-7 breast cancer cell line (Gehm et al., 1997; Gehm et al., 2004). In contrast, 
other studies documented apparent ER antagonist action in the same cell line (Kim et 
al., 2004). 
 
1.1.1 Sources of resveratrol  
The main dietary sources of resveratrol include fruits (e.g grapes, lingberry, cranberry, 
jackfruit) and also peanuts. In the plant, resveratrol is also synthesised in flowers and 
leaves (e.g in gentum, scots pine, spruce, and butterfly orchid tree).  The activity of 
stilbene synthase, the enzyme responsible for resveratrol synthesis, can be induced 
within few hours` of exposure to ultraviolet (UV) radiation, mold invasion, injury or 
fungal infection, with the intensity and/or duration of the challenge being related to  
the concentration of resveratrol in the plant (Fremont, 2000). Resveratrol occurs in 
different types of wine at concentrations dependent on the time of fermentation 
(Siemann and Creasey, 1992). Table 1.1 summarises the concentration of resveratrol 
found in some food sources (Mukherjee et al., 2010).  
 
1.1.2 The structure of resveratrol  
Structurally, resveratrol consists of two aromatic rings connected by a styrene double 
bond. There are two isomers of resveratrol: cis and trans, and the trans isomer 
appears to have greater biological activity than the cis form (Basly et al., 2000). The 
  3 
trans isomer is pH and light sensitive (Trela et al., 1996), and can photo-isomerise to 
the cis-form when exposed to UV (Figure 1.1) (Soleas et al., 1997).  
 
             
 
 
 
 
 
 
 
 
 
       Figure 1.1: The photo- isomerisation of trans- resveratrol into cis- resveratrol   
 
 
 
 
 
 
 
 
 
 
 
trans-resveratrol cis-resveratrol 
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Table 1.1: The concentration of resveratrol in natural foods. Adapted from 
(Mukherjee et al., 2010). The data were collected from different studies, thus 
different units of concentration are stated.  
Source Resveratrol concentration 
100% Natural peanut butter ~0.65 μg/g 
Bilberries ~16 ng/g 
Blueberries ~32 ng/g 
Boiled peanuts ~5.1 μg/g 
Cranberry raw juice ~0.2 mg/L 
Dry grape skin ~24.06 μg/g 
Grapes 0.16–3.54 μg/g 
Peanut butter 0.3–1.4 μg/g 
Peanuts 0.02–1.92 μg/g 
Pistachios 0.09–1.67 μg/g 
Ports and sherries <0.1 mg/L 
Ref grape juice ~0.50 mg/L 
Red wines 0.1–14.3 mg/L 
Roasted peanuts ~0.055 μg/g 
White grape juice ~0.05 mg/L 
White wines <0.1–2.1 mg/L 
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1.1.3 Resveratrol bioavailability and metabolism  
Several studies, in vivo as well as in vitro, report that resveratrol is absorbed rapidly 
and metabolised by the small intestine. In vitro, Kaldas and colleagues (2002) 
measured the transport and metabolism of 5-40 µM resveratrol by the human 
intestinal Caco-2 epithelial cell line, cultured in transwells. They documented that, for 
all concentrations of resveratrol, transcellular absorption occurred and this absorption 
appeared to be concentration-dependent. Furthermore, the metabolism of resveratrol 
was investigated by incubating a high concentration (100 µM) of resveratrol with 
Caco-2 cells for 6 hours. Under these conditions resveratrol was converted into two 
types of conjugates: a glucuronidated conjugate (trans-resveratrol-3-O-glucuronide) 
and a sulphated conjugate (trans-resveratrol-3-sulfate). Under conditions where 
resveratrol was at physiological concentrations, sulphate conjugation was greater than 
glucuronidation. On the other hand, at higher concentrations of resveratrol 
glucuronidation became more predominant.  
In studies in vivo, the highest plasma concentration of resveratrol metabolites 
[sulphate (13 µM); and glucuronide (5 µM)] was recorded in the first 15 minutes after 
oral administration of resveratrol (20 mg/kg of body weight) to mice. In contrast, only 
traces of free resveratrol were detected (Yu et al., 2002). These results indicate that 
the bioavailability of free resveratrol in plasma is very low and approximates zero 
soon after ingestion.  
 
In studies in humans, the highest concentration of resveratrol metabolites (2µM) was 
detected within 60 minutes after oral administration of resveratrol at 25 mg to six 
healthy men and woman.  In contrast, only traces of free resveratrol were observed 
indicating rapid metabolism and clearance (Waller et al, 2004). In a second study, oral 
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administration of 25 mg resveratrol per 70 kg of body weight in different foods to 12 
healthy men resulted in the highest plasma concentration of resveratrol and 
metabolites being observed 30 minutes after administration (Goldberg et al., 2003). In 
another study, the bioavailability of resveratrol in wine appeared not to differ when it 
was consumed on an empty stomach or with a meal, challenging the idea that food 
matrix influences resveratrol bioavailability (Vitaglione et al., 2005).  
 
Contrasting with intestinal absorption, buccal delivery was reported as a route through 
which free resveratrol was bioavailable. When 1mg/ml of resveratrol in 50 ml 
solution was held in the mouth, a peak of unconjugated resveratrol (37 ng/ml) was 
detected after two minutes (Asensi et al., 2002). 
 
The transport of resveratrol across the small intestinal epithelium is probably through 
a passive diffusion mechanism (Li et al, 2003). In contrast, the uptake of resveratrol 
in hepatic cells results from the contribution of two mechanisms, a passive diffusion 
mechanism and a carrier-mediated pathway (Lancon et al, 2004). The main pathway 
of resveratrol excretion is through urine (Boocock et al., 2007).  
 
1.1.4 Resveratrol toxicity 
There is little information about resveratrol toxicity and its target organs. To date, a 
small number of studies have investigated the potential toxic effects of resveratrol in 
animals. Juan et al. (2002) documented that oral administration of resveratrol at 20 
mg/kg of body weight to rats for 28 days resulted in no toxic effects except limited 
changes in serum liver enzymes. Furthermore, a single dose of 2000 mg/kg of body 
weight of resveratrol did not induce any signs of toxicity in the rat. 
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In a second study in rats, oral administration of resveratrol at 300, 1000, and 3000 
mg/kg of body weight for 28 days resulted in signs of toxicity at 3000mg/kg only. 
These effects included reduced food consumption and loss of body weight, along with 
increased kidney weight and signs of nephrotoxicity including elevated serum blood 
urea nitrogen and creatinine concentrations, and changes in gross renal pathology. 
Early death was recorded in two male rats on day 24. In these two rats, microscopic 
investigation of the kidneys identified lesions that were the probable cause of early 
death. On the other hand, administration of 1000 or 300 mg/kg of resveratrol did not 
result in nephrotoxic symptoms. These finding identify the kidney as a target organ 
for toxicity caused by resveratrol at high doses (Crowell et al., 2004). 
 
1.1.5 Biological effects of resveratrol 
Resveratrol is a plant antibiotic produced in large quantities in various plants in 
response to stress, injury or pathyogenic infection. Thus, resveratrol has an important 
role in the plant’s defence system, mainly against fungi (Jeandet et al., 1995; Zhan et 
al., 2010). Traditionally, roots of polygonum cuspdatum, the richest sources of 
resveratrol, have been used in traditional Asian medicine to treat a wide range of 
diseases, including fungal infection, skin inflammation, and disease of the liver, heart, 
and blood vessels (Arichi et al., 1982).  
 
Numerous studies have reported resveratrol as being protective against cardiovascular 
disease, having anti-oxidant functions (Miller et al., 1995; de Lastra and Villegas, 
2007), anti-inflammatory action (Gentilli et al., 2001), reducing blood-glucose, 
having estrogenic action (Deng et al., 2008), and protecting against cancer (Shankar 
et al., 2011).   
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The mechanisms by which resveratrol induces these biological effects are still unclear. 
A possible mechanism is that the pharmacological actions of resveratrol may result 
from its effect as antioxidant and/or its estrogenic properties (Gehm et al., 1997, 
Runqing and Ginette, 1999). The potential roles of resveratrol as antioxidant factor 
and its property as phytoestrogen are discussed in section 1.1.5.1 and section 1.1.5.2 
respectively. 
 
1.1.5.1 Resveratrol as an antioxidant 
As a consequence of metabolism in normal living cells, free radical molecules with 
unpaired electrons are formed. These compounds are considered to be highly reactive 
molecules that induce considerable damage to cell contents such as DNA and 
membranes (proteins and lipids). Furthermore, the presence of free radicals can 
generate highly reactive molecules known as reactive oxygen intermediates (ROI). 
These compounds contain an oxygen atom and include superoxide (O2
–
), the hydroxyl 
radical (OH·) and hydrogen peroxide (H2O2) (Pervaiz, 2003). Under normal 
physiological conditions, excessive accumulation of ROI is controlled by the cellular 
antioxidant defence system. This system comprises several enzymes including 
catalase and superoxide dismutase (SOD), along with the tripeptide glutathione (GSH) 
(Pervaiz, 2003; Vermerris, 2006).   
A defect in the ability of cells to control the production of ROI results in their 
excessive accumulation, a state that leads to oxidative stress. Exposure of 
macromolecules such as lipids, proteins, and nucleic acids to ROI result in their 
deleterious oxidation. For example, the oxidative modification of low density 
lipoproteins (LDL) is associated with increased the incidence of cardiovascular 
diseases such as atherosclerosis. The oxidized form of LDL attaches strongly to a 
  9 
non-regulated scavenger receptor system causing LDL to accumulate excessively in 
monocytic subendothelial cells (Pervaiz, 2003). 
 
In laboratory studies, antioxidant action of resveratrol has been reported in various 
pathways. Firstly, resveratrol inhibited oxidation of polyunsaturated fatty acids found 
in LDL. This inhibitory effect results from the ability of resveratrol to prevent copper-
catalyzed oxidation (LDL has a high affinity for copper) (Frémont et al., 1999). 
Secondly, resveratrol has been reported to inhibit the membrane lipid peroxidation by 
reducing the toxicity of the ROI in living cells. In in vitro, administration of 
resveratrol to rat adrenal pheochromocytoma cells (PC12) which had been exposed to 
ethanol-induced oxidation, resulted in protection against cell death (Sun et al., 1997; 
Chan and Chang, 2006). This effect results from the ability of resveratrol to block 
internalization of oxidized lipoproteins. Furthermore, resveratrol has been shown to 
have an inhibitory effect on oxidised lipoprotein-induced neuronal cell death 
(Draczynska-Lusiak et al., 1998; Zhang et al., 2010).   
 
1.1.5.2 Resveratrol as a phytoestrogen 
Phytoestrogens are “nonsteroidal compounds of plant origin that can bind to estrogen 
receptors as agonists and consequently mimic biological actions of endogeneous 
estrogens” (Grynkiewicz and Opolski, 2005). These compounds have a chemical 
structure similar to 17β-estradiol (Kuiper et al., 1997), and have an ability to bind to 
estrogen receptors (ER) to induce estrogenic and/or antiestrogenic effects (Gehm et al, 
1997, Bowers et al, 2000). Although the affinities of these compounds for the ER are 
at least 1000-10,000 times lower than estradiol, they are unquestionably able to 
induce endocrine effects. For example, phytoestrogens have been reported to have 
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beneficial effects on the cardiovascular system, relieve menopausal symptoms, and 
decrease the risk of breast cancer and osteoporosis. Furthermore, phytoestrogens have 
been reported to decrease cholesterol levels without inducing hypertriglyceridemia. 
These data indicate that phytoestrogens, including resveratrol, may be an alternative 
hormone therapy for postmenopausal women (Wuttke et al, 2003, Beck et al, 2005). 
 
Resveratrol has been reported to bind to ERα and ERβ, with high affinity to ERβ 
(Bowers et al., 2000). Resveratrol has been shown to have a mixture of agonist and 
antagonist effects at ERs. For example, resveratrol has been shown to have agonist 
activity when it binds with ERα. In in vivo studies, resveratrol treatment of stroke-
prone spontaneously hypertensive rats demonstrated an estrogen-like effect, resulting 
in endothelium-dependent vascular relaxation induced by acetylcholine, and 
protection from a reduction in strength of the femoral bone caused by ovariectomy 
(Bhat et al., 2001). However, in this study it was not possible to dissociate effects 
mediated through ERα with those mediated through ERβ. Furthermore, treatment of 
MCF-7 cells with resveratrol stimulated gene expression and promoted cell 
proliferation (Gehm et al., 1997; Gehm et al., 2004) in a manner similar to estrogen.  
In contrast, an antagonist effect that contrasts with the response to estrogen has been 
observed. For example, Kim et al. (2004) reported that treatment of the MCF-7 cell 
line with resveratrol resulted in inhibition of cell growth. 
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Figure 1.2: Chemical structures of selected phytoestrogens and 17βestradol. 
Adapted from (Rice and Whitehead, 2006) 
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1.1.5.3 Resveratrol and age-related diseases 
Several studies have demonstrated that resveratrol may be able to play a role in 
reducing the incidence of age-related disease such as cardiovascular disease 
(Petrovski and Gurusemy, 2011) and cancer (Sun et al., 2006, Raylam et al., 2008; 
Dhar et al., 2011), as well as Alzheimer disease (Karuppagounder, 2008; Vingtdeux et 
al.,2008). The potential roles of resveratrol in delaying common age-related diseases 
are discussed in the following sections.   
 
1.1.5.3.1 Resveratrol as an anti-cancer factor 
Carcinogenesis is a process that involves unlimited growth of the cells such that the 
tumour expands locally by invasion and spreads systemically by metastasis. The 
carcinogenesis process consists of three different phases: initiation, promotion and 
progression. The first phase, initiation, involves a mutation of DNA in normal cells. 
Mutations may be induced by exposure to procarcinogenic agents such as polycyclic 
aromatic hydrocarbone (PAH), or nitrosamines (Grynkiewicz and Opolski, 2005). 
The second stage is promotion, which results from expression of the mutated DNA. 
Proliferation of the initiated cell results, followed by further progression through the 
carcinogenesis pathway. The third phase is advancement and invasion. This stage is 
associated with the growth of the initiated cells into a biologically malignant tissue. 
True cancer develops in this stage, when a portion of the tumour cells is transformed 
into malignant forms. In this case chemopreventive intervention is ineffective due to 
the advanced state of the tumour. In the final stage of invasion, tumour cells can 
invade the other tissues that are distant from their original site to start new clones of 
growth (Grynkiewicz and Opolski, 2005).  
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Resveratrol, as anti-cancer agent, has been shown to inhibit tumour cell proliferation 
during all three stages of cancer- initiation, promotion and progression- in several 
types of tumour including breast cancer, prostate cancer (Fang et al., 2012), colon 
cancer and pancreatic cancer (Shanker et al., 2011). Studies in vivo using animal 
models, recorded that the oral administration of resveratrol inhibited the development 
of different types of tumours including espophageal cancer (Li et al., 2002), intestinal 
cancer (Tessitone et al., 2000) and breast cancer (Bhat et al., 2001; Banerjee et al., 
2002).  Furthermore, oral administration of resveratrol has been reported to protect 
against colon cancer in rats exposed to carcinogenic compounds such as 1,2-
dimethylhydrazine (Sengottuvelan et al., 2006 a; Sengottuvelan et al., 2006 b).  
 
There are several mechanisms by which resveratrol may suppress the cancer process. 
For example, resveratrol may suppress the initiation stage of tumorigenesis by 
inhibiting the phase I cytochrome P450 enzymes such as CYP1A1, CYP1B1, which 
are overexpressed in various human tumours including breast cancer, lung, liver and 
colon cancer (Chang et al., 2000; Chan and Delucchi, 2000). Oxidation by these 
enzymes involves either unmasking or adding a polar group such as hydroxyl (-OH), 
amino (-NH2) or sulphydryl (-SH) to promote degradation and elimination of 
xenobiotics (pro-carcinogens and drugs) by making them water-soluble (Sheweita and 
Tilmisany, 2003; Jancova et al., 2010).  
Moreover, resveratrol can stimulate phase II drug metabolising enzymes such as 
glutathione S-transferase, UDP-glucuronosyl transferase, and menadione oxido-
reductase, which have a fundamental role in reducing DNA damage (Savouret and 
Quesne, 2002). Conjugation by these phase-II enzymes with large polar groups such 
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as glucuronide, glutathione or sulphate plays a critical role in increasing solubility and 
clearance (Sheweita and Tilmisany, 2003; Jancova et al., 2010).  
Depending on the relative carcinogenicity of the parent molecule and metabolite, 
phase- I and II enzyme action may either be beneficial or detrimental with respect to 
cancers-protection, hence inhibition by resveratrol may equally be of benefit or harm. 
Effective action of these enzymes may have a protective effect as a result of 
catalysing the conversion of carcinogenic xenobiotics compounds to less active and/or 
more rapidly eliminated metabolites (Sheweita and Tilmisany, 2003). However, other 
actions of these enzyme families can convert pro-carcinogens to carcinogens, thus the 
interactions are complex. 
 
A third mechanism through which resveratrol can be chemopreventive is by 
stimulation of DNA repair systems. Excessive exposure to UV irradiation and 
xenobiotics is associated with DNA damage. Failure of cellular system to repair this 
damage leads to carcinogenesis. For protecting cellular DNA against the effects of 
mutational damage, several genes such as p53 survey the genome for damage and / or 
to repair this damage.  
P53, a tumor suppressor protein, has many biological functions including cell-cycle 
regulation, DNA damage repair, induction of apoptosis, development, differentiation, 
and cellular senescence (Bai and Zhu, 2006). As a tumor suppressor, p53 is essential 
in protecting DNA against mutagenic damage in addition to its role in preventing 
inappropriate cell growth.  DNA damage has been reported to activate p53 through a 
mechanism depending on phosphorylation at Ser 15 (She et al., 2001). This activation 
of p53 promotes the transcriptional activity of several genes involved in the DNA 
repair system and induces cell cycle arrest in the G1, G2 and S phases to provide 
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additional time for the cell to repair DNA damage (Bai and Zhu, 2006; She et al., 
2001). Mutation or loss function of the p53 gene has been shown to increased 
susceptibility to cancer by 50% (Olivier et al., 2010).   
 
Resveratrol is able to stimulate DNA repair by increasing the activity of p53 in 
various cell lines. Resveratrol also inhibits tumour promotion by modulation of the 
cell cycle and by the induction of apoptosis (Benitez et al., 2006).  Resveratrol may 
also induce apoptosis by activating MAP kinases such as ERKs and p38 kinase, which 
play essential roles in stimulating p53 phosphorylation at Ser 15 (She et al., 2001).  
 
1.1.5.3.2 Resveratrol as an anti-cardiovascular disease factor 
The protective role of resveratrol against coronary disease appears to result from 
several features of its activity. Firstly, resveratrol has been documented to reduce the 
production of nitric oxide (NO) from vascular endothelium, which is involved in the 
inflammatory responses (Tsai et al., 1999, Donnelly et al., 2004). Increased levels of 
NO can induce vascular damage, which is increased by development of atheromatous 
plaques (Orsini et al., 1997). Secondly, a potential effect of resveratrol is to inhibit 
oxidation of LDL, which plays a critical role in atherosclerosis (Fan et al., 2008). 
Thirdly, resveratrol has been shown to inhibit platelet aggregation, a critical factor 
associated with atherosclerosis process (Olas et al., 2001, Fraczek et al., 2012). This 
process of thrombus formation is induced when platelets attach to the endothelial 
surface of blood vessels. This aggregation of platelets sets into motion the process of 
vascular occlusion. A dose-dependent decline in platelet aggregation has been 
documented with resveratrol, providing further evidence of its protective properties 
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against coronary artery disease. This effect has been associated with the ability of 
resveratrol to suppress eicosanoid synthesis (Fremont, 2000, Stocco et al., 2012). 
 
1.1.5.4  Resveratrol and longevity    
Dietary restriction is known to delay the aging process in short- lived organisms 
including yeast, flies, worms and mice. Ongoing studies in primates, including 
humans, are indicating that dietary restriction induces metabolic and physiological 
changes consistent with longevity in these longer-lived organisms also (Messaoudi et 
al, 2006). A possible mechanism through which dietary restriction may enhance 
longevity – additional to protection against specific age-related diseases- includes 
reduced generation of free radical molecules by mitochondria that cause oxidative 
damage of macromolecules (protein, lipid, and DNA). Moreover, dietary restriction 
(DR) has been reported to improve body energy efficiency by inducing the biogenesis 
of mitochondria that produce fewer free radical molecules and consume less oxygen 
(Civitarese et al., 2007). In vivo, DR has been demonstrated to increase the size of the 
T-cell population, which has an important role in protecting against infection and 
cancer, in both mice and rhesus monkeys (Messaoudi et al, 2006). In rhesus monkeys, 
DR delayed the incidence of age-related diseases, decreased body weight, improved 
immune functions, decreased the level of lipid in blood, and reduced blood pressure, 
but an effect to prolong life was not observed (Mattison et al., 2003, Mattison et al., 
2012) 
 
Resveratrol has been reported to mimic to DR and extend lifespan in diverse species 
(Howitz et al., 2003; Wood et al, 2004; Baur et al., 2006) through mechanisms that 
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may be dependent on activation of Sirt1 (Baur et al., 2006). A further overview of 
Sirt1 function and its possible role in the response to DR is provided in section 1.4.  
In lower organisms, such as the yeast Saccharomyces cerevisiae, resveratrol 
significantly increased life span through a mechanism dependent on Sirt1 (Howitz et 
al., 2003). Resveratrol was also reported to promote extended lifespan in worms, fruit 
flies (Wood et al., 2004; Bass et al., 2007) and vertebrate fish (Valenzano et al., 2006) 
by similar mechanisms. In mammals, resveratrol mimics effects of dietary restriction 
in improving health. Effects of resveratrol consistent with lifespan extension include 
reduced insulin-like growth factor-1 (IGF-I) levels, increased insulin sensitivity, 
increased mitochondrial number, and improved motor function. In mice, resveratrol 
was reported to oppose the effects of a high-fat diet (Baur et al., 2006; Lagouge et al., 
2006; Brasnyo et al., 2011) and  long term consumption of low doses (4.9 mg/kg/day) 
induced expression of genes in brain, skeletal muscle and heart in pattern similar to 
DR (Barger et al, 2008a; Barger et al, 2008b). For example, uncoupling protein 3 
(upc3) increased in response to DR (2.8 fold, P=0.01) and resveratrol (2 fold, P=0.018) 
treatment. Chromodomain-helicase-DNA-binding protein 1 (CHD1) and DNA 
(cytosine-5)-methyltransferase 3A (DNMT3A) were also increased with both DR and 
resveratrol treatment. Sirt5 was significantly decreased in response to DR and 
resveratrol treatment (Barger et al, 2008a; Barger et al, 2008b).   
 
1.2 Estrogen receptors  
Estrogen receptors are ligand-activated transcription factors belong to the large 
superfamily of receptors known as nuclear receptors located inside the target cells of 
estrogen action. There are two functional forms of estrogen receptors, ERα and ERβ, 
which are encoded by different genes located on separate chromosomes. The ERα 
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gene (ESR1) is located on chromosome 6q25.1, whereas the ERβ gene (ESR2) is 
located on chromosome 14q23.2 (Li, 2003). These receptors mediate the biological 
functions of the hormone 17-β estradiol.  Although ERα and ERβ bind with high 
affinity to the same ligand, they respond differently and induce opposite effects 
(Dahlman-Wright, 2006).   
 
1.2.1 Estrogen receptor structure 
Estrogen receptors are composed of six structural domains designed A through to F. 
The amino- terminal region, composing domain A and B, includes the transactivation 
region, known as activation function 1 (AF-1). This region is able to enhance 
transcription regulatory activity of the receptor in the absence of bound hormone 
(Felig et al., 1995; Kong et al., 2003; Kumar, 2011). Also, the A/B domain contains a 
coregulator region, which allows coactivators and corepressors to bind and modulate 
the transcriptional activity of the ER.  The DNA-binding domain, comprising to C 
region, has two zinc finger motifs that play an essential role to recognize and bind to 
specific sequences known as estrogen response elements (EREs) within the promoter 
of the target gene. The ER dimerization and hinge region, the D domain, is required 
for ER dimerization and also for binding to the ERE of the target gene.  The E domain 
is the hormone binding domain and has a binding cavity for estrogen and is also 
binding site for agonist/antagonist compounds. The C-terminal domain – the F 
domain- also contains a transcriptional activation domain known as activation 
function 2 (AF-2), which is a ligand-dependent region (Kumar, 2011).  
Structurally, ERα and ERβ show a considerable homology in the DNA-binding 
domain (96%) and dimerization /ligand-binding domain (60%) but the A/B domain 
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and dimerization and hinge (D) domain are not well conserved between ER α and 
ERβ (Figure 1.3) (Kumar, 2011).  
 
 
Figure 1.3: Estrogen receptor structure. Estrogen receptors are composed of six 
structural domains: A and B domain, DNA binding domain (C), hinge domain (D), 
ligand binding domain (E), and F domain. ERα and ERβ are homologous in the 
DNA-binding domain (96%) and ligand-binding domain (60%). Adapted from 
Akingbemi et al., 2005)  
 
 
1.2.2 Tissue distribution of estrogen receptor  
Estrogen receptors are expressed in many tissues. ERα and ERβ have been detected in 
breast and ovarian tissues, heart, bone, urogenital tract and the hypothalamus 
(Yaghmaie et al., 2005). The liver and the epithelium of the reproductive duct in male 
were reported to express ERα exclusion (Gustafsson, 1999, Hess, 2003). In contrast, 
only ERβ was detected in the gastrointestinal tract (Langen et al., 2011). 
 
1.2.3 Estrogen receptor activation and action 
Estrogen is a hydrophobic compound that is able to diffuse through the phospholipid 
membrane of the cell to bind and to activate intracellular ER. Two major mechanisms 
have been described to explain the action of the ligand-ER complex: the classic 
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pathway, known as the genomic pathway, and the nongenomic pathway (Kong et al., 
2003).  
 
1.2.3.1  Genomic pathway 
The genomic pathway, also known as the classical pathway, involves the direct 
binding of estrogen with the ER located in the cytoplasm. This binding can release the 
ER from heat shock proteins (HSPs). Subsequently, the ER-ligand complex migrates 
from the cytoplasm into the nucleus where homodimers form, then bind to the 
estrogen response element (ERE) in the DNA to activate gene transcription 
(Bjornstrom and Sjoberg, 2005; Mason et al., 2010). Activation of this pathway 
involves interaction of ER-ligand complex with other transcription factors including 
nuclear factor-KappB 1 (NF-KappaB1), activator protein 1, and specific protein 1 
(Sp-1) to influence gene transcription (Levin, 2005).  
 
1.2.3.2  Nongenomic pathway 
In addition to the ERs located in the nucleus and cytoplasm, it has been reported that 
some are associated with cell surface membrane and are rapidly activated by binding 
to estrogen. This binding stimulates various intracellular signaling cascades to recruit 
second messengers including physphatidylinosinol-3 kinase (PI3K) and mitogen-
activated protein kinase (MAPKs), which regulate transcription of specific genes 
(Bjornstrom et al., 2005). 
 
1.2.4  Estrogen receptors and reproduction 
Estrogen receptor knockout (KO) mice have revealed functions of the estrogen 
receptors. Estrogen receptor α knockout mice (αERKO), estrogen receptor β 
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knockout mice (βERKO) and estrogen receptors α and β knockout mice (α βERKO) 
reveal further roles of the specific estrogen receptors (α and β). Uses of αERKO mice 
demonstrated the role of ERα in sexual maturation and fertility. For example, female 
αERKO mice have estrogen insensitivity associated with defects in the reproductive 
tract, including hypergonadism and haemorrhagic (blood-filled) ovarian cysts, plus 
abnormality in pubertal mammary gland development. Males develop phenotypes 
including testicular degeneration, lack of spermatogenesis and inactive sperm. 
Consequently, both sexes of these mice are sterile and show severe defects in sexual 
behaviour (Emmen and Korach, 2003; Hewitt and Korach, 2003). With respect to 
reproductive function, lack of ERβ has much more minor consequences, βERKO 
female mice have compromised fertility, a reduction in the corpora lutea associated 
with defective follicle development and ovulation. Interestingly, these mice show 
normal reproductive behaviour, a normal response to the estrogen and normal 
mammary gland development. No effect was observed on the fertility and sexual 
behaviour of male mice (Korach, 1994). Taken together, these studies suggest that the 
action of ERα and ERβ are independent and gender- specific.  
 
1.2.5 Estrogen receptors and ageing 
Various lines of evidence point towards a decline in ER expression with ageing, with 
ageing-related phenotypic consequences. For example, a study in humans using 
retinal tissue extracted from three females at 35, 49 and 74 years indicated that the 
expression of estrogen receptor ERα reduced with age, suggesting that alterations in 
estrogen receptor expression may be involved in pathologies associated with age, such 
as reduction of visual function, cataract, glaucoma, and dry eye (Ogueta et al., 1999). 
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In female rats, the number of cells expressing estrogen receptor ERβ in the brain 
nuclei (AVPV region) dramatically decreased in old animals (24-26 months) 
compared with young animals (3-4 months), whereas an age-related increase in the 
number of cells expressing ERα was observed. The AVPV region plays an important 
role in reproductive physiology and behaviour, suggesting the importance of ERβ 
signalling in mediating reproductive behaviour (Chakraborty et al., 2003). In a study 
with the aim to investigate the effect of age on estrogen receptor expression and 
whether or not this effect was opposed in response to DR, male rats (at 2-18 months 
old) were subjected to DR and estrogen receptor expression was measured in the 
testicular tissues. An age-related reduction in ERα and ERβ was observed, which may 
explain the functional deficit of the testicular cells observed with age. In contrast, ER 
expression was maintained at higher levels under conditions of DR, indicative of a 
protective effect (Hamden et al., 2008). 
 
1.2.6 Estrogen receptors and obesity 
A growing body of evidence using estrogen receptor knockout (KO) mouse models 
indicates that estrogen receptors may be involved in the regulation of fat deposition.  
Heine et al (2000) reported that knockout of ERα in mice was associated with 
different phenotypes including obesity, insulin resistance, increased plasma leptin and 
decreased plasma adiponectin associated with a reduction in energy expenditure. 
Recently, further study using ERα KO mice provided evidence for a contribution of 
ERα to the regulation of fat deposition and insulin resistance (Manrique et al., 2012).     
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1.2.7 Estrogen receptors and cancer  
Several studies have demonstrated that changes in estrogen receptor expression can be 
associated with cancer development in different tissues including breast (Dotzlaw et 
al., 1999), ovarian (Rutherford et al., 2000), and colon (Foley et al., 2000) tissues.   
In ER-positive cancer such as breast cancer, overexpression of estrogen receptor ERα 
and reduced expression of ERβ has been reported, suggesting that the ratio of ERα: 
ERβ may determine the susceptibility of the tissue to tumorgensis (Roodi et al., 1995;  
Leygue et al., 1998; Iwao et al., 2000).   
Estrogen receptors have been identified as a target for cancer treatment using 
endocrine therapy, selective estrogen receptor modulators (SERMS) compounds with 
the ability to bind and to modulate estrogen receptor activity. These compounds 
include tamoxifen, which acts as an ER antagonist in breast cancer (Osborne, 1998, 
Sestak and Cuzick, 2012) and fulverstrant, which acts as a potential antagonist and 
promotes estrogen receptor degradation (Wakeling et al., 2000, Buzdar, 2008;  Larsen 
et al., 2012). 
 
1.3  Chromatin and histone proteins 
In the nucleus of eukaryotic cells, DNA is packed as chromatin, consisting of repeated 
nucleosome unites. Typically, a nuclosome consists of genomic DNA (147 base pairs) 
wrapped around an octomer of the core histone proteins H2A, H2B, H3, and H4 
(Figure 1.4) (Luger et al., 1997, Izzo and Schneider, 2011). Chromatin exists in two 
major forms heterochromatin, which is transcriptionally silent, and euchromatin, 
which is transcriptionally active (Grewal and Moazed, 2003). 
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Figure 1.4: Chromatin structure. Adapted from (Sparmann and Lohuizen, 2006). In 
the nucleus of eukaryotic cells, DNA is wrapped around an octomer of the core 
histone proteins H2A, H2B, H3 and H4 to form a nuclosome. Repeated nucleosome 
unites are packed to form chromatin. Chromatin is then folded to form chromosomes.  
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1.3.1 Histone protein features  
There are two types of histone proteins- core histone proteins- including H2A, H2B, 
H3 and H4, and a linker histone known as H1. These proteins are rich in the positively 
charged amino acids which bind tightly to the negative charge of DNA. Each of core 
histone proteins has a flexible N-terminal tail extending outward. In addition, histones 
H2A and H2B have a C-terminal tail that also extends outward from the nucleosome 
(Izzo and Schneider, 2011).    
 
1.3.1.1  Histone genes  
Several subtypes of each histone protein are encoded by different genes. These genes 
are divided, based on their expression, into three major groups: (1) replication-
dependent histone genes, whose expression is tightly coupled with the S-phase of the 
cell cycle. In total, 58 histone genes have been identified as replication-dependent 
histone genes. These genes lack introns and encode an mRNA that lacks a poly (A) 
tail. (2) Replication- independent histone genes, which encode replacement histones. 
These variant histone proteins are synthesized from polyadenylated mRNAs that are 
expressed throughout the cell cycle and in non-dividing differentiated cells. (3) Genes 
expressed in specific tissues such as H1t and H3t genes, which are expressed in 
testicular tissues (Albig et al., 1997; Marzluff et al., 2002).  
Approximately 80% of the histone genes are clustered on the short arm of 
chromosome 6 (6p21.3-22). Several genes encoding core histone proteins (H2a, H2b, 
H3 and H4) are clustered on long arm of chromosome 1 (1q21) (Albig et al., 1997; 
Marzluff et al., 2002).  
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1.3.1.2  Regulation of histone gene expression  
The replication-dependent histone mRNAs are tightly cell-cycle regulated and their 
expression is dependent on the process of DNA replication. Three major pathways 
have been reported to regulate the levels of histone mRNAs synthesis during the cell 
cycle. The first pathway regulates histone mRNA transcription at G1/S phase 
transition. Histone gene transcription increases three to five fold during G1/S phase 
transition and then decreased to baseline level at the end of S phase (Marzluff and 
Duronio, 2002).  The two remaining pathways regulate histone mRNA production at a 
posttranscriptional level.  The first pathway of posttranscriptional regulation occurs in 
the cytoplasm to govern the half-life of histone mRNAs through their degradation 
when DNA synthesis is inhibited. For example, the half-life of histone mRNAs in S-
phase dropped from 30-60 minutes to 10-15 minutes when chromosome replication is 
blocked with inhibitors of DNA chain elongation (Marzluff and Duronio, 2002; 
Gunjan et al., 2005).  The second pathway of posttranscriptional regulation occurs in 
the nucleus to produce mature histone mRNA. Since histone genes lack introns, the 
formation of mature histone mRNA requires only one RNA- processing reaction, 
which involves an endonucleolytic cleavage to form the 3` end of the mRNA. This 
reaction is directed by a purine-rich sequence, termed the histone downstearm element, 
that is complementary to the 5` end of U7 snRNA. Additionally, the 3` end of the 
histone mRNA tail contains a stem-loop that interacts with a specific protein termed 
the stem-loop binding protein (SLBP). This protein participates in many steps of 
histone mRNA metabolism in both the nucleus and cytoplasm. SLBP remains 
associated with mature histone mRNA to form a complex to protect histone mRNA 
from degradation during S-phase. At the end of S-phase, the histone mRNA-SLBP 
  27 
complex disassociates, allowing rapid degradation of both histone mRNA and SLBP 
(Marzluff and Duronio, 2002; Gunjan et al., 2005).  
 
Histone protein synthesis and DNA replication are considered to be interdependent 
process. For example, DNA replication is affected by the rate of histone protein 
synthesis. Overexpression of the HIRA protein, which represses transcription of all 
the replication-dependent histone genes, arrests cells in S-phase (Marzluff and 
Duronio, 2002; Gunjan et al., 2005).   
 
1.3.2 Histone modification 
The core histone proteins and their tails (N-terminal and C-terminal) undergo a 
variety of post-translational modifications such as acetylation (ac) of lysine residues, 
methylation (me) of lysine and arginine residues, phosphorylation (ph) of serine, 
threonine and tyrosine (Y) residues, mono-ubiquitination (ub) of lysine residues, 
SUMOylation of lysine residues, and ADP-ribosylation (ar) of lysine residues 
(reviewed in Perterson, 2004). These modifications are highly specific, occurring in 
specific amino residues within specific histone proteins (Bartova et al., 2008; Izzo and 
Schneider, 2011) and mostly occurring in amino terminal tails (Figure 1.5). Among 
these modifications of histone, histone acetylation is a highly dynamic process. 
Histone H3 and histone H4 proteins in particular are subject to extensive 
modifications (Cosgrove et al., 2004).   
 
Histone modifications play fundamental roles in gene expression, DNA repair, 
apoptosis, DNA replication and chromosome condensation (Cheung et al., 2000). In 
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addition, histone acetylation and histone methylation are involved in epigenetic 
regulation of chromatin (Bartova et al., 2009).  
 
1.3.2.1  Histone acetylation 
Histone acetylation is a highly dynamic process involving the addition of acetyl 
groups to lysine amino groups on the N-terminal tails of the core histones. This 
reaction is catalysed by histone acetyltransferases (HATs) and requires acetyl 
coenzyme A (acetyl co-A) as an acetyl group donor. Different lysine (K) residues are 
known to be targets for acetylation within histones. These sites are H3K9, H3K14, 
H3K18, H3K23, and H3K27 at histone H3 and H4K5, H4K8, H4K12, H4K16 at 
histone H4. In addition, H2AK5 at histone H2A and H2BK5, H2BK12, H2BK15 and 
H2BK20 at histone H2B are recognised to be acetylation sites (Bartova et al., 2008).  
The hyperacetylation of lysine residues is associated with activation of gene 
expression by neutralising the positively charged lysine residues in the histone tails, 
which decreases their affinity for DNA. This process influences nuclosome unfolding 
and thereby facilities binding of transcription factors to the promoter of the target 
gene (Jacobson et al., 2000).  
 
Histone acetylation is a reversible process in which the acetyl group is removed from 
acetylated lysine residues by histone deacetylase enzymes (HDACs). These enzymes 
are subgroubed into three classes. Class I histone deacetylase enzymes comprise small 
proteins (377-488aa) and include HDAC-1, HDAC-2, HDAC-3 and HDAC-8 
(Bjerling et al., 2002). Class II HADCs are larger proteins (669-1215aa) and include 
HDAC-4, HDAC-5, HDAC-6, HDAC-7 and HDAC-9 (Fischle et al., 2002). Class III 
HADCs are NAD-dependent proteins, and include the mammalian sirtuin (Sirt1-7) 
  29 
family, and its homolog Sirt2 in yeast (Delage and Dashwood, 2008). Class I and 
class II histone deacetylases require zinc as a co-factor (Hernick and Fierke, 2005). 
Class III HADCs require one molecule of NAD+ for each acetyl group removed from 
the target protein (Blander and Guarenet, 2004). Generally, histone deacetylation has 
been associated with transcriptional repression.  
 
Links between histone acetylation and ageing have been reported.  For example there 
was a significant decrease in the level of histone H3 acetylation at K9 in liver in old 
(30 months) rats compared with young (15 months) rats (Kawakami et al., 2009).  
Two possible mechanisms were suggested to explain this reduction of histone 
acetylation with age: (1) upregulation of Sirt 1, which catalyses the deacetylation of 
histone proteins and downregulates on of histone acetyltransferase with age, and (2) a 
histone turnover, where acetylated histone is replaced by newly synthesize protein 
(Kawakami et al., 2009).  
In contrast, a study in yeast reported an increase in the level of histone 4 acetylation 
(H4K16ac). This increase in histone acetylation was associated with a progressive 
decrease in the level of the Sir2 deacetylase protein with age (Dang et al., 2009).  
 
1.3.2.2   Histone methylation 
Lysine, arginine, and histidine residues in the histone proteins can be substrates for 
methylation (Kouzarides, 2007). Lysine residues can be monomethylated, 
dimethylated or trimethylated (Sims et al., 2003) with specific targets being  H3K4, 
H3K9, H3K27, H3K36, H3K79 and H4K20 (Garcia et al., 2004). Lysine methylation 
of histone proteins is site and state-specific and is catalyzed by lysine 
methyltransferases (KMT) (Dillon et al., 2005). This process is reversed by histone 
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demethylase enzymes such as lysine specific demethylase 1 (LSD1), which is specific 
for mono-methylated and di-methylated residues (Shi et al., 2004).  
 
Arginine (R) residues can be mono-methylated or di-methylated. The reaction is 
catalysed by enzymes of the protein arginine methyl transferase family (PRMT). The 
reverse reaction is catalysed by peptidylarginine deiminase 4 (PAD4) (Cuthbert et al., 
2004; Wang et al., 2004).  Three sites are known to be targets for arginine 
methylation in histone H3 (R2, R17, and R26) whereas one site (R3) in H4 has been 
reported to be methylated (Izzo and Schneider, 2011).      
 
Histone methylation plays essential role in the regulation of many biological 
processes such as, development, differentiation, cell-cycle, and DNA damage. The 
functions of histone methylation depend mainly on the methylation status and the 
genomic location.  For example, For example, H3K9 methylation is associated with 
heterocromatin formation and euchromatic gene silencing, whereas, H3K27 
methylation plays an essential role in HOX genes suppression and in X chromosome 
inactivation and imprinting during development (Greer and Shi, 2012).  
Alteration in the methylation of specific histones has been reported to be associated 
with disease and ageing (Greer and Shi, 2012). Histone methyltransferase (EZH2), 
which catalyzes the trimethylation of histone 3 on lysine 27 (H3K27me3), is 
upregulated in different types of cancer such as breast cancer, prostate cancer, and 
lymphoma (review in Greer and Shi, 2012). The resulting effect to reduce H3K27me3 
may be in part, associated with the cancer process. 
In rat liver, the level of trimethylation of histone H4 at lysine 20 (H4K20me3) was 
seen to increase with age (Sarg et al., 2002).  
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Histone methylation may be linked also to lifespan. Knockdown of the ASH-2 and 
WDR-5, members of an H3K4 trimethylation (H3K4me3) complex, or the regulator 
protein SET-2 extends lifespan of worms. All these proteins catalyse H3K4 
trimethylation in both the developing and the adult germline in the worm. In line with 
this finding, overexpression of RBR-2, the H3K4me3 demethylase in the worm, 
extends lifespan, whereas knockdown of RBR-2 reverses this effect (Greer et al., 
2010).   
 
1.3.2.3    Histone phosphorylation 
All histone proteins are subject to phosphorylation at serine (S), threonine (T) and 
tyrosine (Y) residues. This modification is catalyzed by several distinct kinases, and is 
also dependent on phosphatise activity (Singh and Gunjan, 2011). Histone 
phosphorylation has important roles in regulating gene expression, chromatin 
condensation, the DNA damage response and apoptosis (Nowak and Corces, 2004). 
For example, phosphorylation of H2AX at S139 is rapidly increased in response to 
DNA damage causing activation of DNA repair genes and a delay of the cell cycle. 
Defects in H2AX phosphorylation have been associated with cancers (Singh and 
Gunjan, 2011).  
Phosphorylation of H3 at S10 (H3S10) has been reported to promote gene activity 
through cross-talk with other histone modifications. For example, H3S10 
phosphorylation can supporting an active transcriptional state by stimulating 
acetylation of histone H3K14, inhibiting acetylation of histone H3K9, and modulating 
methylation of histone H3K9. Furthermore, phosphorylation of H3T11 activates 
transcription by enhancing demethylation of H3K9. Phosphorylation of H3S10 along 
with H3T45 and H2BS14 is implicated in apoptosis (Cohen et al., 2011).  
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There is very limited published data on the effect of age on histone phosphorylation, 
however the link was studied in the rat liver.  This study reported an increase in H3 
phosphorylation at S10 in 30 month-old rats compared with 15 month-old animals 
(Kawakami et al., 2009). 
 
1.3.2.4   Histone ubiquitinylation 
Ubiquitin is a small protein that can be covalently attached to specific lysine residues 
in proteins including the histone proteins (Peterson and Laniel, 2004).  Ubiquitination 
occurs on specific lysine residues in the C-terminal region of histone H2A and histone 
H2B (Sun and Allis, 2002). A single molecule of ubiquitin is covalently attached to 
both H2A at Lys 119 (ubH2A) and H2B at Lys 120 (ubH2B) (Cao and Yan, 2012).   
The monoubiquitination of H2A and H2B has been reported to alter chromatin 
dynamics and regulate gene expression. H2A ubiquitination is associated with gene 
silencing, whereas ubiquitination of H2B is associated with active transcription (Cao 
and Yan, 2012).  Crosstalk between H2B ubiquitination and histone H3 methylation 
has been reported. H2B ubiquitination is required for H3K4 and H3K79 methylation. 
This histone crosstalk seems to function unidirectionally. Mutations affecting H2B 
ubiquitination, reduced level of H3 methylation. In contrast, mutation of the H3 
methylation sites or methyltransferases has no effect on H2B ubiquitination (He and 
Lehming, 2003). 
Similar to H2B, crosstalk between H2Aub and histone H3K4 methylation has been 
observed. For example, H2Aub inhibits MLL3, which mediates di- and trimethylation 
of histone H3 at Lys-4 causing transcriptional repression (Nakagawa et al., 2008).  
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A link between histone ubiquitination and ageing was observed in mouse brain where 
the level of histone ubiquitination was increased by 30% in old mice compared with 
young animals (Morimoto et al., 1993).  
 
1.3.2.5   Histone SUMOylation 
SUMO is a small ubiquitin-related modifier that can be attached covalently to histone 
proteins at specific lysine residues and is associated with transcriptional repression of 
the associated region of the genome (Shiio and Eisenman, 2003). Several sites are 
recognised to be targets for SUMOylation including K6 and K7 in H2B, K126 in H2A, 
K16/17 in H2B and all five lysines in the N terminal region of H4. This modification 
is catalysed by dedicated E1 activating (SAE1/SAE2) and E2 conjugating (UBC9) 
enzymes to form a peptide bond between the C-terminus of SUMO and the amino 
group of the target lysine (Iñiguez-Lluhí, 2006).  
 
In addition to direct effects of SUMOylation on histone proteins, chromatin structure 
is affected indirectly through effects on histone-modifying enzymes. For example, 
SUMOylation reduces the activity of histone deacetylases. Additionally, the activity 
of histone demethylase LSD1, which catalyses removal of methyl groups from mono- 
or di-methylated histone H3 at lysine 4 (H3K4), is repressed by SUMO.  Loss of 
SUMOylation thus promotes transcriptional repression by stimulating both histone 
acetylation and histone demethylation (Iñiguez-Lluhí, 2006; Ouyang and Gill, 2009). 
 
SUMO plays critical role in the regulation many biological processes such as cell 
cycle progression, genomic stability, and transcription by modifying various enzymes 
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and cofactors that are important for regulated gene expression, as well as coordinating 
chromatin structure and histone modifications (Ouyang and Gill, 2009). 
 
1.3.2.6   Histone ADP- ribosylation 
This modification involves the addition of (anionic) ADP ribose polymers to histone 
proteins by the action of PARPs (poly-ADP ribose polymers), predominating at lysine 
residues in the tails of histone H4 (K13), H2B (K30), H3 (K27 and K37) and H4 
(K16). These modifications take place during or after histone synthesis.  ADP-
ribosylation has important roles in various biological processes such as DNA repair, 
cell cycle regulation replication or transcription (Hottiger, 2011). The recognized sites 
of ADP-ribosylation are also targets for other histone modifications, such as 
acetylation, methylation, and phosphorlation, thus ADP-ribosylation may interact 
with these other histone modifications.  For example, acetylation of H4 at K16 
inhibits ADP-ribosylation of H4. Furthermore, ADP-ribosylation of histones reduces 
their phosphorylation and prevents demethylation of H3K4me3 (Messner and 
Hottiger, 2011).   
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Figure 1.5: Histone modifications. Adapted from (Rodriguez-Paredes and Esteller, 
2011). The core histone proteins (H2A, H2B, H3 and H4) and their tails (N-terminal 
and C-terminal) are subjected to a variety of post-translational modifications such as 
acetylation (Ac) of lysine residues, methylation (Me) of lysine and arginine residues, 
phosphorylation (P) of serine, threonine and tyrosine residues, and mono-
ubiquitination (Ub) of lysine residues. SUMOylation of lysine residues, and ADP-
ribosylation of lysine residues (not show) are additional modifications.  
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1.3.3 Epigenetic modification 
Epigenetic modification is a heritable change in gene expression that results from 
molecular mechanisms that are not mediated through changes in the DNA sequence. 
In some cases, epigenetic modifications are inherited across generations (Cheung and 
Lau, 2009). Two major components of epigenetic modification are histone/chromatin 
modifications and DNA methylation (Kimura et al., 2005, Bartova et al., 2009). 
Histone modifications and DNA methylation play a key role in controlling 
differentiation during embryonic development, inactivation of the X chromosome in 
the female, genomic imprinting and in DNA repair and DNA double strand break 
(DSB) repair systems (Richardson, 2002, Celeste et al., 2003). 
 
Histone acetylation, which is catalyzed by histone acetyl transferases, results in a 
more open euchromatin configuration, which leads to activation of associated loci. 
This activation of euchromatin can be suppressed by histone deacetylases enzymes, 
which catalyse the histone deacetylation reaction. In contrast, histone methylation 
inactivates heterochromatin by providing a binding site for the chromodomain-
containing heterochromatin protein 1, which leads to transcriptional repression 
(Eberharter and Becker, 2002; Bartova et al., 2009). 
 
A second major mechanism associated with epigenetic modification is DNA 
methylation. DNA methylation is a biological process that involves the addition of a 
methyl group at the fifth carbon position at cytosine residues in DNA by DNA 
methyltransferase enzymes (Figure 1.6) (Richardson, 2002).  
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There is a cyclical relationship between DNA methylation and histone modifications. 
DNA methylation affects histone modification through the recruitment of proteins 
including histone deacetylases. Histone acetylation and methylation can, in turn, 
influence DNA methylation (Cheung and Lau, 2009).  DNA methylation levels can be 
altered, therefore, by changes in expression or acting of DNA methyltransferase 
enzymes or as a result of changes in histone acetylation status. 
 
 
 
 
 
 
 
 
 
Figure 1.6: DNA methylation mechanism. Adapted from (Chen and Riggs, 2011) 
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1.4 Sirtuins, focusing on Sirt1  
Silent information regulator (SIR) enzymes comprise a large family of proteins 
referred as sirtuins, which are expressed widely in various species from yeast to 
mammals (Baur et al., 2012). The first sirtuin gene, Sirt2, was identified in 
Saccharomyces cerevisiae by Klar and colleagues (1979).  Later on, Sirt2 homologues 
were identified in fruit flies, worms, bacteria, plants and mammals (Table 1.2). 
Sirtuins are NAD
+
- dependent histone deacetylases and categorized as class III 
histone deacetylase (Figure 1.7) (Salminen et al, 2009).  
 
In mammals, seven sirtuins (SIRT1-7) have been identified and roles in the regulation 
of metabolism, growth (McBurney et al., 2003) and inflammation (Pfluger, 2008), as 
well as a role in lifespan extension, have been described. Among the sirtuins, Sirt1 
has been studied extensively and appears to deacetylate a large number of cellular 
substrates (Baur et al., 2012).  
 
In lower organisms, Sirt2 has been reported to regulate lifespan. For instance, 
overexpression of Sirt2 was observed to increase lifespan in yeast (Kaeberlein et al., 
1999), worms (Tissenbaum and Guarente, 2001), and fruit flies (Rogina and Helfand, 
2004). In contrast, deletion of Sirt2 in yeast resulted in reduction in lifespan 
(Kaeberlein et al., 1999).   
 
In mammals, Sirt1 plays an essential role in regulation wide range of cellular process 
such as transcriptional regulation, apoptosis, stress responses, and longevity by 
deacetylation of multiple proteins such as p53, p73, Ku70, and forkhead transcription 
factors (FOXOs).  For example, Sirt1 has been reported to suppress the apoptosis 
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pathway by deacetylation the tumour suppressor p53 at multiple lysine residues.  
Moreover, Sirt1 has been reported to deacetylate and repress FOXO protein which 
leads to reduction of cellular stress (Brunet et al., 2004; Motta et al., 2004). Sirt1 has 
also been reported to induce apoptosis, increase expression of DNA repair and cell 
cycle checkpoint genes, and to protect pancreatic β-cells against cytotoxicity induced 
by glucose (Kitamura et al., 2005, Banks et al., 2008; review in Kelly, 2010).    
 
It is believed that Sirt1 may promote longevity and protect from age- related diseases 
by regulating metabolism and endocrine pathways (Brooks et al., 2009). Mice with 
Sirt1 overexpressed at low levels were protected from diabetes and hepaticlipid 
damage resulting from a high fat diet (Bordone et al, 2007; Banks et al., 2008).  Mice 
lacking Sirt1 (Sirt1-null mice) have been shown to have a metabolic dysfunction 
compared with wild-type mice (Boily et al., 2008). Furthermore, heart-specific 
overexpression of Sirt1 in mice enhanced resistance to oxidative stress and slowed the 
heart-ageing process (Alcendor et al, 2007).  
 
1.4.1 Sirt1 and insulin/ IGF signalling 
The insulin/insulin-like growth factor 1 signalling (IIS) pathway has been reported to 
modulate lifespan in different species (Rinco et al., 2004; Rinco et al., 2005).  A 
single gene mutation in the insulin like growth factor (IGF) signalling pathway has 
been reported to extend lifespan in various species including worms (Kenyon et al., 
1993), flies (Clancy et al., 2001), and mice (Al-Regaiey et al., 2003). In worms, 
mutants in this gene Daf2 (homologous to insulin receptor in mammals) had increased 
lifespan. In flies, lack of insulin receptor substrate CHICO (Clancy et al., 2001)  or 
insulin receptor IR (Tatar et al., 2001)  were shown to increase lifespan. Flies 
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homozygous for CHICO mutations had lifespan increased by 48% compared with an 
increase of 36% in heterozygotes.    
In a mouse model, Holzenberger et al (2003) reported that heterozygous IGF-1 
knockout resulted in extended lifespan in compared with wild type mice. The same 
finding has been reported for adipose-specific homozygous IGF-1 knockout mice 
(Blüher et al., 2003).  
 
1.4.2 Sirt1 and dietary restriction (DR) 
Dietary restriction (DR), reduction of food intake below ad libitum without 
malnutrition, has been reported to promote longevity in diverse species from yeast to 
mammals (McCay et al., 1935; Walker et al., 2005) through a mechanism proposed 
by some researchers to be dependent on Sirt1 in mammals and on its homologue Sir2 
in yeast (Cantó and Auwerx, 2009). In mammals, a growing body of evidence 
supports the view that Sirt1 is involved in mediating the effect of DR on lifespan 
extension. Firstly, levels of Sirt1 have been documented to increase in mammal tissue 
in response to DR (Brunet et al., 2004; Nisoli et al., 2005; Barger et al., 2008; Kanfi 
et al., 2008). Secondly, mice lacking Sirt1 (Sirt1-null mice) showed a metabolism 
dysfunction and did not respond to DR compared with wild-type mice (Boily et al., 
2008). Additionally, the physical activity of these mice was decreased in response to 
DR (Chen et al., 2005a). In contrast, whole-body overexpression of Sirt1 induced 
effects similar to the DR in mice, including reduced body weight and enhanced 
glucose homeostasis. In addition, there was a reduction in the level of insulin, glucose 
and cholesterol in pattern similar to those were subjected to DR (Bordone et al., 2007).  
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Table1.2: List of sirtuin genes expressed in several species, their intracellular 
localisation and their enzyme activities. Adapted from (Dong and Zou, 2010). The 
identified sirtuins genes for each organism are listed and, where known, sub-cellular 
location and activity is stated. ART= ADP-ribosyltransferase. 
  
   Organism Gene Sub-cellular localization Enzymatic activity 
S. cerevisiae Sir2 Nucleus Deacetylase/ART 
 Hst1 Nucleus Deacetylase 
 Hst2 Cytoplasm Deacetylase 
 Hst3 Nucleus Unknown 
 Hst4 Nucleus Unknown 
C. elegans Sir-2.1 Nucleus Deacetylase 
 Sir-2.2 Unknown Unknown 
 Sir-2.3 Unknown Unknown 
 Sir-2.4 Unknown Unknown 
D. melanogaster dSir2 Nucleus Deacetylase 
 dSirt2 Unknown Deacetylase 
 dSirt4 Unknown Unknown 
 dSirt6 Unknown Unknown 
 dSirt7 Unknown Unknown 
Mammals SIRT1 Nucleus Deacetylase 
 SIRT2 Cytoplasm Deacetylase/ART 
 SIRT3 Mitochondria Deacetylase/ART 
 SIRT4 Mitochondria ART 
 SIRT5 Mitochondria Unknown 
 SIRT6 Nucleus Deacetylase/ART 
 SIRT7 Nucleus Unknown 
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Figure 1.7: The enzymatic activities of sirturins. Sirtuin act as deacetylase (a) and 
or ADP ribosyltransferase (b) enzymes and regulate the activities of target proteins. 
Adapted from (Dong and Zou, 2010). 
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1.5   Hypothesis 
The hypothesis underlying the study was that some of the beneficial effects of 
resveratrol on lifespan/aging are mediated through effects on histone expression that 
oppose changes observed in ageing, and that these actions of resveratrol influence the 
expression of genes that affect the ageing process. A second hypothesis was that these 
effects of resveratrol are mediated through ERα and/or ERβ.  
 
 
 
 
Figure 1.8: Diagrammatic representation of the hypothesis. It is hypothesised that histone 
(H2A, H2B, H3 and H4) expression may increase with age and the beneficial effects of 
resveratrol on lifespan/longevity are mediated through this effect on histone protein 
expression.  
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1.6   Objectives of the study 
The specific objectives of the study were:   
1. To examine the effect of resveratrol on histone expression. 
2. To investigate the effect of age on histone expression. 
3. To identify specific genes and pathways affected by resveratrol treatment. 
4. To study whether the estrogen receptors are essential for resveratrol to affect 
histone expression.  
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2 Materials and Methods 
 
Reagents and chemicals were purchased from Sigma (Poole, Dorset, UK) unless 
otherwise stated. 
All solutions and plastic consumables were sterilised by autoclaving at high pressure 
and temperature. Sterile MilliQ water was used and was generated by deionisation 
using a Millipore filtration unit (Millipore, Massachusetts, USA)  
 
2.1 Cell culture 
Tissue culture was carried out in a class II laminar flow hood using aseptic 
techniques. All culture medium and supplements were obtained sterile (Gibco BRL, 
UK) unless otherwise stated. Cells were grown as monolayer cultures in sterile 75 cm
2
 
flasks (Greiner Bio-one, Gloucestershire, UK) and were incubated at 37 ºC in a 5% 
CO2 atmosphere.  
 
2.1.1 Growth and maintenance of cells 
Human breast cancer MCF-7 cells (passage number 72-89) were grown in improved 
minimal essential medium (IMEM) containing Glutamax plus 4.5 g/L glucose, 
supplemented with 10% (v/v) foetal calf serum (FCS), 10000 IU/ml penicillin, 10000 
µg/ml streptomycin, 1% (v/v) nonessential amino acids (NEAA), and 1% (v/v)  
sodium pyruvate.  Caco-2 human colonic adenocarcinoma cells (passage number 21-
28) were grown in Dulbecco`s modified Eagle`s medium (DMEM) containing 
Glutamax plus 4.5 g/L glucose,  supplemented with 10% (v/v) FCS,  1% (v/v) NEAA, 
and 0.06 % (v/v) gentamycin.   
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Cells were routinely subcultured when 90% confluent by removing the medium, 
washing with 15 ml sterile phosphate buffered saline (PBS), followed by adding 2 ml 
trypsin, and incubation for 5 minutes at 37°C. After incubation, cells were 
resuspended in 10 ml of medium and transferred to 25 ml universal tubes and 
centrifuged for 5 minutes at 1500 rpm. The supernatant fluid was removed and cell 
pellets were resuspended in 10 ml of normal growth medium. One milliter of the 
resuspended cells was transferred to a new 75 cm
2
 flask and 15 ml of the medium was 
added and cells were incubated at 37 °C in 5% CO2 in air.  
 
2.1.2 Cell counting 
Fifteen microlitres of cell suspension were mixed with equal volume of trypan blue 
dye solution. The trypan blue cell suspension was pipetted onto a haemocytometer 
and the viable cell numbers per ml calculated using the following formula: 
Number of cells per ml = 2 (average number of viable cells in 16 squares) X 10000 
 
2.1.3 Cell treatment  
Resveratrol (trans-isomer), supplied in a powder form, was dissolved in DMSO (100 
mM stock solution) and added to phenol red- free culture medium to reach a final 
concentration of 10 µM resveratrol. Caco-2 cells were seeded in 6 well culture plates 
at a density of 3x10
5
 cells/well. After 24 hours incubation in growth medium, cells 
were treated with either 0.01% DMSO (vehicle control)  or 10 µM resveratrol for 48 
hours in the presence or absence of the ER antagonist Fulvestrant (0.1 µM). Treated 
or untreated cells were then processed to extract total cell protein. MCF-7 cells were 
treated with resveratrol following the same procedure. 
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2.1.4 Preparation of cell lysate  
Cells (Caco-2, MCF-7) were washed with phosphate buffered saline (PBS). PBS 
containing 1x protease inhibitor cocktail (Roche) was added just before lysis. Cells 
were scraped from the plastic, transferred into 1.5 ml microcentrifuge tubes and 
centrifuged at 13000 rpm for 15 minutes at 4 °C.  The pellets were resuspended in 
50µl of resuspension buffer (100 mM NaCl, 10 mM  Tris-HCl, 1 mM EDTA and 1x 
protease inhibitor cocktail).   
 
2.1.5 Determination of protein concentration 
Protein concentrations were determined using the Nanodrop spectophotometer 
(Thermo, USA). Typically, 1µl of each sample was applied directly onto the nanodrop 
lower optical surface. Protein concentration was calculated by nanodrop software.  
MilliQ water was used as a blank. 
 
2.2 Extraction of histone proteins from mouse intestine 
Histone extraction was carried out according to a published procedure (Jeong, 2004, 
Druesne, 2004). Briefly, small pieces of small intestine from young and old female 
mice (12 months and 38 months) were homogenized in cold-ice 1x PBS, and 
centrifuged at 12,000 g for 10 minutes. Subsequently, pellets were resuspened in 
hypotonic buffer (1.5 mM MgCl2, 10 mM HEPES, 0.5 mM dithiothreitol, 0.2 mM 
phenylmethylsulfonyl fluoride, 10 mM KCl) and kept on ice for 10 minutes. The 
suspension was then sonicated for 15 minutes. After sonication, suspensions were 
centrifuged at 3300 g for 15 minutes and the cytoplasmic fractions were discarded. 
The pellets were resuspended in 0.2 M H2SO4 and kept overnight at 4 ºC. The 
suspensions were then centrifuged at 10000 g for 15 minutes. Histone proteins were 
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precipitated using 1 ml acetone and incubating overnight at -20 ºC. Acetone was 
removed after centrifuging at 10000 g for 15 minutes at 4 ºC and the pellets were 
neutralized in 10 µl NaOH 2M and 40 µl MilliQ water.  Protein concentrations were 
measured using the Nanodrop as described in section 2.1.5.  
 
2.3 Human colonic tissue samples 
Human samples used were kind gift from Professor John Mathers (Institute for Aging 
and Health, Newcastle University, UK). Total protein samples were extracted from 
human colon biopsies of eleven males (at 21, 23, 33, 43, 64, 66, 73, 74, 77 or 82 years 
old). Human samples were homogenised in a total volume of 40 µl buffer prepared by 
mixing 20 µl of lysis buffer (100 mM NaCl, 10 mM  Tris-HCl, 1 mM EDTA and 1x 
protease inhibitor cocktail) with 20 µl of gel loading buffer (1 M Tris-HC pH6.8, 50% 
glycerol, 12.5 % SDS, 0.1 % bromophenol blue, 1 M dithiottheitol (DTT) and 5 % β-
mercaptoethanol). Cell lysis was achieved through the SDS content (6.25%) in the 
combined buffer. Samples were then denatured at 95 ºC for 5 minutes, and then 
resolved by SDS-PAGE as described in section 2.4.4.  
 
 2.4 Western blot analysis 
2.4.1 Antibodies 
Primary antibodies, obtained from rabbit, were diluted in 1x PBS, 5% (w/v) non fat 
milk powder and 0.05 % (v/v) Tween-20 as follows: anti-H2A (1:250), anti-H2B 
(1:250), anti-H3 (1:1000), anti-H4 (1:250) and anti-alpha tubulin (1:250). Secondary 
antibody, anti rabbit IgG peroxidase conjugate, was diluted (1:3000) in 1x PBS, 5% 
(w/v) non fat milk powder and 0.05% (v/v) Tween-20 (Table 2.1). 
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2.4.2 Protein sample preparation 
Protein samples were mixed with 5x protein loading buffer [1 M Tris-HC pH6.8, 50% 
glycerol, 12.5% SDS, 0.1% bromophenol blue, 1M dithiothreitol (DTT) and 5% β-
mercaptoethanol]. Proteins were then denatured at 95 ºC for 5 minutes. The samples 
were briefly centrifuged at room temperature to collect the mixture at the bottom of 
the microfuge tube.  
 
2.4.3 Gel preparation 
Separating gel was prepared using 2.19 ml of 40 % bis acrylamide (37.5:1), 2.8 ml of 
2.5x separating gel buffer [1.875 M Tris-HCl  pH 8.9, 0.25 % SDS], 6 µl of TEMED, 
65 µl of 10 % ammonium persulfate (APS) in a total volume of 5.45 ml. A 10 % 
stacking gel was prepared using the following reagents: 0.25 ml of 40 % bis 
acrylamide (37.5:1), 0.4 ml of 5x stacking buffer [0.3 M Tris-HCl pH 6.7, 0.5% SDS], 
2.5 µl TEMED, 18 µl of 10 % APS in a total volume of 2.175 ml. 
 
2.4.4 SDS polyacrylamide gel electrophoresis and transfer of protein to a solid 
support membrane 
Proteins were subject to SDS polyacrylamide gel electrophoresis (SDS-PAGE). Five 
micrograms of protein was loaded in each lane of a 12.5 % polyacrylamide gel 
(section 2.4.3). Gels were run at 80V for 2 hours in 1x protein electrophoresis running 
buffer [made up as 5x/L: 60.6 g Tris Base, 144.1 g glycine, 5 g SDS]. ColorBrust 
electrophoresis marker (M.W 8000-220,000, Sigma) was used as a molecular weight 
standard. Following electrophoresis, proteins were transferred to activated PVDF 
membranes using a semi dry blotter at 15V for 50 minutes. The PVDF membranes 
were activated by incubating in methanol for 30 seconds, washing in milliQ water for 
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2 minutes and soaking in membrane transfer buffer (80 % 1x protein electrophoresis 
buffer, 20% methanol) for 10 minutes at room temperature.  After protein transfer, the 
PVDF membranes were incubated in blocking solution [1x PBS, 5 % (w/v) non fat 
milk powder, 0.05 % (v/v) Tween-20] overnight on a rocking platform at 4 ºC.  
 
2.4.5 Probing membrane with antibodies and signal detection 
Following overnight blocking, PVDF membranes were stained with primary 
antibodies (anti-H2A, anti-H2B, anti-H3, or anti-H4) for 1 hour at room temperature 
on a rocking platform. Membranes were then washed 4 times, for 10 minutes each, in 
membrane wash solution [1x PBS, 0.05 % (v/v) Tween-20]. Subsequently, the 
membranes were incubated with secondary antibody (section 2.4.1) for 1 hour at room 
temperature on a rocking platform. Membranes were washed 5 times, for 10 minutes 
each, in membrane wash solution. Protein-antibody complexes were detected using 
the Enhanced Chemiluminescence System (ECL, Amersham, UK). Briefly, 
membranes were incubated with a 40:1 mixture of solutions A and B respectively. 
Then the excess liquid was removed using thick blotting paper (Whatman), and the 
membranes were wrapped in acetate membrane, placed in an X-ray film cassette and 
overlaid with high performance chemiluminescence film.  Exposed film was 
developed using an automated developer/ fixer.  
 
2.4.6 Probing membranes with antibody to a reference protein  
To assess protein loading and transfer efficiency, membrane blots were probed for α-
tubulin as a reference. Typically, membranes were incubated with a primary antibody 
immunoreactive against α-tubulin for an hour at a room temperature on a rocking 
platform. Membranes were then washed 4 times, for 10 minutes each, in membrane 
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wash solution (section 2.4.5). Membranes were then incubated with secondary 
antibody (section 2.4.1) for an hour at room temperature on a rocking platform, 
followed by washing 5 times, for 10 minutes each, in membrane wash solution. 
Protein-antibody complexes were detected using ECL as described in section 2.4.5. 
 
2.4.7 Colloidal blue staining of protein gels          
Colloidal blue stain was used to assess protein loading when a house keeping 
antibody could not be used. The colloidal blue stain was prepared following the 
manufacturer’s instructions (Invitrogen, UK). Briefly, stain was made up of 55 % 
deionised water, 20 % methanol, 5 % stain B and 20 % stain A.  Protein samples were 
resolved by SDS-PAGE, run at 80V for 2 hours in 1x protein electrophoresis running 
buffer. Gels were then incubated in colloidal blue stain overnight on a rocking 
platform at room temperature. Subsequently, gels were destained in distilled water for 
2 hours on a rocking platform at room temperature. Gels were examined on a light 
transilluminator and images were recorded using Uvitec gel documentation with 
UVIband software (UVtech, Cambridge, UK). 
 
2.4.8 Band quantification by densitometry 
The intensities of protein bands were measured using densitometry software [UVItec 
(UVIband software), UK)] on a gel documentation system [UVItec (Model (BTS-
26M), UK)]. 
 
2.4.9 Data analysis 
All data were statistically analysed using a commercially available software package 
(InStat, Graphpad Software, USA).  Differences between groups were detected by one 
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way ANOVA followed by Dunnett's post test, unless otherwise indicated in the text or 
figure legends. Results are expressed as mean ±standard error of the mean (SEM) for 
all experiments. Data were taken to differ significantly only at a p value of 0.05 or 
less.  
 
2.5 RNA microarray and bioinformatics analysis 
2.5.1 RNA extraction and purification 
Human intestinal Caco-2 cells or human MCF-7 breast cancer cells were treated with 
resveratrol (10 µM) for 48 hours (section 2.1.3). Total RNA was extracted using 
TRIzol Reagent according to the manufacturer's instructions (PureLink
®
RNA Mini 
Kit, Invitrogen). One millilitre of Trizol was added to each well and the cell lysate 
was passed several times through a pipette tip before transferring into a microfuge 
tube. After incubation at room temperature for 5 minutes, 200µl chloroform was 
added. The tube was shakenvigorously by hand for 15 seconds and incubated at room 
temperature for 2-3 minutes and centrifuged at 12,000xg for 15 minutes at 4 °C. Four 
hundred microlitres of the colourless, upper phase containing the RNA was 
transferred to a fresh RNase-free tube. Equal volume of 70% ethanol was added and 
mixed well by vortexing. Up to 700 µl of samples were transferred to a spin cartridge 
with a collection tube and centrifuged at 12,000xg for 15 seconds at room 
temperature. The flow-through was discarded and the spin cartridge was reinserted 
into the same collection tube. 700 µl wash buffer 1 was added to the spin cartridge 
and centrifuged at 12,000xg for 15 seconds at room temperature. The flow-through 
and the collection tube were discarded and the spin cartridge was inserted into a new 
collection tube.  Five hundred microlitres wash buffer II with ethanol was added to 
the spin cartridge and centrifuged at 12,000xg for 15 seconds at room temperature. 
 53 
The flow-through was discarded and the spin cartridge was reinserted into the same 
collection tube and centrifuged at 12,000xg for 1 minute at room temperature to dry 
the membrane with bound RNA. The collection tube was discarded and the spin 
cartridge was inserted into a recovery tube. Thirty microlitres of RNase-free water 
was added to the centre of the spin cartridge, incubated at room temperature for 1 
minute followed by centrifuging at 12,000xg for 1 minute at room temperature. The 
flow-through containing RNA was stored in -80 °C until used. 
 
2.5.2 Determination of RNA concentration and purity 
RNA concentration was measured using the Nanodrop spectophotometer (Thermo, 
USA). Briefly, 1µl of each sample was applied directly onto the nanodrop lower 
optical surface. RNA concentration was automatically measured by nanodrop 
software.  RNA free water was used as a blank. 
To assess RNA purity, the ratios of A260/A280 and A260/A230 were analysed by 
Nanodrop. Basically, RNA with an A260/A280 ≥ 2.0 and an A260/A230 ≥1.8 was 
considered as a highly intact RNA. 
  
2.5.3 Determination of RNA stability using the Agilent 2100 bioanalyser 
RNA integrity was measured using the Agilent 2100 Bioanalyzer (RIN=10). Agilent 
RNA 6000 Nanochips were loaded with RNA using the RNA 6000 Nano assay kit 
(Agilent Technologies, workingham, UK) following the manufacturer’s instructions.  
A RIN (RNA integrity number) is generated by an algorithm as a measure of the 
degradation of RNA molecules. The value of a RIN ranges from 1 (totally degraded 
RNA) to 10 (totally intact RNA). For downstream applications RINs above a 
threshold of 7 are considered acceptable. 
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2.5.4 Gene expression profiling  
Global gene expression profiles were determined by hybridization to the whole 
genome Illumina HumanHT-12v3 single colour beadchip microarray. Two biological 
replicates for each cell line (Caco-2 and MCF-7) and each condition (control or 
resveratrol treated) were hybridised separately to arrays. Sample processing and 
hybridisation was carried out by Arrayexpression (Leiden, the Netherlands). Ingenuity 
Pathway Analysis (IPA) was used to identify the pathways affected by resveratrol 
treatment. 
 
2.5.5 Analysis of microarray data 
Microarray data were imported to GeneSpring GX 11 (Agilent) for visualisation. 
Hierarchical clustering analysis was used to measure the relative similarity among 
biological replicates. Probes with an lllumina detection p value >0.6 in all samples in 
replicate groups were considered as expressed. Rank products (Rank Prod) analysis 
was used to identify differential expression between groups as probes with a 
percentage of false positives (PFP) of <0.05 over 100 permutations of the class labels 
with a resulting fold change of >1.5. 
 
2.5.6 Gene identifier conversion 
To compare data generated by microarray analysis of RNA extracted from Caco-2 and 
MCF-7 cell lines and data compiled from published studies in mice, all gene 
identifiers were converted to the equivalent Ensembl identifier, using the Ensemble 
Biomart Gene Conversion Tool at www.ensembl.org/biomart.  
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2.5.7 Gene list intersections 
Gene lists converted into Ensembl identifiers (section 2.5.8) were compared and 
duplicates identified using the Advanced Filter> Unique Records option in Excel 
(Microsoft). 
 
2.5.8 Statistical analysis of gene list intersections  
To determine whether the number of genes shaved between different lists was greater 
or fewer than expected of independent groups by chance, the representation factor 
was calculated by applying the following equation: 
X/[(nD)/N] 
where X was the number of genes common between groups, n was the number of 
genes in one list, D the number of genes in the other list and N the total number of 
genes. A representation factor of >1 indicated a larger intersections than would be 
expected from two unrelated independent groups. 
 
The cumulative hypergeometric probability was calculated by applying the following 
equation: 
h ( ≥ X; N, n, D ) = [ DCX ] [ N-DCn-X ] / [ NCn ] 
 
where N is the total number of genes, n is the number of genes in one list,  D is the 
number of genes in the other list,  X is the number of genes common between groups, 
and  DCX is the number of combinations of D event, taken X at a time. The StatTrek 
hypergeometric calculator tool at http://stattrek.com was used to calculate cumulative 
hypergeometric probability.  
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2.6 Gene expression analysis 
2.6.1 Design of PCR primers  
Gene or cDNA sequences were identified using tools available through NCBI 
http://www.ncbi.nlm.nih.gov/. Oligonucleotide primers were designed using 
PrimerQuest
SM
 (http://eu.idtdna.com/Scitools/Applications/Primerquest/Default.aspx).   
Primers were between 18 and 24 bases in length with a melting temperature greater 
than 55 °C and GC content 50-60%. To improve efficiency of binding to the DNA 
template, oligonuclotides contained a G or C residue at the 3` end. Primers were 
synthesised by MWG Biotech Ltd., UK. 
 
2.6.2 RNA extraction  
Total RNA was extracted from Caco-2 and MCF-7 cells using TRIzol reagent, 
according to the manufacturer's instructions (Invitrogen).  
 
2.6.3 Determination of RNA concentration and purity 
RNA concentration and purity were measured using the Nanodrop spectophotometer 
(Thermo, USA).  
 
2.6.4 DNase treatment of RNA 
RNA samples were routinely subjected to DNase treatment to remove any DNA 
contamination. Each reaction mixture contained 4.5µg of RNA, 4.5 U DNase (Roche) 
and 2µl of 10x DNase buffer (Roche). RNase free water was added to reach a final 
volume 20µl. The reaction was incubated at 37 ºC for 30 minutes, then 4 µl of stop 
solution (EDTA, 20 mM, PH 8.0) was added. The samples were incubated at 65 °C 
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for 10 minutes then the RNA was placed on ice if required for use immediately or 
stored at -80 °C.   
 
2.6.5 Reverse transcription 
Five microlitres (approximately 2µg) of RNA were reverse transcribed to 
complementary DNA (cDNA). The reverse transcription reaction consisted of two 
steps. In the first step, 5 µl of RNA (2 µg), 1 µl random primers, 0.4 µl dNTP (100 
mM) and sterile MilliQ water were mixed to total volume of 13 µl. This mixture was 
incubated at 65 ºC for 5 minutes and then transferred to ice. The second step consisted 
of the addition 4 µl of 5x First Strand Buffer (250 mM Tris-HCl), 1µl 0.1 M DTT, 1µl 
RNase inhibitor (40 u/µl) and 1 µl Superscript reverse transcriptase (SSIII, 
Invitrogen) (200 u/µl). To act as a negative control a second reverse transcriptive 
reaction was carried out omitting the SSIII enzyme. These mixtures were incubated at 
25 ºC for 5 minutes, 50 ºC for 45 minutes and the reaction was held at 4 ºC. 
 
2.6.6 Polymerase chain reaction (PCR) 
PCR reactions were performed using the following: 0.15 µl of 5 u/µl Taq DNA 
polymerase (Bioline), 1x Thermostart H-buffer (MgCl2 free), 1.2µl of 25 mM MgCl2, 
0.3µl of 25 mM dNTPS, 2 µl of 5 µM sense primer and 2 µl of 5 µM antisense primer 
made up to final volume of 20 µl with MilliQ water and including 1 µl of reverse 
transcription-generated cDNA. 
 
Thermal cycling for reactions to ERα and ERβ was as follows: 
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95 ºC for 15 minutes (hot start)  
95 ºC for 30 seconds denaturation 
60 ºC for 30 seconds annealing 
72 ºC for 90 elongation 
72 ºC for 2 minutes final elongation 
4 ºC hold 
Thermal cycling for amplification of GAPDH, a reference gene, was as follows: 
 
95 ºC for 15 minutes (hot start)  
95 ºC for 30 seconds denaturation 
55 ºC for 30 seconds annealing 
72 ºC for 90 elongation 
72 ºC for 2 minutes final elongation 
4 ºC hold 
 
All primers are listed in Table 2.2 A. After PCR, the products were analysed by 
agarose gel electrophoresis.  
 
2.6.7 Agarose gel electrophoresis 
For DNA analysis, agarose gels were prepared by boiling 1% agarose in 1x TBE 
buffer (made up as 10x: 108g/l Tris base, 55 g/l boric acid, 40 ml 0.5 M EDTA; pH 
8.0). Two microlitres of ethidium bromide (10 mg/ml) was added to the cooled gel 
solution before pouring into the gel apparatus. Five microlitres of PCR products were 
mixed with 2 µl 5x gel loading buffer (50 mM Tris-HCl pH 8, 5 mM EDTA, 20 % 
glycerol and 0.1 % Bromophenol Blue) and loaded onto agarose gels. DNA ladder-I 
40 cycles 
29 cycles 
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(Bioline) was used as a molecular weight standard. The gel was run for 30 minutes at 
70V. DNA was visualised on a UV transilluminator and images were recorded using 
Uvitec gel documentation with UVIband software (UVtech, Cambridge, UK). 
 
2.7 Generation and manipulation of DNA plasmid constructs 
2.7.1 Determination of gene promoter sequence 
The sequence of the promoter region of the histone H3 gene was retrieved in FASTA 
format using the Gene2promoter software (Genomatrix, Germany). To ensure the 
promoter lay upstream of the transcription start site (TSS), the promoter sequence was 
aligned against the transcript. 
  
2.7.2 Polymerase chain reaction (PCR) 
PCR reactions were performed as described in section 2.6.6.  Thermal cycling for 
amplification of the histone H3 promoter was as follows: 
 
 
95 ºC for 15 minutes (hot start)  
95 ºC for 30 seconds denaturation 
60 ºC for 30 seconds annealing 
72 ºC for 90 elongation 
72 ºC for 2 minutes final elongation 
4 ºC hold 
 
After PCR, the products were analysed by agarose gel electrophoresis as described in 
section 2.6.7. All primers are listed in Table 2.2 B  
35 cycles 
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2.7.3 Cloning of PCR products into pBlue-TOPO 
PCR products were cloned into the pBlueTOPO vector (Invitrogen, UK) according to 
the manufacturer's protocol. Briefly, 4µl of PCR product were mixed with 1 µl salt 
solution and 1µl vector. The ligation reaction was incubated for 5 minutes at room 
temperature, and then 2 µl of this reaction was added to chemically competent 
OneShot TOP E.coli cells, which were then incubated on ice for 30 minutes, then 
heat-shocked at 42 °C for 30s, before adding 250 µl SOC media. Cells were incubated 
with shaking for 1 hour at 37 °C. The transformed cells were grown overnight at 
37 °C on Luria Bertani (LB)-agar plates (1% peptone, 1% NaCl, 0.5% yeast extract, 
15 g/L agar) containing 50 µg/ml ampicillin.   
 
2.7.4 Plasmid DNA preparation 
Single bacterial colonies were cultured in 5 ml LB-broth (1% peptone, 1% NaCl, 
0.5% yeast extract) containing 50 µg/ml ampicillin at 37 °C with shaking overnight. 
Plasmid DNA was extracted using the Eppendrof Miniprep Kit (Qigaen) according to 
the manufacturer’s protocol. To extract plasmid DNA in large quantities, an 
endotoxin-free maxiprep kit (Qiagen) was used according to the manufacturer’s 
instructions. 
 
2.7.5 Digestion of plasmid DNA with restriction endonucleases 
To determine if plasmid DNA contained the correct insert, digestion with Hind III 
was used. The reaction was prepared by adding 5 U Hind III to 1x reaction buffer in a 
final volume of 20 µl. The reaction was then incubated at 37 °C for 1-2 hours. The 
digestion products were detected by agarose gel electrophorsis as described in section 
2.6.7.   
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2.7.6 DNA sequencing 
Plasmids were sequenced by MWG Biotech. 
 
2.8 Mutagenesis of promoter-reporter plasmid constructs 
Estrogen response elements (ERE) identified within the histone H3 promoter 
sequence included in the promoter reporter construct were mutated using a PCR-
based method. Primers were designed to introduce mutations into three sites at which  
consensus ERE sequences were present within the histone H3 promoter region in the 
construct using PCR with the wild-type promoter-reporter construct as the template. 
PCR product including mutated regions was then subcloned into the pBlue TOPO 
vector (Invitrogen) as described in section 2.7.4.   
 
 The procedure involved introducing each mutation sequentially in three PCR 
reactions, the products of which were joined also by PCR. To avoid reamplifying the 
wild-type promoter sequence from contaminating wild-type plasmid in the final step, 
random primer sequences were introduced at the 5` and 3` ends of the required 
product, and primers matching these sequences were used for the final amplification. 
In the first PCR reaction the 5` region of the promoter including one of the EREs was 
generated and the ERE was replaced with random sequence. In the second reaction, 
the middle region of the promoter including the second ERE was generated and the 
ERE was replaced with random sequence. These two products were then joined in a 
third PCR reaction. In a fourth PCR reaction the 3` region of the promoter including 
the third ERE was generated and the ERE was replaced with random sequence. The 
products of the third and fourth PCR reaction were then joined using the unique outer 
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primers (to the random sequence). All PCR reactions were carried out using the 
following thermal cycling parameters: 
 
 
95 ºC for 15 minutes (hot start)  
95 ºC for 30 seconds denaturation 
65, 64, 63…,50 ºC for 30 seconds annealing 
72 ºC for 90 elongation 
72 ºC for 2 minutes final elongation 
4 ºC hold 
The successful mutation of the three EREs in the histone H3 promoter sequence was 
confirmed by sequencing (MWG Biotech).  All primers are listed in Table 2.2 C  
 
2.9 Transient transfection of mammalian cells 
For transfection, Caco-2 cells were seeded into 6-well plates at a density 3.5x10
5
 
cells/well and incubated for 24 hours at 37 °C. After 24 hours incubation, cells were 
transfected using GeneJammer tansfection reagent (Stratagene Europe, Netherlands). 
For each well, a 100 µl volume of transfection mixture was prepared by adding 4.5 µl 
GenJammer to 1.75 µg plasmid DNA in serum and antibiotic-free medium. Cells 
were supplemented with 900 µl growth medium and transfection mixture was added 
in dropwise manner. Then, cells were incubated for 4 hours at 37 ºC prior to the 
addition of 1ml of complete medium. Cells were incubated for a further 24 hours. 
Transfected cells were subjected to treatment with resveratrol as described in section 
2.1.3.  
 
40 cycles 
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2.10 Reporter gene assays  
2.10.1 Preparation of whole cell lysate  
Cells in 6-well plates were washed with 1 ml ice-cold PBS per well, followed by 
addition 100 µl of lysis buffer (0.25 M Tris (pH7.4), 0.25 % (v/v) Nonident P40, 2.5 
mM EDTA). Cells were then frozen at -20 °C for 30 minutes. After 30 minutes, cells 
were thawed at room temperature. Cells in each well were harvested using a sterile 
cell scraper, transferred to 1.5 ml microcentrifuge tubes and centrifuged at 13,000 g 
for 5 minutes at 4 °C.  The supernatant fluids were transferred to new tubes. 
  
2.10.2 Determination of protein concentration 
The bradford assay was used to measured protein concentration of cell lysates using a 
96 well plate. A standard curve was generated by preparation of 0, 20, 40, 60, 80, 100 
µM solution of bovine serum albumin (BSA) in a final volume 50 µl. Bradford 
reagent (Biorad, UK) was diluted (1:5), and 200 µl of the reagent was added to 50 µl 
of diluted cell lysates (1:50) or BSA standard.  Standards were prepared and measured 
in triplicate and samples in duplicate. Absorbance was measured at 595 nm using a 
plate-reader (Thermo Labsystems Multiskan Ascent). Protein concentrations of 
samples were measured from the standard curve.   
 
2.10.3 β-galactosidase reporter assays 
Reporter assays were carried out by adding 20 µl of cell lysate to 130 µl of 1.2 mg/ml 
chlorophenol red-β-D-galactopyranoside (CPRG) in buffer containing 25 mM MOPS, 
100 mM NaCl, 10 mM MgCl2,  at pH 7.5 and incubating at 37 °C. When a red colour 
was observed, the reaction was stopped by the addition of 80 µl 0.5 M Na2CO3. 
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Absorbance was measured at 650 nm on a plate-reader (Thermo Labsystems 
Multiskan Ascent). 
 
2.10.4 Data analysis 
The activity of β-galactosidase was measured as nanomoles of chlorophenol red 
formed per minute per mg of total protein. All data were statistically analysed using a 
commercially available software package (InStat, Graphpad Software, USA).  
Differences between groups were detected by one way ANOVA followed by 
Dunnett's post test. Results are expressed as mean ±standard error of the mean (SEM) 
for all experiments. Significance was taken as a p value of 0.05 or less.  
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2.11 Antibodies and Oligonucleotide 
Table 2.1: Antibodies 
A 
Primary antibodies Symbol Source Dilution 
Anti- histone 2A  
Anti- histone 2B  
Anti- histone 3  
Anti- histone 4  
Anti-alpha tubulin 
H2A 
H2B 
H3 
H4 
Abcam 
Abcam 
Sigma 
Abcam 
Sigma 
1:250 
1:250 
1:1000 
1:250 
1:250 
 
B 
Secondary antibody Source  Dilution  
Anti-rabbit IgG peroxidase conjugate Sigma 1:3000 
 
 
Table 2.2: Oligonucleotide 
A 
Target and   
Genbank accession no. 
Primer sequences (5`→3`) Product 
size (bp) 
ERα 
NM 000125 
  GGATACGAAAAGACCGAAGAG   
  GTCTGGTAGGATCATACTCGG  
 
  236 bp 
ERβ 
NM 001437  
  TAGTGGTCCATCGCCAGTTATCAC   
 GCACTTCTCTGTCTCCGCACAA  
 
  438 bp 
GAPDH 
NM 002046 
TGAAGGTCGGAGTCAACGGATTTG  
CATGTAAACCATGTAGTTGAGGTC  
 
  170 bp 
 
 66 
B 
Target and   
Genbank  
accession no. 
Product  Primer sequences  Product 
size (bp) 
Histone 3 ( H3m)  
M26150 
H3For 
H3Rev 
GTGGGAGAAGTGCCATGCAGCAC 
CTTGCCTGCAGAGACGTCTGTG 
862 bp 
 
C: The primers were used to generate the histone H3 promoter-reporter construct 
contained with mutations introduced at three identified sites with ERE consensus 
sequence. The unique primer sequences are in lower case, the mutated sequence is 
highlighted in red.  
Product  Primer sequences (5`→3`) 
H3unq1 tattaccgacgcccggcggc 
H3unq2 aaagtgaatggcgtgtgggc 
H3Fwdunq1 tattaccgacgcccggcggcGTGGGAGAAGTGCCATGCAGCAC 
H3Revunq2 aaagtgaatggcgtgtgggcCTTCCTGCAGAGACGTCTGTG 
H3MutFor1 GGAAGTGTTAAAACCCGCATCAAACACACAAGTTTGAATATG 
H3MutRev1 CATATTCAAACTTGTGTGTTTGATGCGGGTTTTAACACTTCC 
H3MutFor2 CTAAGAGCATTTTTCTAATATAGAACACTTCTTATGCGACACCC 
H3MutRev2 GGGTGTCGCATAAGAAGTGTTCTATATTAGAAAAATGCTCTTAG 
H3MutFor3 CGTCAGAGTAGCTACGGTAATACCACGGAGCCTCTCTTAATCTGC 
H3MutRev3 GCAGATTAAGAGAGGCTCCGTGGTATTACCGTAGCTACTCTGACG 
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3 The effect of resveratrol on histone expression  
3.1  Introduction  
Resveratrol, a phytoalexin natural product, is produced in several plants to protect against 
infection by bacteria or fungi (Fremont, 2000). The presence of resveratrol in red wine 
attracted the attention of scientists as a possible explanation for the phenomenon known as 
the “French paradox”, which is a term used to describe the relatively low rates of 
cardiovascular disease and obesity among the French population despite their high fat diet 
and regular consumption of red wine (Renaud and de Lorgeril, 1992). Several studies have 
further reported potential biological benefits of resveratrol as a factor in the aetiologies of 
diseases including cardiovascular disease (Wang et al., 2012), cancer (Sun et al., 2008), and 
diabetes (Palsamy and Subramanian, 2008). Additionally, resveratrol has been reported to 
promote longevity/lifespan in various species from yeast to mouse (Howitz et al., 2003; 
Cohen et al., 2004; Borra et al., 2005), potentially through stimulating the NAD
+ 
-dependent 
deacetylases enzymes, Sirt2 and Sir1, respectively (Howitz et al., 2003; Cohen et al., 2004). 
These enzymes deacetylate a large number of proteins and regulate many critical cellular 
processes including transcription, metabolism, DNA repair, and stress resistance (review in 
Kelly, 2010). 
 
The mechanism by which resveratrol induces these biological effects is not completely 
understood. This study aimed to investigate the mechanism by which resveratrol influences 
longevity/lifespan. The ability of resveratrol to stimulate the histone deacetylase Sirt1 raises 
the question as to whether resveratrol promotes longevity through its effects on histone 
acetylation.  To answer this question previous work in the laboratory investigated the effect 
of resveratrol on histone acetylation.  Caco-2 cells were treated with 10 µM resveratrol for 48 
hours, then semi-purified histone proteins were analysed by western blotting using an 
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antibody specific for histone 4 (H4) acetylated at Lys16 or using an antibody immunoreactive 
against H4 irrespective of acetylation status. As shown in figure 3.1 both anti-H4 antibodies 
revealed a marked reduction in the H4 signal after treatment of Caco-2 cells with resveratrol 
indicating that resveratrol treatment reduced H4 protein expression, rather than affecting 
acetylation status (L Wakeling and D Ford, personal communication). 
 
Based on this finding, it was proposed that the ability of resveratrol in promoting longevity 
may be mediated through effects on histone expression. Therefore, the effect of resveratrol 
(at a physiological concentration at 10 µM) on histone expression was investigated using two 
different cell lines: Caco-2 (human intestinal) and MCF-7 (human breast cancer). 
 
 
 
                                                              
 
      
Figure 3.1: The effect of resveratrol (+) on histone 4 (H4) acetylation and H4 expression 
in the Caco-2 cell line. H4 acetylation and H4 expression were detected by western blot 
analysis using an antibody specific for H4 acetylated at Lys16 or using antibody 
immunoreactive against H4 irrespective of acetylation status. (A) Western blot using an 
antibody with reacting against H4 acetylated at Lys16. A notable decreased in histone H4 
acetylation in the cells treated with resveratrol is evident. (B) Western blot using antibody 
immunoreactive against H4 irrespective of acetylation status. There is a marked reduction in 
total H4 expression in treated cells with resveratrol (L Wakeling and D Ford, personal 
communication). 
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3.2  Effect of resveratrol on histone expression in Caco-2 and MCF-7 cell lines 
 
The current study investigated the hypothesis that some of the beneficial effects of resveratrol 
on lifespan/aging are mediated through effects on histone expression that oppose changes 
observed in ageing. A further suggestion, although not addressed through the work presented 
in this chapter, is that these epigenetic actions of resveratrol influence the expression of genes 
that affect the ageing process.  
 
For this purpose, two different cell lines were used to determine whether or not the response 
to resveratrol observed previously was cell line specific and to indicate if estrogen receptor 
(ER) status was a determinant of responsiveness. The MCF-7 (ERα-positive, ERβ-positive) 
and Caco-2 (ERβ-positive) cell lines were treated with either 0.01% DMSO (vehicle control) 
or 10 µM resveratrol (in 0.01% DMSO) for 48 hours. Total cell lysate was then analysed by 
western blotting using antihistone antibodies immunoreactive against H2A, H2B, H3, and H4. 
To ensure equal amounts of protein were loaded, the same membrane was probed with an 
antibody immunoreactive against α-tubulin. Quantitative data were derived by densitometric 
quantification of band intensities. Densitometric analysis of the protein bands in relation to α-
tubulin indicated that expression of histone H2A, H2B, H3, and H4 was decreased 
significantly in cells treated with resveratrol (Figure 3.2-3.3).  
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Figure 3.2: The effect of resveratrol (REV) on the level of histone expression in the MCF-7 
cell line. (A) Western blot analysis using anti-histone antibodies for histone H2A, H2B, H3, 
and H4. Typical data are shown. (B) Results of densitometric analysis of western blots 
detecting expression of histone proteins. Data are shown as mean ± standard errors (SEM) 
(n=9, based on four experiments), *P <0.05, **P<0.01, ***P<0.001. The expression of 
histone H2A, H2B, H3, and H4 were significantly decreased in cells treated with resveratrol.  
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Figure 3.3: The effect of resveratrol (REV) on the level of histone expression in the Caco-2 
cell line. (A) Western blot analysis using anti-histone antibodies for histone H2A, H2B, H3, 
and H4. Typical data are shown. (B) Results of densitometric analysis of western blots 
detecting expression of histone protein. Data are shown as mean ± standard errors (SEM) 
(n=9, based on four experiments), **P <0.01, ***P<0.001. The expression of histone H2A, 
H2B, H3, and H4 were significantly decreased in treated cells with resveratrol.  
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3.3 The effect of age on histone expression 
Based on the observations that resveratrol reduced histone protein expression (H2A, H2B, H3, 
and H4) in cultured human (Caco-2 and MCF-7) cells, this study investigated if this reduction 
in histone expression could play a role in the regulation of lifespan/longevity by determining 
if histone expression changed with age. It was hypothesised that the ageing process may be 
associated with an increase in histone expression and that a reversal of this process may 
underline some of the apparent anti-ageing effects of resveratrol. 
 
3.3.1  The effect of age on histone expression in mouse intestine 
To investigate the effect of age on the level of histone expression, small intestinal tissues 
from young and old female mice (at 12 months or 38 months) were studied. Histone 
extraction was conducted using the low concentration acid extraction procedure, followed by 
western blot analysis using anti-histone antibodies for H2A, H2B, H3, and H4. Colloidal blue 
staining of protein preparations resolved by SDS PAGE on gels run in parallel to those used 
for western blotting was used to ensure equal loading of protein samples and to normalise 
protein concentrations. 
 
Figure 3.4 shows histone expression in these young and old mice. The results of 
densitometric analysis of the protein bands show that histone H2A, H2B, and histone H4 
were significantly increased in old mice (38 months) compared with younger mice (12 
months). In contrast, histone H3 did not show a significant change in level of expression. 
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Figure 3.4: The effect of age on histone expression in mouse intestine. Histones were 
detected by western blot analysis using anti-histone antibodies for H2A, H2B, H3, and H4. (A) 
Densitometric analysis of western blot data shown as mean ± standard errors (SEM) (n=3), 
*P <0.05, **P<0.01.  Data are pooled from one analysis for each of H2A and H2B, three 
analyses for H3 and five analyses for H4 and are expressed normalised to the histone signal 
intensity for the young mice. Histone H2A, H2B, and H4 were significantly increased in old 
mice (38 months) compared with younger mice (12 months). Histone H3 did not show a 
significant change in level of expression. (B) Colloidal blue staining of a parallel gel was 
used to ensure equal loading of protein samples. Sizes of molecular weight markers running 
in parallel (left hand lane, as labelled) are indicated. 
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3.3.2  The effect of age on histone expression in human intestine 
To determine if the observation that histone expression increased with age in mouse intestine 
extended to humans, the effect of age on the level of histone expression in human subjects 
was investigated. Total protein was extracted from human colon biopsies of eleven males (at 
21, 23, 33, 43, 64, 66, 73, 74, 77 or 82 years old). Western blot analysis was carried out using 
anti-histone antibodies for H2A, H2B, H3, and H4. Numerical data were derived by 
denstiometric quantification of band intensities.  Blots were probed also with anti α-tubulin 
antibody and data expressed as a ratio of intensities of the two signals.   
 
Figure 3.5 shows the level of histone expression measured in the colon biopsies of these 
young and old males. There was no apparent affect of age on the level of histone expression 
(H2A, H2B, H3, and H4) among these human subjects. 
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Figure 3.5: The effect of age on histone expression in human colon biopsies. Densitometric 
analysis of western blot data shown as mean with standard errors. The age of each subject is 
indicated. Data are pooled from two analysis for each of H2A, H2B and H3 and one analysis for H4 
and are expressed as mean ± standard errors (SEM) normalised to the histone signal intensity for 
the youngest subject. There was insufficient material to measure H4 expression in all subjects. There 
was no apparent effect of age on histone expression levels among these human subjects. 
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3.4  Discussion 
 
Histone proteins are essential proteins that are involved in DNA packing into nucleosomes. 
There are two types of histone proteins, core histone proteins including H2A, H2B, H3 and 
H4, and a linker histone known as H1. Each of the core histone proteins has a flexible N-
terminal tail extending outward. In addition, histones H2A and H2B have a C-terminal tail 
that also extends outward from the nucleosome (Jenuwein et al., 2001, cited in Bilsland, 
2005).    
 
The core histone proteins and their tails (N-terminal and C-terminal) undergo a variety of 
post-translational modifications, together comprising what is known as the "histone code". 
These modifications include acetylation, ubiquitination, methylation and phosphorylation 
(Jenuwein et al., 2001, citied in Bilsland, 2005). These modifications of histone proteins play 
a fundamental role in the regulation of gene expression.  
 
Recently, histone methylation/ acetylation has attracted increased attention as a result of 
findings that indicate role in regulating lifespan in different species. For example, mutations 
in members of the histone H3 methyltransferases have been documented to extend life span 
in the worm (Greer et al., 2010; Maures et al., 2011). Furthermore, stimulation of Sirt1 and 
Sirt2 histone deacetelyeses, by resveratrol or dietary restriction, has been reported to promote 
longevity in different species (Howitz et al., 2003).   
 
Studies in the laboratory, designed with the intention of investigating if resveratrol affects 
histone acetylation, indicated, unexpectedly, an effect on the expression level (rather than 
acetylation status)  of histone proteins in the human intestinal Caco-2 cell line (L Wakeling 
and D Ford, personal communication).  
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The current study investigated the hypothesis that some of the beneficial effects of resveratrol 
on lifespan/aging are mediated through effects on histone expression. Further work would 
then investigate if these epigenetic actions of resveratrol influence the expression of genes 
that affect the ageing process. Towards this goal, the effect of resveratrol on the level of 
expression of histone proteins was investigated in two human cell lines. Caco-2 and MCF-7 
cell lines were treated with resveratrol for 48 hours. Then western blot analysis using 
antihistone antibodies was conducted. The results showed that histone H2A, H2B, H3 and H4 
expression was decreased in response to resveratrol treatment in both cell lines (P<0.05). 
Whereas both cell lines are reported to express ERβ, the Caco-2 cell line is reported to lack 
expression of ERα. The observations therefore indicate that if the observed effect of 
resveratrol is mediated through the ER then ERβ is functional in this regard. Further studies, 
presented in Chapter 5, investigated specifically the role of the ER in mediating effects of 
resveratrol on histone expression.   
The concentration of resveratrol used in the current study (10 µM) is in line with 
concentrations considered achievable physiologically, for example through the consumption 
of resveratrol-rich foods (Mukherjee et al., 2010). The observation may thus indicate an 
effect of resveratrol that could be achieved in vivo; however confirmation using either an 
animal model or, preferably, an intervention study in human participants is necessary to 
confirm such an effect. Studies in vivo would take into account the fact that resveratrol 
undergoes extensive metabolism, with glucuronide and sulphate conjugate being the 
prominent metabolite observed following ingestion (Yu et al., 2002). Resveratrol glucuronide 
and sulphate conjugates are also major circulating metabolites observed in human subjects 
after oral ingestion of resveratrol (Goldberg et al., 2003). Metabolism of resveratrol to 
dihdroresveratrol-glucuronides is also observed as reported in (Rotches-Ribalta et al., 2012). 
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Other confirmatory research could include treatment of cells in vitro with metabolites of 
resveratrol to determine if these compounds have similar effects as the parent molecule on 
histone expression. 
 
The impact, if any, of a reduction in histone expression on lifespan is still unclear but 
conceivable mechanisms through which effects may be mediated included effects on gene 
expression.  To seek supporting data that resveratrol may promote lifespan through its effect 
on histone protein expression, further investigation focused on how histone expression 
changed with age.  
 
There is little information about the effect of age on histone expression. To date, a small 
number of studies have reported a change in histone expression and/or chromatin 
configuration with age. For example, Chaturvedi et al (1985) reported that chromatin 
becomes more compact with age in the rat brain, and it has been observed that ageing in yeast 
is associated with a reduction in histone expression (Feser et al., 2010).      
 
The data presented here indicate that changes in histone expression are associated with age in 
mice. The expression levels of histone H2A, H2B and H4 were increased significantly in the 
intestine of old mice (at 38 months old) compared with young mice (at 12 months old). In 
contrast, no significant difference in the level of histone H3 expression between the two 
groups was detected, but a trend towards the same response as observed for the other histone 
proteins may indicate a need to analyse additional samples to detect an effect that reaches 
statistical significance. The mechanism underlying the influence of ageing on histone 
expression is still unclear. Similarly, the consequences of the observed reduction in histone 
expression are unknown but given that tight association of DNA with histones is a repressive 
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configuration, an expected effect may be reduced expression of genes associated with 
affected histones. Speculatively, such gene repression may lead to progressive ageing, age-
related diseases such as cancer and, ultimately, death (Burzynski, 2003). 
 
In contrast to the observations made in mouse intestine, Feser and colleagues (2010) reported 
a reduction in H3 and H4 expression with age in yeast. The possible explanation for the 
discordant observations may relate to the difference between unicellular yeast and mouse 
tissues.   
In contrast to the observations made in mice, no age-associated difference in histone 
expression in the intestine of human subjects was detected.  
The lack of consistency between the two sets of data-based on samples from mice and 
humans may be due to a number of different factors such as a difference between species, a 
difference between the small intestine (mice) and colon (humans) and a greater inter-
individual variability in human samples, invoking the need to analyse a larger number of 
individuals to observe differences. 
 
Since histone proteins were extracted from gut samples comprising the full thickness, cells in 
the sample would be from the mucosa, submucosa, muscularis, and serosa.  The cell 
population would thus be heterogeneous and include absorptive cells, goblet cells, stem cells, 
enteroendocrine cells, and Paneth cells. (Treuting et al., 2012).  Levels of histone proteins 
detected would thus have reflected the levels of expression in these different cell types, and it 
is possible that the relative proportions of these cells differed with tissue age. An additional 
confounding factor may have been stage of cell cycle. During the cell cycle, histone mRNAs 
accumulate at the maximal levels during S phase. As cells exit S phase, the level of histone 
mRNAs decrease rapidly (Marzluff and Duronio, 2002). Thus, the histone protein quantity 
extracted would differ according to the proportion of cells at different stages in the cell cycle.  
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4  Global effects of resveratrol on gene expression  
4.1  Introduction 
Dietary restriction (DR), reduction of food intake below ad libitum without malnutrition, has 
been reported to promote longevity in diverse species from yeast to mammals (McCay et al., 
1935; Walker et al., 2005). There is evidence that the mechanism is dependent on Sirt1 in 
mammals and on its homologue Sir2 in yeast, but this view has been to subject of vigorous 
challenge, based to a large degree on inconsistent observations made in yeast and flies 
(Burnett et al., 2011). Evidence for the involvement of Sirt1 in mediating the effect of DR on 
lifespan extension in mammals includes that levels of Sirt1 have been documented to increase 
in some mammalian tissues in response to DR (Cohen et al, 2004; Nisoli et al., 2005), and 
that mice lacking Sirt1 (Sirt1-null mice) do not response to DR (Boily et al., 2008).  
While there are potential benefits of DR, the challenges associated with this practice in 
humans has driven attempts to identify natural or artificial compounds with ability to mimic 
the effect of DR. Resveratrol has been reported to mimic to DR and extend lifespan in diverse 
species (Howitz et al., 2003; Wood et al, 2004; Baur et al., 2006). Furthermore, resveratrol 
has been reported to promote longevity of mice under conditions of a high fat diet and to 
oppose the physiological effects of high caloric intake in manner similar to DR (Baur et al., 
2006). The mechanisms by which resveratrol mimics DR and influences lifespan are not 
completely understood. Opinions about the mechanism of action through which resveratrol 
has effects relevant to ageing/ or lifespan are at variance. Some investigators have a view that 
the mechanism is through activation of Sirt1 (Baur et al., 2006), but others challenge this 
opinion (Pacholec et al., 2010).  
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To begin to address the controversy around the possible role of Sirt1 in mediating effects of 
resveratrol that may mimic DR, the response of Caco-2 and MCF-7 cells to resveratrol was 
determined at the level of the transcriptiome with the aim of identifying if genes or pathways 
affected were also affected by manipulation of the expression level of Sirt1, for which a 
comparative data set was available from Caco-2 cells. These data were derived through 
previous work in the laboratory (LJ Ions and D Ford, personal communication).  The extent 
to which genes affected by resveratrol intersected with a list of genes reported to be affected 
by dietary restriction (derived through previous in silico work in the laboratory; LJ Ions and 
D Ford, personal communication) was also determined. 
4.2  The effect of resveratrol on global gene expression in Caco-2 and MCF-7 cell 
lines  
Since reduced histone protein expression in response to resveratrol in Caco-2 and MCF-7 
cells had been previously observed, it was important to conduct this transcriptiome analysis 
on cells where the same response was confirmed, reasoning that many effects on gene 
expression resulting from treatment with resveratrol could be a consequence of these changes 
in histone protein expression. After treatment of cells with 10 µM resveratrol for 48 hours, 
the usual response to resveratrol (reduction in histone protein expression) was confirmed. 
Total cell lysate from control and treated cells was analysed by western blotting using 
antihistone antibodies immunoreactive against H2A, H2B, H3 and H4.  As shown in (Figure 
4.1) histone H2A, H2B, H3 and H4 expression was decreased in response to resveratrol 
treatment in both cell lines.   
RNA was extracted from Caco-2 and MCF-7 cells treated in parallel with 10 µM resveratrol 
for 48 hours. RNA concentration, purity and integrity were measured using the NanoDrop 
spectrophotometer and the Bioanalyzer (Figure 4.2). Global gene expression profiles were 
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determined by hybridization of RNA to the whole genome Illumina HumanHT-12v3 single 
colour beadchip microarray. Two biological replicates for each cell line (Caco-2 and MCF-7) 
and each condition (control or resveratrol treated) were hybridised separately to arrays. 
Sample processing and hybridisation was carried out by Arrayexpress (Leiden, the 
Netherlands).  
Changes in gene expression were considered significant at p <0.05 with a fold change ≥ 1.2.  
The 1.2 fold “cut off” was selected empirically based on the numbers of genes showing 
changes of particular magnitudes. Cut off values in microarray experiments are typically 
guided by characteristics of individual datasets in this way (McCarthy and Smyth, 2009; 
Bjornsdottir et al., 2011).  A relatively low threshold such as this is generally applied in 
studies looking at effects of dietary components on gene expression, where effects tend to be 
modest, and other studies have applied the same (Bjornsdottir et al., 2011) or similar (1.3-
fold) (Huggins et al., 2008) cut off values.  
 
Tables 4.1 and 4.2 list the changes in gene expression in the Caco-2 cell line in response to 
resveratrol treatment. Tables 4.4 and 4.5 list the genes affected by resveratrol treatment in 
MCF-7 cells.  
The pathways affected by resveratrol treatment were analysed using Ingenuity Pathway 
Analysis (IPA). The major pathways that were significantly affected by resveratrol treatment 
in Caco-2 and MCF-7 are presented in Table 4.3 and Table 4.6 respectively. 
Resveratrol affected several metabolic pathways in the Caco-2 cell line. These pathways 
included propanoate metabolism, pyruvate metabolism and synthesis and degradation of 
ketone bodies. Estrogen receptor signalling and glucocorticoid receptor signalling pathways 
were also significantly affected by resveratrol treatment. 
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In the MCF-7 cell line, resveratrol affected several immune system pathways including: 
CTLA4 Signalling in Cytotoxic T Lymphocytes, PKCθ Signalling in T Lymphocytes, 
Calcium-induced T Lymphocyte Apoptosis, and Role of NFAT in Regulation of the Immune 
Response. 
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 Figure 4.1: The effect of resveratrol (REV) on histone protein expression in Caco-2 and 
MCF-7 cells. (A) Results of densitometric analysis of western blots detecting expression of 
histone proteins in Caco-2 cells are shown as mean with standard errors (n=3) *P <0.05, 
**P<0.01. The expression of histone H2A, H2B, H3 and H4 were significantly decreased in 
cells treated with REV. (B) Results of densitometric analysis of western blots detecting 
expression of histone proteins in MCF-7 cells are shown as mean with standard errors (n=3) 
*P <0.05. The expression of histone H2A, H2B, H3 and H4 were significantly decreased in 
cells treated with REV. Sample western blots are shown under each panel. 
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Figure 4.2: Analysis of RNA integrity using the Agilent 2100 bioanalyser. (A) Gel-like 
image generated from bioanalyser electropherogram output of the analysis of RNA samples 
of the control (control) and treated with resveratrol (REV) extracted from Caco-2 and MCF-
7cells. (B) Typical bioanalyser electropherogram output from the control (number1) of Caco-
2 cell line. RNA integrity number (RIN) above the threshold of 7 was required for 
downstream application. 
A 
B 
                                             Sample ≠ 1 of the control of Caco-2 cell line   
RIN: 10                                   
Caco-2 cells MCF-7 cells 
Control (n=3) Control (n=3) +REV (n=3) +REV (n=3) Ladde
r  
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Table 4.1: Genes upregulated in the Caco-2 cell line after treatment with resveratrol  
 
Gene symbol Description Fold change 
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 1.26 
APCDD1 Adenomatosis polyposis coli down-regulated 1 1.20 
AQR Aquarius homolog (mouse) 1.22 
ATP10A ATPase, class V, type 10A 1.25 
BAT3 HLA-B-associated transcript 3 1.21 
BOLA3 BolA homolog 3 1.22 
CCNF Cyclin F 1.32 
DGCR11 DiGeorge syndrome critical region gene 11 1.20 
FKBP5 FK506 binding protein 5 1.20 
IGSF3 Immunoglobulin superfamily member 3 1.20 
MIR586 MicroRNA 586 1.26 
NAT5 n-terminal acetyltransferase b complex catalytic subunit nat5 1.20 
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 1.20 
PIGO Phosphatidylinositol glycan anchor biosynthesis, class O 1.30 
RPS27 Ribosomal protein S27 pseudogene 1.26 
SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) 1.23 
SNRPF Small nuclear ribonucleoprotein polypeptide F 1.25 
UTP14A UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) 1.26 
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Table 4.2: Genes down regulated in the Caco-2 cell line after treatment with resveratrol 
Gene symbol Description Fold change 
AADACL4 Arylacetamide deacetylase-like 4 1.28 
AKR1D1 Aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-
5-beta-reductase) 
1.21 
AMH Anti-Mullerian hormone  1.20 
AOF2 Amine oxidase (flavin containing) domain 2 1.25 
ARID4B AT rich interactive domain 4B (RBP1-like) 1.22 
ARL3 ADP-ribosylation factor-like 3 1.21 
ATF4 Activating transcription factor 4 1.21 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 1.22 
BAZ1A Bromodomain adjacent to zinc finger domain, 1A 1.20 
C1GALT1C1 C1GALT1-specific chaperone 1 1.22 
CBS Cystathionine-beta-synthase 1.34 
CCNC Cyclin C 1.24 
CCT3 Chaperonin containing TCP1, subunit 3 (gamma) 1.29 
CD55 CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) 
1.52 
CGA Glycoprotein hormones, alpha polypeptide 1.42 
CNOT8 CCR4-NOT transcription complex, subunit 8 1.25 
CREB1 cAMP responsive element binding protein 1 1.26 
CSNK1D Casein kinase 1, delta 1.24 
DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 1.31 
DENND1A DENN/MADD domain containing 1A 1.24 
DKFZP761E198 DKFZp761E198 protein 1.20 
DKK3 Dickkopf homolog 3 (Xenopus laevis) 1.25 
FLJ44124 Uncharacterized LOC641737 1.36 
FOSB Fosfomycin resistance protein FosB 1.20 
FZD2 Frizzled homolog 2 (Drosophila) 1.25 
GADD45G Growth arrest and DNA-damage-inducible, gamma 1.30 
HBP1 HMG-box transcription factor 1 1.22 
HSPB1 Heat shock 27kDa protein 1 1.22 
IFT172 Intraflagellar transport 172 homolog (Chlamydomonas) 1.21 
KLF10 Kruppel-like factor 10 1.22 
KLF4 Kruppel-like factor 4 (gut) 1.26 
LGSN  Lengsin, lens protein with glutamine synthetase domain 1.20 
MAK10 
 
MAK10 homolog, amino-acid N-acetyltransferase subunit, (S. 
cerevisiae) 
1.30 
 
MCM8 Minichromosome maintenance complex component 8 1.42 
MED1 Mediator complex subunit 1 1.20 
MIR197 MicroRNA 197 1.24 
NFAT5 Nuclear factor of activated T-cells 5, tonicity-responsive 1.30 
NHLRC3 NHL repeat containing 3 1.25 
NIPSNAP1 Nipsnap homolog 1 (C. elegans) 1.25 
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Continued  
 
Gene symbol Description Fold change 
OVOL1 OVO homolog-like 1 (Drosophila) 1.31 
OXR1 Oxidation resistance 1 1.26 
PAPOLA Poly(A) polymerase alpha 1.26 
PCSK5 Proprotein convertase subtilisin/kexin type 5 1.21 
PCYOX1 Prenylcysteine oxidase 1 1.20 
PINK1 PTEN induced putative kinase 1 1.23 
RPS6KA3 Ribosomal protein S6 kinase, 90kDa, polypeptide 3 1.35 
SAMD4B Sterile alpha motif domain containing 4B 1.27 
SCGN Secretagogin, EF-hand calcium binding protein 1.28 
SCML1 Sex comb on midleg-like 1 (Drosophila) 1.27 
SCYL1 SCY1-like 1 (S. cerevisiae)  1.20 
SKA2 Spindle and kinetochore associated complex subunit 2 1.40 
SLC22A18AS Solute carrier family 22 (organic cation transporter), member 18 
antisenseBottom of Form 
Top of Form 
 
1.26 
SLC39A7 Solute carrier family 39 (zinc transporter), member 7 1.26 
STXBP6 Syntaxin binding protein 6 (amisyn) 1.20 
TINAGL1 Tubulointerstitial nephritis antigen-like 1 1.22 
TP53INP1 Tumor protein p53 inducible nuclear protein 1 1.20 
UBXN6 UBX domain protein 6 1.20 
UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 1.21 
ZNF607 Zinc finger protein 607 1.21 
ZSWIM4 Zinc finger, SWIM-type containing 4 1.22 
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Table 4.3: Pathways affected by resveratrol treatment in the Caco-2 cell line 
 
Ingenuity Canonical Pathways -log(p-value) Genes  
Propanoate Metabolism 3.07E00 ALDH1A1, ACAT2, PCCA, ACAT1, 
ACACA, LDHA 
p53 Signaling 3E00 SCO2, TP53INP1, JMY, GADD45G, 
MED1, CSNK1D, PML 
Pyruvate Metabolism 2.66E00 ALDH1A1, ACAT2, PCK2, ACAT1, 
ACACA, LDHA 
Melanocyte Development and Pigmentation 
Signaling 
2.53E00 RPS6KB1, MITF, CREB1, ADCY1, 
RPS6KA3, ATF4 
Hypoxia Signaling in the Cardiovascular 
System 
2.26E00 CREB1, CSNK1D, ATF4, UBE2J1, 
LDHA 
Glucocorticoid Receptor Signaling 1.86E00 TGFBR2, NFAT5, TAF5, PCK2, 
MED1, CREB1, NCOR2, NFATC4, 
FKBP5, SMARCA4 
Circadian Rhythm Signaling 1.82E00 CREB1, CSNK1D, ATF4 
Cleavage and Polyadenylation of Pre-
mRNA 
1.77E00 PAPOLA, CSTF3 
Synthesis and Degradation of Ketone 
Bodies 
1.77E00 ACAT2, ACAT1 
ERK5 Signaling 1.68E00 RPS6KB1, CREB1, RPS6KA3, ATF4 
Estrogen Receptor Signaling 1.68E00 TAF5, CCNC, PCK2, MED1, NCOR2, 
SMARCA4 
Valine, Leucine and Isoleucine Degradation 1.53E00 ALDH1A1, ACAT2, PCCA, ACAT1 
 
FLT3 Signaling in Hematopoietic 
Progenitor Cells 
1.47E00 RPS6KB1, CREB1, RPS6KA3, ATF4 
Role of IL-17F in Allergic Inflammatory 
Airway Diseases 
1.44E00 CREB1, RPS6KA3, ATF4 
VDR/RXR Activation 1.37E00 CCNC, MED1, NCOR2, KLF4 
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Table 4.4: Genes upregulated in the MCF-7 cell line after treatment with resveratrol  
 
Gene symbol Description Fold change 
CD79A CD79a molecule, immunoglobulin-associated alpha 1.20 
DBN1 Drebrin 1 1.23 
GRINA Glutamate receptor, ionotropic, N-methyl D-aspartate-
associated protein 1 (glutamate binding) 
1.22 
GSTTP2 Glutathione S-transferase theta pseudogene 2 1.35 
IMPDH2 IMP (inosine 5'-monophosphate) dehydrogenase 2 1.20 
MIR1974 MicroRNA 1974 1.30 
NUCB1 CG32190 gene product from transcript CG32190-RA 1.21 
OAZ2 Ornithine decarboxylase antizyme 2 1.22 
PGM5 Phosphoglucomutase-like protein 5 1.44 
SS18L1 
 
Synovial sarcoma translocation gene on chromosome 18-like 
1 
1.21 
STXBP2 
 
Syntaxin binding protein 2 1.20 
ZNF334 Zinc finger protein 334 1.22 
ZNF773 Zinc finger protein 773 1.22 
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Table 4.5: Genes downregulated in the MCF-7 cell line after treatment with resveratrol 
  
Gene symbol Description Fold change 
ANKRD32 Ankyrin repeat domain 32 1.20 
ASB7 Ankyrin repeat and SOCS box containing 7 1.20 
C6orf148 KH homology domain containing 1 1.24 
DCDC2B Doublecortin domain containing 2B 1.21 
GRN Granulin 1.39 
HMG20A High mobility group 20A 1.23 
IFI6 Interferon, alpha-inducible protein 6 1.40 
INSIG1 Insulin induced gene 1 1.21 
KANK2 KN motif and ankyrin repeat domains 2 1.24 
KIF23 Kinesin family member 23 1.21 
LOC441131 Actin related protein 2/3 complex, subunit 3 pseudogene 
5 
1.24 
LOC647349 AP-3 complex subunit sigma-1-like 1.22 
MRPS16 Mitochondrial ribosomal protein S16 1.24 
NUDT9 Nudix (nucleoside diphosphate linked moiety X)-type 
motif 9 
1.23 
PCGF3 Polycomb group ring finger 3 1.20 
RABIF RAB interacting factor 1.23 
RAD51C RAD51 homolog C (S. cerevisiae) 1.22 
UBIAD1 UbiA prenyltransferase domain containing 1 1.20 
ZNRD1 Zinc ribbon domain containing 1 1.23 
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Table 4.6: Pathways affected by resveratrol treatment in the MCF-7 cell line 
 
Ingenuity Canonical Pathways -log(p-value) Genes  
B Cell Development 2.2E00 HLA-DQB1, HLA-DRB5, 
CD79A 
Role of NFAT in Regulation of the Immune 
Response 
2.01E00 HLA-DQB1, GNB1, NRAS, 
LAT, HLA-DRB5, CD79A 
Ephrin Receptor Signaling 2.01E00 PTK2, GNB1, NRAS, 
EPHA1, EFNA3, GRINA 
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis 
1.89E00 HLA-DQB1, TNFSF11, 
HLA-DRB5, CD79A 
Virus Entry via Endocytic Pathways 1.82E00 AP1G2, NRAS, PRKCD, 
TFRC 
CTLA4 Signaling in Cytotoxic T 
Lymphocytes 
1.79E00 HLA-DQB1, AP1G2, LAT, 
HLA-DRB5 
One Carbon Pool by Folate 1.62E00 SHMT1, GART 
Calcium-induced T Lymphocyte Apoptosis 1.56E00 HLA-DQB1, PRKCD, HLA-
DRB5 
PKCθ Signaling in T Lymphocytes 1.48E00 HLA-DQB1, NRAS, LAT, 
HLA-DRB5 
IL-15 Production 1.46E00 PTK2, PTK7 
IL-4 Signaling 1.46E00 HLA-DQB1, NRAS, HLA-
DRB5 
Macropinocytosis Signaling 1.46E00 NRAS, RAB5A, PRKCD 
Glycine, Serine and Threonine Metabolism 1.37E00 TDH, SHMT1, SMOX 
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4.3  The intersections between lists of genes responding to dietary restriction (DR) 
and genes affected by resveratrol treatment 
To investigate if resveratrol has effects similar to dietary restriction (DR), the intersections 
between the lists of genes affected by resveratrol treatment determined in the current 
investigation and a list of genes that respond to DR was identified. For this analysis the list of 
genes affected by dietary restriction was compiled from published studies in mice (LJ Ions 
and D Ford, personal communication). The representation factor (RF) and cumulative 
hypergeometric probability were calculated. A representation factor >1 indicates a greater 
overlap than expected between two independent groups, and hypergeometric probability 
indicates if any over-representation is statistically significant. 
As shown in Figure 4.3, 51 genes were significantly changed in their expression in response 
to both DR and resveratrol treatment in the Caco-2 cell line (Table 4.7B). Out of these genes, 
ten genes were associated with pathways that significantly changed in response to resveratrol 
treatment. These genes are ACAT1, ACAT2, ALDH1A1, ATF4, CSNK1D, FKBP5, GADD45G, 
KLF4, LDHA, and SMARCA4.   
In the MCF-7 cell line, 30 genes responded to both DR and resveratrol treatment (Table 
4.7A). Seven of these genes were associated with pathways that significantly changed in 
response to resveratrol treatment. These genes are AP1G2, CD79A, GRINA, NRAS, PRKCD, 
SHMT1, and TFRC.  
Importantly, both overlaps were greater than expected by chance (RF>1 and P<0.05). 
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Figure 4.3: Intersections between lists of genes affected by resveratrol treatment in Caco-2 
and MCF-7 cell lines and genes responding to dietary restriction (DR), based on a list 
compiled from published studies in mice. 
 
 
 
 
Genes affected by resveratrol 
treatment and DR in Caco-2 
cells (n=51, see Table 4.7B) 
RF=1.34 and P=0.007 
Genes affected by resveratrol 
treatment and DR in MCF-7 
cells (n=30, see Table 4.7A) 
RF=1.3 and P=0.027 
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Table 4.7: List of genes affected resveratrol treatment and DR in Caco-2 and MCF-7 cell lines 
 (A) Genes affected by resveratrol treatment and DR in MCF-7 cells (n=30) 
ENSMUSG00000003379 Cd79a ENSMUSG00000029198 Grpel1 
ENSMUSG00000018882 Mrpl45 ENSMUSG00000030824 Nucb1 
ENSMUSG00000019889 Ptprk ENSMUSG00000034308 Sdr42e1 
ENSMUSG00000020241 Col6a2 ENSMUSG00000034708 Grn 
ENSMUSG00000020534 Shmt1 ENSMUSG00000038145 Snrk 
ENSMUSG00000021203 Otub2 ENSMUSG00000038582 Pptc7 
ENSMUSG00000021286 Zfyve21 ENSMUSG00000039114 Nrn1 
ENSMUSG00000021948 Prkcd ENSMUSG00000040701 Ap1g2 
ENSMUSG00000022464 Slc38a4 ENSMUSG00000049470 Aff4 
ENSMUSG00000022564 Grina ENSMUSG00000053916 Nanp 
ENSMUSG00000022797 Tfrc ENSMUSG00000055053 Nfic 
ENSMUSG00000024145 Pigf ENSMUSG00000056917 Sipa1 
ENSMUSG00000026203 Dnajb2 ENSMUSG00000059208 Hnrnpm 
ENSMUSG00000027852 Nras ENSMUSG00000060126 Tpt1 
ENSMUSG00000029064 Gnb1 ENSMUSG00000031438 Rnf128 
(B) Genes affected by resveratrol treatment and DR in Caco-2 cells (n=51) 
ENSMUSG00000001416 Cct3 ENSMUSG00000028454 Pigo 
 ENSMUSG00000002910 Arrdc2 ENSMUSG00000028776 Tinagl1 
ENSMUSG00000002996 Hbp1 ENSMUSG00000028967 Errfi1 
ENSMUSG00000003032 Klf4 ENSMUSG00000029068 Ccnl2 
ENSMUSG00000003545 Fosb ENSMUSG00000030337 Vamp1 
ENSMUSG00000018736 Ndel1 ENSMUSG00000030772 Dkk3 
ENSMUSG00000018900 Slc22a5 ENSMUSG00000032041 Tirap 
ENSMUSG00000020260 Pofut2 ENSMUSG00000032047 Acat1 
ENSMUSG00000020262 Adarb1 ENSMUSG00000032187 Smarca4 
ENSMUSG00000021453 Gadd45g ENSMUSG00000034285 Nipsnap1 
ENSMUSG00000022037 Clu ENSMUSG00000034584 Exph5 
ENSMUSG00000022415 Syngr1 ENSMUSG00000035248 Zcchc6 
ENSMUSG00000022957 Itsn1 ENSMUSG00000037465 Klf10 
ENSMUSG00000023075 Akirin1 ENSMUSG00000037601 Nme1 
ENSMUSG00000023832 Acat2 ENSMUSG00000038641 Akr1d1 
ENSMUSG00000024039 Cbs ENSMUSG00000041058 Wwp1 
ENSMUSG00000024222 Fkbp5 ENSMUSG00000042406 Atf4 
ENSMUSG00000024487 Yipf5 ENSMUSG00000045160 Bola3 
ENSMUSG00000024713 Pcsk5 ENSMUSG00000045954 Sdpr 
ENSMUSG00000025035 Arl3 ENSMUSG00000050213 Snip1 
ENSMUSG00000025129 Ppp1r27 ENSMUSG00000053279 Aldh1a1 
ENSMUSG00000025162 Csnk1d ENSMUSG00000055491 Pprc1 
ENSMUSG00000025395 Prim1 ENSMUSG00000063229 Ldha 
ENSMUSG00000026730 Pter ENSMUSG00000066026 Dhrs3 
ENSMUSG00000027803 Wwtr1 ENSMUSG00000072082 Ccnf 
ENSMUSG00000031438 Rnf128 
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4.4 The intersections between lists of genes affected by resveratrol treatment and 
genes affected by Sirt1 knockdown 
Towards addressing the question of whether or not resveratrol acts through Sirt1, the 
intersections between lists of genes affected by resveratrol treatment as identified in the 
current analysis and genes affected by knockdown of Sirt1 expression was identified. For this 
analysis a list of genes affected by Sirt1 knockdown in Caco-2 cells derived through previous 
research in the laboratory was used (LJ Ions and D Ford, personal communication). 
As shown in Figure 4.4, only one gene was changed in its expression in response to both 
knockdown of Sirt1 expression and resveratrol treatment in the Caco-2 cell line (Table 4.8B). 
In the MCF-7 cell line, two genes responded to resveratrol treatment that also appeared on the 
list of genes that were affected by Sirt1 knockdown in Caco-2 cells (Table 4.8A). There was a 
remarkable distinction between the genes that responded to resveratrol treatment and to Sirt1 
knockdown in the Caco-2 cell line. As expected, since genes that responded to resveratrol 
treatment in the Caco-2 and MCF-7 cell lines tended also to be distinct, there was also little 
overlap between the list of genes that responded to resveratrol treatment in the MCF-7 cell 
line and to Sirt1 knockdown in Caco-2 cells. 
 
4.5 Occurrence of the ERE in the promoter region of genes affected by resveratrol 
Given that resveratrol has structural similarity to estrogen, promoter regions of the genes 
affected by resveratrol treatment in both cell lines were searched for occurrences of the 
estrogen-response element (ERE) consensus sequence using Genomatix software. Of the 448 
genes affected by resveratrol treatment in Caco-2 cells, the ERE was identified in only 9 
genes. These genes are: NFATC4, NME1, NRG1, CCNC, MED1, NCOR2, PCK2, SMARCA4 
and TAF5. Thus, the analysis indicated either that there was no enrichment of genes likely to 
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respond to estrogen among those responsive to resveratrol or that genes that are estrogen 
responsive have binding sites for the ligand ER complex that differ from the sequence(s) used 
for this search.   
 
 
                 
 
 
Figure 4.4: Intersections between lists of genes affected by resveratrol treatment in Caco-2 
and MCF-7 cell lines and genes affected by knockdown of Sirt1 expression in Caco-2 cells. 
 
 
 
Genes affected by resveratrol 
treatment and Sirt1 knockdown 
in MCF-7 cells (n=2, see Table 
4.8A) 
Genes affected by resveratrol 
treatment and Sirt1 knockdown 
in Caco-2 cells (n=1, see Table 
4.8B)  
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Table 4.8: Genes affected by knockdown of Sirt1 expression and resveratrol treatment in 
Caco-2 and MCF-7 cell lines 
 
(A)  Genes affected by resveratrol treatment and Sirt1 knockdown in MCF-7 cells 
 
Gene symbol Description 
RPS29 Ribosomal protein S29  
TPT1 Tumor protein, translationally-controlled 1 
 
(B) Genes affected by resveratrol treatment and Sirt1 knockdown in Caco-2 cells 
 
Gene symbol Description 
IPO11 Importin 11 
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4.6  Discussion 
Dietary restriction (DR) and resveratrol have been reported to promote longevity in diverse 
species from yeast to mammal through a mechanism that may be dependent on Sirt1 in 
mammals and on its homologue Sir2 in yeast.  
In the work presented in this chapter, we investigated if resveratrol (at a concentration that is 
achievable physiologically) has a similar effect to that of DR or to that of manipulating Sirt1 
expression at the level of gene expression in a human epithelial cell line model. Microarray 
analysis was carried out on RNA extracted from Caco-2 or MCF-7 cell lines treated with 10 
µM resveratrol for 48 hours. The intersections between the derived list of genes affected by 
resveratrol treatment in both cell lines and an available list of genes responsive to DR were 
identified. The finding that both overlaps were greater than expected by chance lends support 
to the view that responses to resveratrol and to dietary restriction have some commonality 
and that resveratrol may mimic some effects of dietary restriction.  
 
Towards investigating if resveratrol exerts its effects through Sirt1, the intersections between 
the lists of genes affected by resveratrol treatment and an available list achieved by 
knockdown of Sirt1 expression in Caco-2 cells was identified. The finding that there was 
very little overlap between genes affected by resveratrol treatment and by knockdown of 
Sirt1 expression adds to accumulating evidence that, contrary to previous opinion, resveratrol, 
at the concentration used in these experiments, does not act through effects on Sirt1. This 
view is supported by in vivo evidence based on a rodent model (Barger et al., 2008a).  In 
contrast, incubation of exogenous Sirt1 with human hyperacetylated histones caused a 
deacetylation at H4K16 and H3K9 (Vaquero et al., 2004).  Moreover, resveratrol treatment of 
a Sirt1
-/-
 mouse myoblast cell line failed to induce the deacetylation of the Sirt1 substrate 
PGC-1α  observed in wild-type myoblasts (Lagouge et al., 2006), suggesting that the 
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resveratrol effect is mediated through Sirt1. Recently, Park and colleagues (2012) reported 
that the activation of Sirt1 by resveratrol appears to be indirect, through cAMP-mediated 
activation AMP-activated protein kinase (AMPK). Resveratrol-activated AMPK may 
increase the level of NAD
+
 in the cell and thereby activate Sirt1 (Um et al., 2010).  
We observed a remarkable lack of commonality between lists of genes and between the 
pathways affected by resveratrol in Caco-2 (intestinal) and MCF-7 (breast cancer) cell lines. 
This observation is concordant with effects reported in vivo, indicating tissue-specific actions 
of resveratrol including actions on Sirt1. For example, Sirt1 expression was regulated 
differently by resveratrol in different tissues of resveratrol-treated mice. The expression of 
Sirt1 was downregulated in the heart but upregulated in the muscle, and did not change in the 
brain (Barger et al., 2008b). Dose dependency is also a factor that should be considered. For 
instance, mice treated with high dose of resveratrol (22.4 mg/kg of body weight) showed 
enhanced longevity and also effects suggesting a role for Sirt1 (Baur et al., 2006). In contrast, 
a low dose of resveratrol (4.9 mg/kg of body weight) showed no effect on lifespan in mice 
and no effect on Sirt1 expression (Barger et al., 2008a). However, direct comparison between 
these two studies is not possible because the background diet differed substantially; mice in 
the study by Baur and colleges received a high fat diet. Dietary levels of resveratrol that may 
be effective thus remain undefined. The concentration of resveratrol used in the current study 
(10 µM) is considered to be physiologically achievable through normal consumption of 
resveratrol-rich foods, but our cell culture models do not necessary reflect exposure of tissues 
in vivo to effects of dietary resveratrol, given that the compound undergoes substantial 
metabolism to glucuronide and sulphate conjugates (Goldberg et al., 2003; Rotches-Ribalta et 
al., 2012). The Caco-2 (intestinal) model may reflect more accurately effects of dietary 
resveratrol given that the metabolites are exposed to the parent compound. For both cell lines, 
101 
 
it would be of interest to measure the level of metabolism of resveratrol that occurs under our 
treatment conditions.    
These data show that resveratrol affected several metabolic pathways in the Caco-2 cell line 
including propanoate metabolism, pyruvate metabolism and synthesis and degradation of 
ketone bodies. A possible explanation for these observations is that, as an intestinal cell line, 
Caco-2 represents the tissue that first encounters absorbed dietary metabolic substrates, so 
perhaps these pathways are particularly susceptible to perturbation.  On the other hand, 
immune system pathways were the principal target of resveratrol in the breast cancer MCF-7 
cell line. These pathways included calcium-induced T lymphocyte apoptosis, and role of 
NFAT in regulation of the immune response. The immune system has a contributory effect in 
early-stage breast cancer (Mouawad et al., 2011), perhaps reflecting that these pathways are 
particularly prone to perturbation in breast cancer cells and thus providing a possible 
explanation for the observed effects of resveratrol. This apparent tissue-specific response to 
resveratrol is also apparent from the microarray data on an individual gene level. For example, 
amyolid precursor protein (APP) gene was upregulated in Caco-2 cells but downregulated in 
MCF-7 cells. This gene is of particular interest in the context of ageing. The APP gene is 
located on chromosome 21 (21q
21.2
) and expressed in different tissues with the highest 
expression in neuronal cells in the central nervous system (CNS) (Zhang et al., 2011). The 
functions of APP protein not fully understood, but a role in regulation of neuron growth and 
survival seems evident (Turner et al., 2003; Priller et al., 2006). The APP protein is the 
precursor molecule of beta-amyloid (Aβ), which is involved in the formation of amyloid 
plaques in the brain of Alzheimer disease patients. Mutation of the APP gene has been 
reported to increase the risk of early-onset of Alzheimer disease (Goate et al., 1991). 
Furthermore,   APP 
-/- 
mice showed features of ageing and neurodegenerative disease 
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including loss of body mass and weakness with reduced expression of synaptic markers 
associated with learning deficit and losses of memory (Prille et al., 2006).  
Some key genes - FOXO1, PGC-1α  and IGF-1- that have been linked with ageing and 
particularly with a modulating effect of DR and/ or Sirt1- were absent from the lists of genes 
found to be affected by resveratrol in Caco2 and MCF-7 cells (Baur et al., 2006).  In contrast, 
these genes have been reported to be affected in different tissues including heart, liver, brain 
and skeletal muscle extracted from mice treated with resveratrol.  
A possible explanation for these discordant observations is the apparent tissue/ cell specificity 
of resveratrol action at the level of gene expression, as indicated by the very different 
response we observed in Caco-2 compared with MCF-7 cells. Microarray data on gene 
responses to resveratrol in intestinal and breast tissues derived from mice treated with 
resveratrol would allow this idea to be tested, but appear unavailable at present in published 
resources. 
 
Further analysis of the transcriptionic data involved investigating if the estrogen-response 
element (ERE) occurred at a higher frequency than expected by chance in genes regulated by 
resveratrol. The search for occurrences of the ERE consensus sequence in the promoter 
regions of the genes affected by resveratrol treatment in both cell lines was carried out using 
Genomatix software. The analysis indicated that genes including the ERE were not enriched 
within the population of genes that responded to resveratrol treatment in either cell line. This 
finding may indicate that resveratrol affects gene expression, generally, through a mechanism 
independent of direct binding of a resveratrol-ER complex to the ERE. Alternatively, an 
interpretation of the results could be that many of the genes do respond through binding of a 
resveratrol-ER complex to sequences in the promoter regions that act as EREs, but that the 
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criteria we used to define EREs were inappropriate for the detection of these sequences. A 
study that investigated the occurrence of the ERE in genes that responded to 17- β estradiol 
found that the ERE sequence was present in only a fraction (Bourdeau et al., 2004). Indeed, 
there are numerous instances cited in the literature where genes without sequences that 
conform to the ERE consensus respond to ligands of the ER in the conventional manner, so it 
is difficult to define elements in gene promoter regions that function as ER-ligand binding 
sites. Should our analysis have shown enrichment for genes including the consensus ERE 
among those that responded to resveratrol then this would be evidence that supports the idea 
that some effects of resveratrol are ER-mediated. The negative results we obtained, however, 
are not sufficient to allow us to conclude that resveratrol actions on gene expression are 
generally independent of the ER. Further research on this topic is thus required. In chapter 5 
of this thesis a direct approach to investigate if effects of resveratrol on histone H3 expression 
are ER-mediated is presented and further discussion around the general topic is included.   
 
Further analysis of microarray data revealed that resveratrol action may be mediated through 
a non-genomic pathway of estrogen action. Two major signalling proteins have been reported 
to be involved in the activation of intracellular signaling cascades by estrogen through non-
genomic pathway: physphatidylinosinol-3 kinase (PI3K) and mitogen-activated protein 
kinase (MAPKs) (Suzuki et al., 2008; Watson et al., 2009). The microarray data revealed that 
resveratrol had an effect on extracellular-signal-regulated kinase 5 (ERK5) signalling in 
Caco-2 cells. ERK5 is a member of the MAPK family and plays an essential role in the 
regulation of cell proliferation, differentiation, and in cardiovascular development (Nishimoto 
and Nishida, 2006). The absence of this effect of resveratrol on the ERK5 pathway in MCF-7 
cells provides further evidence of the tissue specific effect of resveratrol. Further research is 
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required to uncover the role of non-genomic signalling cascades in the mechanism of action 
of resveratrol.  
Confirmation of the results of RNA microarray analysis using real time PCR is a standard 
step to validate these data. There was insufficient time to carry out this validation as a 
component of the research present in this thesis, but other researchers in the laboratory are 
currently confirming responses to resveratrol in MCF-7 and Caco-2 cells of genes identified 
by the microarray analyses presented. These data will be presented to validate the microarray 
studies in any published work that arises.  
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5 The mechanism of action of resveratrol 
5.1  Introduction   
Resveratrol has a structure similar that of known phytoestrogens so may mediate some 
of its action through its interaction with estrogen receptors ERα and/or ERβ. Some 
studies have reported that resveratrol may act as an ER agonist in the MCF-7 breast 
cancer cell line (Gehm et al., 1997; Gehm et al., 2004). In contrast, other studies 
documented apparent ER antagonist action in the same cell line (Kim et al., 2004). 
 
The work presented in this chapter aimed to investigate the mechanism through which 
resveratrol reduces histone protein expression and whether this effect is mediated 
through estrogen receptor.  The hypothesis, based on the structural similarity between 
resveratrol and 17β-estradiol, was that effects of resveratrol on histone expression may 
be mediated through the estrogen receptor (ER). 
 
5.2  Effect of resveratrol on histone expression in cells with different ER status 
in the presence and absence of the ER antagonist fulvestrant 
 
As presented in chapter 3, resveratrol reduced histone protein expression in Caco-2 and 
MCF-7 cells. The work presented in this chapter was aimed to determine whether or 
not this response was related to the expression of estrogen receptors (ER), which may 
be a mechanism through which effects of resveratrol are mediated.  For this purpose 
two different cell lines which differ in their estrogen receptor expression: MCF-7 
(ERα-positive, ERβ-positive) and Caco-2 (ERβ-positive) were used. 
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5.2.1  Confirmation of the ER status of Caco-2 and MCF-7cells  
To confirm the ER status of Caco-2 and MCF-7 cells, RNA was extracted from the 
cells then cDNA reversed transcribed from RNA was amplified using specific primers 
to ERα and ERβ (primer sequences are presented in table 2.2 A).  Figure 5.1 presents 
the PCR products obtained. Products appeared to be of the predicted size for both ERα 
(236 bp) and ERβ (438 bp). The band derived using the ERα primers was confirmed as 
ERα by sequencing. Sequencing of the ERβ product was unsuccessful, thus its identity 
was not confirmed. ERα expression was detected only in the MCF-7 cell line.  In the 
Caco-2 cell line no expression of ERα was detected. In contrast, ERβ expression was 
detected in both cell lines.  
 
        
 
  
 
Figure 5.1: The expression of estrogen receptors ERα and ERβ in MCF-7 and Caco-
2 cell lines. (A) RT-PCR using primers for ERα.  ERα expression was observed in the 
MCF-7 cell line. In contrast, no expression of ERα was detected in Caco-2 cell line. (B) 
RT-PCR using primers for ERβ. ERβ expression was observed in both cell lines. When 
reverse transcriptase was omitted from all reactions no products were observed (data 
not shown).  
(A) 
 
 
  ERα 
 
 
 
  ERβ 
 
 
 
  HL1 
 
 
MCF-7 
 
 
  Caco-2 
 
 
  236 bp 
 
 
  HL1 
 
 
MCF-7 
 
 
  Caco-2 
 
 
    438 bp 
 
 
(B) 
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5.2.2  Effects of resveratrol in the presence and absence of fulvestrant on histone 
protein expression on Caco-2 and MCF-7 cells 
 
MCF-7 and Caco-2 cells were treated with either 0.01% DMSO (vehicle control) or 10 
µM resveratrol (in 0.01% DMSO) for 48 hours in the presence or absence of the ER 
antagonist fulvestrant (0.1 µM). Total cell lysate was analysed by western blotting 
using antihistone antibodies immunoreactive against H2A, H2B, H3 and H4. To ensure 
equal amounts of protein were loaded, the same membrane blot was probed with an 
antibody immunoreactive against α-tubulin. Quantitative data were derived by 
denstiometric quantification of band intensities in relation to α-tubulin.  
 
Visual inspection of the data shown in Figure 5.2A and Figure 5.3A indicates that 
treatment of MCF-7 and Caco-2 cells with resveratrol resulted in a decrease in histone 
H2A, H2B, H3 and H4 expression. Densitometric analysis of the protein bands in 
relation to α-tubulin indicated that expression of histone H2A, H2B, H3 and histone 
H4 was decreased significantly in cells treated with resveratrol. In both cell lines 
(Caco-2 and MCF-7), the effect of resveratrol on histone expressions was reversed in 
the presence of ER antagonist, fulvestrant, consistent with the action of resveratrol to 
reduce histone expression being an ER- mediated response (Figure 5.2B and 5.3B). 
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Figure 5.2: The effect of resveratrol on histone expression in MCF-7 cells in the 
presence and absence of an ER antagonist. (A) Western blot analysis of histone H2A, 
H2B, H3 and H4. Typical data are shown. (B) Results of densitometric analysis of western 
blots detecting expression of histone proteins. Data are shown as mean ± standard error 
(SEM) (n=6, based on three experiments), *P <0.05, **P<0.01, ***P<0.001 by one way 
ANOVA followed by Dunnett's post test. The expression of histone H2A, H2B, H3 and H4 
were significantly decreased in cells treated with resveratrol (REV). In contrast, there was 
no significant change in histone H2A, H2B, H3 and H4 expression in the treated cells with 
REV in the presence of the ER antagonist fulvestrant (FULV).   
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Figure 5.3: The effect of resveratrol on histone expression in Caco-2 cell line in the 
presence and absence of an ER antagonist. (A) Western blot analysis of histone H2A, 
H2B, H3 and H4. Typical data are shown. (B) Results of densitometric analysis of 
western blots detecting expression of histone proteins. Data are shown as mean ± 
standard error (SEM) (n=6, based on three experiments), *P <0.05, **P<0.01, 
***P<0.001 by one way ANOVA followed by Dunnett's post test.   The expression of 
histone H2A, H2B, H3 and H4 were significantly decreased in cells treated with 
resveratrol (REV), whereas there was no significant change in histone H2A, H2B, H3 
and H4 expression in the cells treated with REV in the presence of ER antagonist 
fulvestrant (FULV).  
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5.3  The effect of resveratrol and ER antagonist fulvestrant on the activity of a 
histone H3 promoter-reporter construct in Caco-2 cells 
 
For further investigation of the mechanism through which resveratrol acts to reduce 
histone expression, a promoter-reporter construct comprising the histone H3 promoter 
upstream of the β-galactosidase reporter gene in the vector pBlue TOPO (Invitrogen) 
was generated. Primers (see table 2.2 B) were designed to amplify 826 bp region of the 
histone H3 promoter using PCR (Figure 5.4). PCR products (Figure 5.5) were then 
subcloned directly into the pBlue TOPO vector (Invitrogen). Transformed E.coli 
colonies containing insert in the vector were detected by restriction digest using Hind 
III (Figure 5.5). The insert in the plasmid generated was sequenced (MWG Biotech) to 
confirm identity to the required sequence (Figure 5.6).   
 
Caco-2 cells were transfected transiently with the H3 promoter-reporter construct. 
After transfection (24 hours later), cells were treated with 10 µM resveratrol in the 
presence or absence of the ER antagonist fulvestrant (0.1 µM) for 48 hours. The 
activity of the histone H3 promoter-reporter construct was determined by measuring 
the expression of β-galactosidase.   
 
As shown in the Figure 5.7 resveratrol reduced reporter gene expression and this effect 
was attenuated by fulvestrant, demonstrating that resveratrol acts to reduce histone H3 
expression at the level of transcription through an ER-mediated mechanism. In contrast, 
cells treated with fulvestrant were associated with an increase in histone H3 expression. 
A possible explanation of this finding is the ability of fulvestrant to promote the 
degradation and clearance of ERs, resulting in reduced  availability of ERs to bind with 
phenolic compounds that may present in the medium and the serum used in cell 
treatments.    
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Accession number: M26150 
 
TTTTGCCTAATATTCAGGCGGTGCTGCTGCCTAAGAAAACTGAGAGCCATCATAAGGCCAAGGGAAAGTG
AAGAGTTAACGCTTCATGCACTGCTGTTTTTCTGTCAGCAGACAAAATCAGCCTAACAGCAAAGGCTCTT
TTCAGAGCCACCTACGACTTCCATTAAATGAGCTGTTGTGCTTTGGATTATGCCGCCCATAAAGATGTTT
TTGAGGTGTTTTTAATGGCTTTGAGTGTGGCACTTTTAGTAATTTGTCCTGCAGAAATTAGATCCATAGA
AACCTCAGGAATTCTAGGTATGTGGGAGAAGTGCCATGCAGCACAAAACATGTTTACAGGGGTGATTCGC
GTTAAGTTTCACACACAGCAGTTACTACATTTTAGAGGAAGGAAATTATACCCATGAGTGCATTCCTAAC
TATCTTGAATGGAAGTGTTAAAACCCGCATGCCCCACACAAGTTTGAATATGTCATACCATTTGCTGTAG
CAATTAATGGCATACACAATTGAGAGCACACACATTACCACTGAACATTTGAGTATGTATTTCCCAAAAT
GAGCTTTTTTCCAGTTTGGGGATGTTTTGCTTTGTTTTGGGGTGGAGTCTCCCTCTCGCCCAAGCTGCAG
TGCAGCGGCGTGATAACAGCTCACTGTAACCTCGAACTCGGGCTCAAGCGATCCTCTTGACAGCCTTCTG
AGTAGCTGGGATTACAGGCGAGAGCCGCCACGCCCGGCTAAGAGCATTTTTCTAATTGCCCACACTTCTT
ATGCGACACCCAGAAAAATACAATTTTAAATAAAGCGCATATGCAAATTTCCCTAATCGTCTCCAATATT
CTCTGATTTCTTTTTTATATTTTAACTAGAAACAATTGGAGGTTTCCGCGTTGCTTTGTGTGGTTGTAAA
TTTTAAGACTTCAGGAAACTTTTCCAGTACAAGACTTGTCCACAGTGGATATAGCAGCTAAGGGGTTAAC
AAAATGACGTCAGAGTAGCTACGGTAATGGGCAGGAGCCTCTCTTAATCTGCAACCAGGCACAGAGATGG
ACCAATCCAAGAAGGGCGCGGGGATTTTTGAATTTTCTTGGGTCCAATAGTTGGTGGTCTGACTCTATAA
AAGAAGAGTAGCTCTTTCCTTTCCTCCACAGACGTCTCTGCAGGCAAGCTTTTCTGTGGTTTTGCCATGG
CTCGTACTAAACAGACAGCTCGGAAATCCACCGGCGGTAAAGCGCCACGCAAGCAGCTGGCTACCAAGGC
TGCTCGCAAGAGCGCGCCGGCTACCGGCGGCGTGAAAAAGCCTCACCGTTACCGCCCGGGCACTGTGGCT
CTGCGCGAGATCCGCCGCTACCAAAAGTCGACCGAGTTGCTGATTCGGAAGCTGCCGTTCCAGCGCCTGG
TGCGAGAAATCGCCCAAGACTTCAAGACCGATCTTCGCTTCCAGAGCTCTGCGGTGATGGCGCTGCAGGA
GGCTTGTGAGGCCTACTTGGTAGGGCTCTTTGAGGACACAAACCTTTGCGCCATCCATGCTAAGCGAGTG
ACTATTATGCCCAAAGACATCCAGCTCGCTCGCCGCATTCGCGGAGAAAGAGCGTAAATGTAAAGTCACT
TTTTCATCAGTCTTAAAACCCAAAGGCTCTTTTCAGAGCCACCCACTTATTCCAACGAAAGTAGCTGTGA
TAATTTTTTGTTGTCTTAACAGAACAAATTTCTAAGGACCCCCCCGGAAAGCATTAGACTATGGTCTTAA
AGTTGATTAACAGAAATAACGGTTTGGTCAGTCTTGCAGTGTAGGTTATTTCTGACCTTATTAAGGTGCT
ATTTGGAGAGAAGCTGTGTAAGTCCACTATCATTCAGGCCTCTAGCTTGCTATGATTAGCATTTGTTTAA
ACAACTTTGTAAGAGTAAGGGAAAAATCTGGTAAGTAGTTAACTGGCGCTTACTAGGCATTTTTGCAAAG
CTTTGAAAAGATTAGAAAATTGTGTCTTGCGAGTTCCAGTG 
 
Figure 5.4: The histone H3 promoter region sequence and related primers.  The 
promoter sequence was taken from the human genome sequence. Primers (underlined) 
were designed for amplification by PCR of an 826 bp region of the histone H3 
promoter sequence to generate a PCR product to sub-clone into the pBlue-TOPO 
reporter vector.  
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Figure 5.5: (A) Agarose gel electrophoresis of human histone H3 promoter PCR 
products. cDNA reverse transcribed from Caco-2 RNA was amplified using specific 
primers to produce an 826 bp product comprising the H3 promoter sequnce. (B) 
Agarose gel electrophoresis of restriction digest by HindiIII of recombinant plasmids 
to screen for those containing the H3 promoter sequence. A DNA molecular weight 
marker (Hyperladder I) was run in the lane marked (HL1) sizes are indicated. (C)  
Diagrammatic representations of insertion of the histone H3 promoter sequence into 
the vector pBlue TOPO to generate the H3 promoter- reporter construct.  
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  301   TGTGGGAGAAGTGCCATGCAGCACAAAACATGTTTACAGGGGTGATTCGCGTTAAGTTTC  360 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  58    tgtgggagaagtgccatgcagcacaaaacatgtttacaggggtgattcgcgttaagtttc  117 
 
  361   ACACACAGCAGTTACTACATTTTAGAGGAAGGAAATTATACCCATGAGTGCATTCCTAAC  420 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  118   acacacagcagttactacattttagaggaaggaaattatacccatgagtgcattcctaac  177 
 
  421   TATCTTGAATGGAAGTGTTAAAACCCGCATGCCCCACACAAGTTTGAATATGTCATACCA  480 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  178   tatcttgaatggaagtgttaaaacccgcatgccccacacaagtttgaatatgtcatacca  237 
 
  481   TTTGCTGTAGCAATTAATGGCATACACAATTGAGAGCACACACATTACCACTGAACATTT  540 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  238   tttgctgtagcaattaatggcatacacaattgagagcacacacattaccactgaacattt  297 
 
  541   GAGTATGTATTTCCCAAAATGAGCTTTTTTCCAGTTTGGGGATGTTTTGCTTTGTTTTGG  600 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  298   gagtatgtatttcccaaaatgagcttttttccagtttggggatgttttgctttgttttgg  357 
 
  601   GGTGGAGTCTCCCTCTCGCCCAAGCTGCAGTGCAGCGGCGTGATAACAGCTCACTGTAAC  660 
        | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  358   gatggagtctccctctcgcccaagctgcagtgcagcggcgtgataacagctcactgtaac  417 
 
  661   CTCGAACTCGGGCTCAAGCGATCCTCTTGACAGCCTTCTGAGTAGCTGGGATTACAGGCG  720 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  418   ctcgaactcgggctcaagcgatcctcttgacagccttctgagtagctgggattacaggcg  477 
 
  721   AGAGCCGCCACGCCCGGCTAAGAGCATTTTTCTAATTGCCCACACTTCTTATGCGACACC  780 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  478   agagccgccacgcccggctaagagcatttttctaattgcccacacttcttatgcgacacc  537 
 
  781   CAGAAAAATACAATTTTAAATAAAGCGCATATGCAAATTTCCCTAATCGTCTCCAATATT  840 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  538   cagaaaaatacaattttaaataaagcgcatatgcaaatttccctaatcgtctccaatatt  597 
 
  841   CTCTGATTTCTTTTTTATATTTTAACTAGAAACAATTGGAGGTTTCCGCGTTGCTTTGTG  900 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  598   ctctgatttcttttttatattttaactagaaacaattggaggtttccgcgttgctttgtg  657 
 
  901   TGGTTGTAAATTTTAAGACTTCAGGAAACTTTTCCAGTACAAGACTTGTCCACAGTGGAT  960 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  658   tggttgtaaattttaagacttcaggaaacttttccagtacaagacttgtccacagtggat  717 
 
  961   ATAGCAGCTAAGGGGTTAACAAAATGACGTCAGAGTAGCTACGGTAATGGGCAGGAGCCT  1020 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  718   atagcagctaaggggttaacaaaatgacgtcagagtagctacggtaatgggcaggagcct  777 
 
  1021  CTCTTAATCTGCAACCAGGCACAGAGATGGACCAATCCAAGAAGGGCGCGGGGATTTTTG  1080 
        |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
  778   ctcttaatctgcaaccaggcacagagttggaccaatccaagaagggcgcggggatttttg  837 
 
  1081  AATTTTCTTGGGTCCAATAGTTGGTGGTCTGACTCTATAAAAGAAGAGTAGCTCTTTCCT  1140 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
  838   aattttcttgggtccaatagttggtggtctgactctataaaagaagagtagctctttcct  897 
 
  1141  TTCCTCCACAGACGTCTCTGCAGGCAAG  1168 
        |||||||||||||||||||||||||||| 
  898   ttcctccacagacgtctctgcaggcaag  925 
 
 
 
Figure 5.6: Alignment of sequence data generated from the histone H3 promoter-
reporter construct (bottom line, lower case) with the required sequence.  
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Figure 5.7: The effect of resveratrol and the ER antagonist fulvestrant on the 
activity of a histone H3 promoter-reporter construct in Caco-2 cells.  Caco-2 cells 
were transfected with a promoter-reporter construct comprising either the histone H3 
promoter or with a corresponding negative control construct (negative control), 
without a promoter sequence insert. After transfection (24 hours later), cells were 
treated with resveratrol (RSV; 10 μM) in the presence and absence of fulvestrant 
(FULV; 0.1μM) for 48 hours. Control cells (Control) were treated with DMSO vehicle 
only. Data are shown as mean ± standard error (SEM) (n=9, based on four 
experiments), **P<0.01, ***P<0.001 by one way ANOVA followed by Dunnett's post 
test. The expression of the reporter gene was decreased significantly in response to the 
REV treatment and this effect was attenuated by fulvestrant.   
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5.4 Investigation of the role of EREs in resveratrol-mediated effects on histone 
H3 gene transcription 
 
Estrogen binds ER receptors then regulates the transcription of estrogen-responsive 
genes by either binding to specific sequences (estrogen response elements) within gene 
promoter regions, or by binding to other DNA-bound  transcription factors, such as 
SP1, AP1 or NF-kappaB (Sun, 1998).  
 
To address the potential role of EREs in mediating the effect of resveratrol on histone 
H3 gene expression, EREs identified within the histone H3 promoter sequence 
included in the promoter reporter construct were mutated using a PCR-based method.   
The primers were designed to introduce mutations into three sites at which consensus 
ERE sequences were present within the histone H3 promoter region in the construct 
using PCR (Figure 5.8). The PCR product including the mutated sites was subcloned 
into the pBlue TOPO vector (Invitrogen). Presence of insert in the vector from colonise 
of transformed E.coli was detected by digestion with Hind III then analysis by agarose 
gel electrophoresis (Figure 5.9 and 5.10). The successful mutation of the three EREs in 
the histone H3 promoter sequence was confirmed by sequencing (MWG Biotech) 
(Figure 5.11).  All primers are listed in table (2.2 C). 
 
Caco-2 cells were transfected transiently with either the histone H3 promoter reporter 
construct or with the equivalent construct containing the introduced mutations at the 
EREs. After transfection (24 hours later), cells were treated with 10 µM resveratrol in 
the presence or absence of the ER antagonist fulvestrant (0.1 µM) for 48 hours. The 
activity of the reporter gene (β-galactosidase) was then measured in cell lysates.  
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The activity of both the H3 promoter- reporter construct and of the equivalent construct 
containing mutations to the EREs was decreased significantly in response to the 
resveratrol treatment and this effect was attenuated by fulvestrant in both cases (Figure 
5.12). The results therefore indicated that resveratrol reduced histone H3 expression at 
the level of transcription through the ER but through a mechanism independent of the 
EREs identified in the region of promoter sequence included in the promoter reporter 
construct.  
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Accession number: M26150 
TTTTGCCTAATATTCAGGCGGTGCTGCTGCCTAAGAAAACTGAGAGCCATCATAAGGCCAAGGGAAAGTG
AAGAGTTAACGCTTCATGCACTGCTGTTTTTCTGTCAGCAGACAAAATCAGCCTAACAGCAAAGGCTCTT
TTCAGAGCCACCTACGACTTCCATTAAATGAGCTGTTGTGCTTTGGATTATGCCGCCCATAAAGATGTTT
TTGAGGTGTTTTTAATGGCTTTGAGTGTGGCACTTTTAGTAATTTGTCCTGCAGAAATTAGATCCATAGA
AACCTCAGGAATTCTAGGTATGTGGGAGAAGTGCCATGCAGCACAAAACATGTTTACAGGGGTGATTCGC
GTTAAGTTTCACACACAGCAGTTACTACATTTTAGAGGAAGGAAATTATACCCATGAGTGCATTCCTAAC
TATCTTGAATGGAAGTGTTAAAACCCGCATGCCCCACACAAGTTTGAATATGTCATACCATTTGCTGTAG
CAATTAATGGCATACACAATTGAGAGCACACACATTACCACTGAACATTTGAGTATGTATTTCCCAAAAT
GAGCTTTTTTCCAGTTTGGGGATGTTTTGCTTTGTTTTGGGGTGGAGTCTCCCTCTCGCCCAAGCTGCAG
TGCAGCGGCGTGATAACAGCTCACTGTAACCTCGAACTCGGGCTCAAGCGATCCTCTTGACAGCCTTCTG
AGTAGCTGGGATTACAGGCGAGAGCCGCCACGCCCGGCTAAGAGCATTTTTCTAATTGCCCACACTTCTT
ATGCGACACCCAGAAAAATACAATTTTAAATAAAGCGCATATGCAAATTTCCCTAATCGTCTCCAATATT
CTCTGATTTCTTTTTTATATTTTAACTAGAAACAATTGGAGGTTTCCGCGTTGCTTTGTGTGGTTGTAAA
TTTTAAGACTTCAGGAAACTTTTCCAGTACAAGACTTGTCCACAGTGGATATAGCAGCTAAGGGGTTAAC
AAAATGACGTCAGAGTAGCTACGGTAATGGGCAGGAGCCTCTCTTAATCTGCAACCAGGCACAGAGATGG
ACCAATCCAAGAAGGGCGCGGGGATTTTTGAATTTTCTTGGGTCCAATAGTTGGTGGTCTGACTCTATAA
AAGAAGAGTAGCTCTTTCCTTTCCTCCACAGACGTCTCTGCAGGCAAGCTTTTCTGTGGTTTTGCCATGG
CTCGTACTAAACAGACAGCTCGGAAATCCACCGGCGGTAAAGCGCCACGCAAGCAGCTGGCTACCAAGGC
TGCTCGCAAGAGCGCGCCGGCTACCGGCGGCGTGAAAAAGCCTCACCGTTACCGCCCGGGCACTGTGGCT
CTGCGCGAGATCCGCCGCTACCAAAAGTCGACCGAGTTGCTGATTCGGAAGCTGCCGTTCCAGCGCCTGG
TGCGAGAAATCGCCCAAGACTTCAAGACCGATCTTCGCTTCCAGAGCTCTGCGGTGATGGCGCTGCAGGA
GGCTTGTGAGGCCTACTTGGTAGGGCTCTTTGAGGACACAAACCTTTGCGCCATCCATGCTAAGCGAGTG
ACTATTATGCCCAAAGACATCCAGCTCGCTCGCCGCATTCGCGGAGAAAGAGCGTAAATGTAAAGTCACT
TTTTCATCAGTCTTAAAACCCAAAGGCTCTTTTCAGAGCCACCCACTTATTCCAACGAAAGTAGCTGTGA
TAATTTTTTGTTGTCTTAACAGAACAAATTTCTAAGGACCCCCCCGGAAAGCATTAGACTATGGTCTTAA
AGTTGATTAACAGAAATAACGGTTTGGTCAGTCTTGCAGTGTAGGTTATTTCTGACCTTATTAAGGTGCT
ATTTGGAGAGAAGCTGTGTAAGTCCACTATCATTCAGGCCTCTAGCTTGCTATGATTAGCATTTGTTTAA
ACAACTTTGTAAGAGTAAGGGAAAAATCTGGTAAGTAGTTAACTGGCGCTTACTAGGCATTTTTGCAAAG
CTTTGAAAAGATTAGAAAATTGTGTCTTGCGAGTTCCAGTG 
 
Figure 5.8: The histone H3 promoter region sequence and related primers used to 
introduce mutations at sites with ERE consensus sequences. The primers which 
introduce mutations at the ERE sites are underlined and in bold. The 5 bp sequences 
highlighted  in blue are the ERE sequences to be mutated.   
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Figure 5.9:  Agarose gel electrophoresis of PCR products at stages in the procedure 
used to obtain a histone H3 promoter-reporter incorporating with mutations at three 
identified sites with ERE consensus sequence. In the first PCR reaction the 5` region of 
the promoter including one of the EREs was generated and the ERE was replaced with 
random sequences. In the second reaction, the middle region of the promoter including 
the second ERE was generated and the ERE was replaced with random sequence. 
These two products were then joined in a third PCR reaction. In a fourth PCR reaction 
the 3` region of the promoter including the third ERE was generated and the ERE was 
replaced with random sequence. The products of the third and fourth PCR reaction 
were then joined using the unique outer primers (to the random sequence). A DNA 
molecular weight marker (Hyperladder I) was run in the lane marked (HL1). 
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Figure 5.10:  Agarose gel electrophoresis of restriction digest by Hind III of 
recombinant plasmids to screen for those containing the H3 promoter sequence. A 
DNA molecular weight marker (Hyperladder I) was run in the lane marked (HL1). 
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       37   GTGGGAGAAGTGCCATGCAGCACAAAACATGTTTACAGGGGTGATTCGCGTTAAGTTTCA  96 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       867  gtgggagaagtgccatgcagcacaaaacatgtttacaggggtgattcgcgttaagtttca  808 
 
       97   CACACAGCAGTTACTACATTTTAGAGGAAGGAAATTATACCCATGAGTGCATTCCTAACT  156 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       807  cacacagcagttactacattttagaggaaggaaattatacccatgagtgcattcctaact  748 
 
       157  ATCTTGAATGGAAGTGTTAAAACCCGCATCAAACACACAAGTTTGAATATGTCATACCAT  216 
            |||||||||||||||||||||||||||||    ||||||||||||||||||||||||||| 
       747  atcttgaatggaagtgttaaaacccgcatgccccacacaagtttgaatatgtcataccat  688 
 
       217  TTGCTGTAGCAATTAATGGCATACACAATTGAGAGCACACACATTACCACTGAACATTTG  276 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       687  ttgctgtagcaattaatggcatacacaattgagagcacacacattaccactgaacatttg  628 
 
       277  AGTATGTATTTCCCAAAATGAGCTTTTTTCCAGTTTGGGGATGTTTTGCTTTGTTTTGGG  336 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       627  agtatgtatttcccaaaatgagcttttttccagtttggggatgttttgctttgttttggg  568 
 
       337  ATGGAGTCTCCCTCTCGCCCAAGCTGCAGTGCAGCGGCGTGATAACAGCTCACTGTAACC  396 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       567  gtggagtctccctctcgcccaagctgcagtgcagcggcgtgataacagctcactgtaacc  508 
 
       397  TCGAACTCGGGCTCAAGCGATCCTCTTGACAGCCTTCTGAGTAGCTGGGATTACAGGCGA  456 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       507  tcgaactcgggctcaagcgatcctcttgacagccttctgagtagctgggattacaggcga  448 
 
       457  GAGCCGCCACGCCCGGCTAAGAGCATTTTTCTAATATCAGAACACTTCTTATGCGACACC  515 
            ||||||||||||||||||||||||||||||||||| |    ||||||||||||||||||| 
       447  gagccgccacgcccggctaagagcatttttctaat-tgcccacacttcttatgcgacacc  389 
 
       516  CAGAAAAATACAATTTTAAATAAAGCGCATATGCAAATTTCCCTAATCGTCTCCAATATT  575 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       388  cagaaaaatacaattttaaataaagcgcatatgcaaatttccctaatcgtctccaatatt  329 
 
       576  CTCTGATTTCTTTTTTATATTTTAACTAGAAACAATTGGAGGTTTCCGCGTTGCTTTGTG  635 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       328  ctctgatttcttttttatattttaactagaaacaattggaggtttccgcgttgctttgtg  269 
 
       636  TGGTTGTAAATTTTAAGACTTCAGGAAACTTTTCCAGTACAAGACTTGTCCACAGTGGAT  695 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       268  tggttgtaaattttaagacttcaggaaacttttccagtacaagacttgtccacagtggat  209 
 
       696  ATAGCAGCTAAGGGGTTAACAAAATGACGTCAGAGTAGCTACGGTAATACCACGGAGCC  754 
            ||||||||||||||||||||||||||||||||||||||||||||||||     |||||| 
       208  atagcagctaaggggttaacaaaatgacgtcagagtagctacggtaatgggcaggagcc  150 
 
       755  TCTCTTAATCTGCAACCAGGCACAGAGTTGGACCAATCCAAGAAGGGCGCGGGGATTTTT  814 
            ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
       149  tctcttaatctgcaaccaggcacagagatggaccaatccaagaagggcgcggggattttt  90 
 
       815  GAATTTTCTTGGGTCCAATAGTTGGTGGTCTGACTCTATAAAAGAAGAGTAGCTCTTTCC  874 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
       89   gaattttcttgggtccaatagttggtggtctgactctataaaagaagagtagctctttcc  30 
 
       875  TTTCCTCCACAGACGTCTCTGCAGG-AAG  902 
            ||||||||||||||||||||||||| ||| 
       29   tttcctccacagacgtctctgcaggcaag  1 
 
 
 
Figure 5.11: Alignment of sequence data generated from the histone H3 promoter-
reporter construct in which ERE sequences were mutated (bottom line, lower case) 
with the required sequence. The 5 bp sequence highlighted in blue are the ERE 
sequences to be mutated.   
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Figure 5.12: The effect of resveratrol and the ER antagonist fulvestrant on the 
activity of an H3 promoter-reporter construct in which three identified ERE 
sequences were mutated in Caco-2 cells.  Caco-2 cells were transfected with a 
promoter-reporter construct including either (A) the histone H3 promoter or (B) an 
equivalent construction in which three ERE sequences were replaced with random 
sequence. After transfection (24 hours later), cells were treated with resveratrol (RSV; 
10 μM) in the presence and absence of fulvestrant (FULV; 0.1μM) for 48 hours. 
Control cells (Control) were treated with DMSO vehicle only. Data are shown as mean 
± standard error (SEM) (n=9, based on four experiments), **P<0.01, ***P<0.001 by 
one way ANOVA followed by Dunnett's post test. There was a reduction in the 
expression of the reporter gene in response to the resveratrol (REV) treatment and this 
effect was attenuated by fulvestrant. There was no difference in the response of the two 
different constructs tested.   
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5.5  The effect of 17-β estradiol and the ER antagonist fulvestrant on the 
activity of a histone H3 promoter-reporter construct in Caco-2 cells 
 
The observed ability of resveratrol to downregulate transcription from the histone H3 
promoter through the ER (attenuated by the ER antagonist fulvestrant) but through a 
mechanism independent of ERE sequences identified within the promoter raises the 
key question as to whether 17-β estradiol influences the histone H3 promoter in the 
same way. The effect of 17-β estradiol (at a physiological concentration of 10 nM) on 
the activity of both the histone H3 promoter-reporter construct and the equivalent 
construct in which ERE sequences were mutated in Caco-2 cells in the presence and 
absence of the ER antagonist fulvestrant was therefore measured.  
 
Caco-2 cells were transfected transiently with one of the two promoter-reporter 
construct to be tested. After transfection (24 hours later), cells were treated with 
resveratrol (10 µM or 200 µM) or 17-β estradiol (10 nM) in the presence or absence of 
the ER antagonist fulvestrant (0.1 µM) for 48 hours. The activity of reporter gene (β-
galactosidase) was measured.   
 
As shown in Figures 5.13 and 5.14 both 17-β estradiol and resveratrol (at physiological 
concentration (10 µM) or pharmacological concentration (200 µM)) reduced the 
activity of the histone H3 promoter irrespective of whether the identified ERE 
sequences were intact or had been replaced with random sequence and this effect was 
attenuated by fulvestrant. These data demonstrated that 17-β estradiol modifies histone 
H3 expression through the ER but, like resveratrol, this action is not dependent on the 
ERE sequences that identified.  
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Figure 5.13: The effect of 17-β estradiol, resveratrol and the ER antagonist 
fulvestrant on the activity of a histone H3 promoter-reporter construct in Caco-2 
cells.  Caco-2 cells were transfected with a promoter-reporter construct comprising a 
region of the histone H3 promoter. After transfection (24 hours later), the cells were 
treated with resveratrol (RSV; 10 μM, 200 μM) or 17-β estradiol (E2; 10 nM) in the 
presence or absence of fulvestrant (FULV; 0.1μM) for 48 hours. Control cells (Control) 
were treated with DMSO vehicle only. Data are shown as mean ± standard error (SEM) 
(n=9, based on three experiments), **P<0.01, ***P<0.001 by one way ANOVA 
followed by Dunnett's post test. Both 17-β estradiol and resveratol reduced the activity 
of the histone H3 promoter and this effect was attenuated by fulvestrant.   
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Figure 5.14: The effect of 17-β estradiol, resveratrol and ER antagonist fulvestrant 
on the activity of an H3 promoter-reporter construct in which three identified ERE 
sequences were mutated in Caco-2 cells.  Caco-2 cells were transfected with a 
promoter-reporter construct comprising a region of the histone H3 promoter in which 
ERE sequences was mutated. After transfection (24 hours later), the cells were treated 
with resveratrol (RSV; 10 μM, 200 μM) or 17-β estradiol (E2; 10 nM) in the presence 
or absence of fulvestrant (FULV; 0.1μM) for 48 hours. Control cells (Control) were 
treated with DMSO vehicle only. Data are shown as mean ± standard error (SEM) 
(n=9, based on three experiments), **P<0.01, ***P<0.001 by one way ANOVA 
followed by Dunnett's post test. Both 17-β estradiol and resveratol reduced the activity 
of the histone H3 promoter in which ERE sequences were mutated and this effect was 
attenuated by fulvestrant.   
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5.6  Discussion 
 
The estrogen receptor is a nuclear hormone receptor. There are two known estrogen 
receptor subtypes, ERα and ERβ, each encoded by different genes. These genes are 
located on chromosome 6q25 and chromosome 14q23-24.1 respectively (Li, 2003). 
These receptors mediate the biological functions of the estrogen hormone.  Although 
ERα and ERβ bind with high affinity to the same ligand, they respond differently and 
induce opposite effects (Dahlman-Wright, 2006).  Transcription of estrogen-responsive 
genes is affected by the estrogen-receptor complex through either binding to specific 
sequences, known as estrogen response elements, or by binding to other DNA-bound  
transcription factors, such as SP1, AP1 or NF-kappaB (Sun, 1998).  
 
Resveratrol is a natural product that belongs to a large group compounds often referred 
to as phytoestrogens. These compounds have a chemical structure similar to 17β-
estradiol (Kuiper et al, 1997), and have an ability to bind to estrogen receptors to  
produce effects that mimic biological actions of estrogen (Grynkiewicz and Opolski, 
2005). 
The work presented in this chapter investigated the hypothesis that effects of 
resveratrol - in particular the reduction that was observed in histone protein expression- 
are mediated through the estrogen receptor (ER). These effects of resveratrol to reduce 
histone expression could potentially be mediated through either ERα, ERβ or both. 
Thus, the ER status of the cell lines used in this study was confirmed by RT-PCR.  In 
accordance with published information, the data confirmed that MCF-7 cells but not 
Caco-2 cells express ERα. Since both cell lines showed reduced histone expression in 
response to resveratrol, this finding indicates that the response to resveratrol is not 
ERα-dependent. On the other hand, expression of ERβ was detected in both cell lines, 
so it is possible that the response to resveratrol is mediated through ERβ. To 
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investigate if resveratrol reduces histone expression through ERs, Caco-2 (ERβ-
positive) and MCF-7 (ERα and ERβ- positive) cell lines were treated with resveratrol 
in the presence and absence of the ER antagonist fulvestrant, and then western blot 
analysis using antihistone antibodies was conducted. The results show that histone 
H2A, H2B, H3 and H4 expression was decreased in response to resveratrol treatment 
in both cell lines (statistically significant). It was observed blockade of the effect of 
resveratrol to reduce histone expression in both cell lines by fulvestrant, consistent 
with resveratrol acting through the ER to bring about this downstream response. The 
fact that these responses were observed in the Caco-2 cell line, which lacks ERα, 
indicates that the responses are mediated through ERβ. This view is recently supported 
by in vitro evidence on mammal cell lines including MRC5 and SHSY5Y (Robb and 
Stuart, 2011).  
 
To investigate the mechanism of action of resveratrol further it was investigated if 
action to reduce histone expression was at the level of histone gene transcription. To 
achieve this goal, a reporter gene assay was used. Caco-2 cells were transfected with a 
histone H3 promoter reporter construct and treated with resveratrol (10 µM, 24 hours) 
in the presence and absence of fulvestrant. The data indicated that the ER-mediated 
mechanism through which resveratrol caused a downregulation in histone H3 
expression was to affect histone gene transcription. Since additional potential 
mechanisms – such as effects on histone mRNA stability and translation and on histone 
protein turnover were not explored- it cannot be concluded that transcriptional actions 
account entirely for the observed reduction in histone expression and further studies 
are warranted.      
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The experiments were extended to investigate if the response to resveratrol treatment 
was through interaction with estrogen response elements (EREs). Three potential EREs 
were identified within the histone H3 promoter region included in the promoter-
reporter construct and replaced with random sequence. Caco-2 cells were transfected 
with this construct and treated with resveratrol.  Also the effects of the endogeneous 
ER ligand 17-β estradiol on both the original and mutated promoter-reporter constructs 
were tested.  Both compounds gave the same response profile: both reduced reporter 
gene expression from both promoter reporter constructs. These observations indicate 
that effects of neither compound, although mediated through the ER, are on the 
specific sequences region we identified and replaced. It is likely that a ligand-ER 
complex binds to other sequences in the promoter region that act as EREs and that we 
failed to identify. Additional modifications to the promoter-reporter construct may 
reveal these sequences. Although effects of the endogenous ligand 17-β estradiol could 
be mimicked in this experiment by resveratrol, the data are insufficient to allow us to 
determine if resveratrol acts primary as an ER-agonist (that activates transcription of 
EREs) or ER-antagonist (that inhibit agonist-induced transcriptional). Complex 
agonist/antagonist/partial agonist effects of dietary phytoestrogens, in particular 
isoflavones, have been reported. The concentration of resveratrol that was used (10 µM) 
is far in excess of that 17-β estradiol (10 nM) so further work is needed to examine in 
detail dose-response profiles and competition between resveratrol and 17-β estradiol 
for ER binding and downstream effects.           
 
The ability of resveratrol to interact with the ER indicates the potential for resveratrol 
to be used in protection against a range of diseases associated with reduced secretion of 
estrogen hormone, including osteoporosis and alleviation of menopausal symptoms. 
Such actions have been attributed to the partial ER-agonistic actions of other dietary 
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phytoestrogens - notably the isoflavones – but the potential for resveratrol to act in a 
similar way remains relatively unexplored. Similarly, the implications of the finding 
that resveratrol acts through EREs should be explored with respect to potential and 
reported  effects of resveratrol to protect against hormone-dependent cancer, including 
breast cancer (Garvin et al., 2005; De Amicis et al., 2011), prostate cancer (Fang et al., 
2011), and colon cancer (Tessitore et al., 2000).  
In ER-positive cancer such as breast cancer, which has an overexpression of ERα 
(Dotzlaw et al., 1999; Speirs et al., 1999), resveratrol has been seen to inhibit growth 
of cancer cells (Garvin et al., 2005; Amicis et al., 2011) through a mechanism that may 
be dependent on downregulation of ERα expression (Amicis et al., 2011), suggesting 
that resveratrol may be considered as a natural selective estrogen receptor modulator 
(SERM). This view may explain the reduction incidence of breast cancer in Asian 
women where the consumption of phytoestrogens is high (Messina et al., 1994). 
However, factors including ethnicity, inherited mutations in genes such as BRCA1 and 
BRCA2 also affect the incidence of breast cancer (Petrucelli et al., 2011), and different 
distributions within populations could be a factor that confounds apparent links with 
diet. 
 
Although the estrogenic/antiestrogenic effects of resveratrol may have many biological 
benefits, no data are available on its interaction with endogenous estrogen during 
embryonic development and early childhood. Resveratrol has a structure similar to 
diethylstilbestrol (DES), a potent synthetic estrogen used widely to protect pregnancies 
from abortion. This medicine has been reported to increase the incidence of 
undescended testes and abnormalities in urogenital tract in male newborns of mothers 
were administrated DES during early pregnancy (Gill et al., 1976). This phenotype 
may be associated with reduced fertility and increased the risk of tumour in the 
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testicular germ cell in later life (Pettersson et al., 2007). This view is supported by 
observation based on mice injected with DES between 9 to16 days of gestation, which 
induced features such as intra-abdominal testes (the testes are located inside the 
abdominal cavity), infertility, and urogenital tract abnormalities in male offspring 
(Greco et al., 1993). Based on these observations and the similarity in the structure 
between resveratrol and DES, consideration should be given to resveratrol as a 
potential endocrine disruptor and clinical investigation of its side-effects during 
pregnancy and neonatal life may be warranted. For this purpose, further research using 
a rodent model is encouraged to examine effects of resveratrol including dosage and 
exposure time on the fetal development.  
 
A further related area for research would be the role – if any- of reduced levels of 
histone expression (downstream of interaction with the ER) on health and disease risk. 
Other ER-mediated actions of resveratrol are likely to be components of the biological 
action of the compound.      
 
The finding that the effects of resveratrol on histone protein expression are ER-
mediated actions may be relevant to the well – studied and highly topical actions of 
resveratrol to protect against phenotypes associated with ageing and against other 
ageing-relating diseases, but the links require extensive further investigation. For 
example, differential effects in tissues of different ER expression profile, sex-specific 
effects and modifying actions of other ER agonists or antagonist in vivo could all be 
explored to begin to address this point.        
 
Further studies in vivo are required to understand the impact of resveratrol on general 
health and on ageing and on ageing-related diseases and whether such effects mimic 
and/or antagonise estrogen actions. 
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6  Discussion and conclusion 
Resveratrol has attracted particular interest as a result of reports that it can delay features of 
the ageing process and/or for extend lifespan in different species in a manner that mimics DR 
(Howitz et al., 2003; Wood et al, 2004; Baur et al., 2006). The mechanisms by which 
resveratrol brings about these effects are not fully understood, and are a subject of 
controversy.  
This study aimed to investigate mechanisms through which resveratrol may have biological 
activity of benefit during the ageing process. The initial hypothesis was that some of the 
beneficial effects of resveratrol on lifespan/aging are mediated through effects on histone 
expression that oppose changes observed in ageing. To investigate this hypothesis human 
epithelial cell line models (Caco-2 and MCF-7 cells) were used.  
Initially, it was investigated the effect of resveratrol, at a concentration achievable 
physiologically (10 µM), on the level of histone proteins in Caco-2 and MCF-7 cells.  The 
results showed that histone protein (H2A, H2B, H3 and H4) expression was decreased in 
response to resveratrol treatment in both cell lines. To seek further evidence to support the 
hypothesis that resveratrol regulates lifespan/longevity by its effect on histone expression, it 
was essential to investigate how histone expression changes with age.  Based on the findings 
concerning the ability of resveratrol to reduce histone expression, it was reasoned that the 
response could potentially counteract/ oppose feature of ageing if the ageing process were 
associated with an increase in histone expression. This idea was explored using small 
intestinal tissue from young and old female mice. A notable increase in histone expression 
(particularly H2A, H2B and H4) was observed in the tissue from the older mice, consistent 
with resveratrol having an effect that opposes changes observed during ageing.  To extend the 
observations made in mice to humans, the effect of age on histone protein expression in the 
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intestine of human subjects was examined. No age-associated differences in histone 
expression in human subjects were observed. The fact that a difference was observed in mice 
but not in human subjects may be due to a number of different factors including:  a difference 
between species, a difference between small intestine (mice) and colon (humans), and greater 
inter-individual variability in human samples, which were very limited in number.  Samples 
from a larger number of individuals and extracted from specific layers of intestine/ colon, 
such as the mucosal layer, should be analysed to draw a more robust conclusion.  
The mechanism underlying the influence of ageing on histone expression is still unclear. 
There is very little information in the literature about the effect of age on the level of histone 
expression in mammals or on functional consequences of reduced levels of histone 
expression. It is therefore difficult to predict the impact of this change in histone expression 
on the ageing process. The close relationship between histone association or modification and 
expression of genes encoded by the associated DNA makes it likely that there will be 
profound effects on gene expression  
This work studied the effect of resveratrol at the level of transcriptiome, to address several 
objectives including: (1) investigating if resveratrol has an effect similar to that of DR at the 
level of gene expression; (2) identifying if genes or pathways affected by resveratrol were 
also affected by manipulation of the expression level of Sirt1, since Sirt1 has been implicated 
as factor that can modify the ageing process; (3) examining if resveratrol influenced the 
expression of genes/pathways related to the ageing process. These objectives were addressed 
using micro-array based technology, as described in Chapter 4.  Genes within the intersection 
of those found to be affected by resveratrol treatment in Caco-2 and MCF-7 cell lines and a 
compiled list of genes responsive to DR were identified. The number of genes in the 
intersection for both cell types was greater than expected by chance, supporting to the view 
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that resveratrol may mimic some effects of DR. In contrast, the intersections between the lists 
of genes affected by resveratrol treatment in both cell lines and a list of genes affected by 
knockdown of SIRT1 expression in Caco-2 cells were very small. This finding indicted that 
resveratrol does not act through effects on Sirt1. This view is supported by previous research 
in vivo based on a mouse model (Barger et al., 2008a), but others challenge this opinion 
(Baur et al, 2006; Park et al., 2012). 
 
To address the third objective, we focused on FOXO1, IGF-1 and PGC-1α, which all appear 
to be linked closely with determining lifespan and/ or modifying the ageing process, 
particularly in response to DR (Baur et al., 2006). The microarray data revealed no apparent 
effect of resveratrol on these genes in either cell line. These findings are at variance with 
other microarray analyses based on mouse models (Baur et al., 2006; Barger et al., 2008a).  
Several factors may explain these differences, including the fact that the published in vivo 
analyses are based on organs such as heart, liver, brain and muscle, rather than intestine or 
breast epithelium as represented by the cell lines studied in this work. Tissue-specific actions 
of resveratrol are indicated by the current study, in the lack of commonalty between genes 
and the pathways affected by resveratrol in Caco-2 (intestinal) and MCF-7 (breast cancer) 
cell lines, and has also been highlighted previously on the basis of in vivo studies (Barger et 
al., 2008b).  A second factor that may account for differences is the dose-dependent action of 
resveratrol, as reported in in vivo studies (Barger et al., 2008a, Barger et al., 2008b, Pearson 
et al., 2008). In these experiments, a low concentration of resveratrol that can be achievable 
physiologically through the diet (10 µM) was used. Higher doses of resveratrol may be 
necessary to elicit effects on these genes. A further consideration is that resveratrol is rapidly 
metabolised to metabolites including glucuronide and sulphate conjugates (Goldberg et al., 
2003; Rotches-Ribalta et al., 2012). It is largely unknown to what extent the activities of 
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resveratrol and its major metabolites differ so it is possible that many of the gene responses 
observed in vivo are to metabolites of resveratrol rather than to the parent compound itself, 
which we assume to be the form to which our cell lines were exposed predominantly (unless 
substantial metabolism occurred under our tissue culture conditions). Many other 
differences/limitations associated with use of cell culture models may lead to results from in 
vivo studies differing from our own observations. 
Since resveratrol has structural similarly to 17-β estradiol, we also analysed the microarray 
data to investigate if the estrogen-response element (ERE) occurred at a higher frequency 
than expected by chance in genes regulated by resveratrol. The analysis indicated that genes 
including the ERE were not enriched within the population of genes that responded to 
resveratrol treatment in either cell line. This finding may indicate that resveratrol affects gene 
expression, generally, through a mechanism independent of direct binding of a resveratrol-ER 
complex to the ERE. Alternatively, an interpretation of the results could be that many of the 
genes do respond through binding of a resveratrol-ER complex to sequences in the promoter 
regions that act as EREs, but that the criteria we used to define EREs were inappropriate for 
the detection of these sequences. A study that investigated the occurrence of the ERE in 
genes that responded to 17- β estradiol found that the ERE sequence was present in only a 
fraction (Bourdeau et al., 2004). Thus, the negative results we obtained are not sufficient to 
allow us to conclude that resveratrol actions on gene expression are generally independent of 
the ER.  
 
To investigate further if effects of resveratrol - in particular the reduction in histone protein 
expression - are mediated through the ER, two different cell lines - Caco-2 and MCF-7 - were 
used. Firstly, the ER status of the cell lines used in this study was confirmed by RT-PCR.  
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The data confirmed that MCF-7 cells but not Caco-2 cells express ERα whereas expression of 
ERβ was detected in both cell lines. Both cell lines were treated with resveratrol in the 
presence and absence of the ER antagonist fulvestrant. The results showed that the effect of 
resveratrol to reduce histone expression (H2A, H2B, H3 and H4) was reversed by fulvestrant, 
suggesting that resveratrol acts through the ER to elicit this downstream response. The fact 
that these responses were observed in the Caco-2 cell line, which lacks ERα, indicates that 
the responses are mediated through ERβ, consistent with other work in cell lines (Robb and 
Stuart, 2011). It was not possible to rule out that the response could also be mediated by ERα; 
to draw such a conclusion a cell line that expresses only ERα would be required. 
Next, it was investigated if the reduction in histone protein expression in response to 
resveratrol treatment was at the level of histone gene transcription using reporter a gene assay 
(described in Chapter 5).  Caco-2 cells were transfected with a histone H3 promoter reporter 
construct and treated with resveratrol (10 µM, 24 hours) in the presence and absence of 
fulvestrant. The data indicated that the ER-mediated mechanism through which resveratrol 
caused a downregulation in histone H3 expression was to affect histone gene transcription. 
The experiments were extended to investigate if the response to resveratrol treatment is 
through interaction with EREs. First, three potential EREs within the histone H3 promoter 
region included in the promoter-reporter construct were replaced with random sequence. 
Caco-2 cells were then transfected with either the original or mutated promoter-reporter 
construct and treated with resveratrol or the endogenous ER ligand 17-β estradiol.  The 
results showed that both compounds reduced reporter gene expression from both promoter 
reporter constructs. These observations indicate that effects of neither compound, although 
mediated through the ER, are through the specific sequences we identified and replaced. It is 
likely that a ligand-ER complex binds to other sequences in the promoter region that act as 
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EREs and that we failed to identify. Although effects of the endogenous ligand 17-β estradiol 
could be mimicked in this experiment by resveratrol, these data are insufficient to allow us to 
determine if resveratrol acts primarily as an ER-agonist or ER-antagonist.  
The finding that the effects of resveratrol on histone protein expression are ER-mediated 
actions has important implications for the use of resveratrol as a natural hormone-
replacement therapy, for example to protect against osteoporosis (Rayalam et al., 2011) and 
to alleviate of menopausal symptoms (Zern et al., 2005).  On the other hand, caution must be 
applied, as resveratrol may interact with endogenous estrogen during embryonic development 
and early childhood. Further study using a rodent model to examine the effect of resveratrol, 
including dosage and exposure time, on fetal development could be valuable in this regard.  
In conclusion, the data indicate that resveratrol reduces histone expression in both Caco-2 and 
MCF-7 cells through an ER-mediated mechanism acting at the level of transcription and that 
this effect may oppose an accumulation of histone proteins (observed in mouse small 
intestine) that accompanies ageing. Microarray data indicated that resveratrol at a 
concentration achievable through diet has an effect similar to DR with respect to many of the 
genes regulated, but (in these experiments) excluding some key genes with well-established 
roles in the ageing process and/or in promoting longevity in response to DR. Effects on gene 
expression were cell line-specific and distinct from effects of Sirt1 manipulation.   
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ProbeID p-value Regulation Symbol Chromosome GI ILMN_Gene 
7160239 3.24E-04 up FOSB chr19 5803016 FOSB 
6200390 2.15E-04 down PRIM1 chr12 41349493 PRIM1 
5550242 0.00822 up 
 
chr17 561211 HS.554608 
2900674 6.27E-10 down IGSF3 chr1 55953132 IGSF3 
3840632 0.001924 up ACSM3 chr16 47458816 ACSM3 
3180168 7.75E-04 down LOC646764 chr19 89052462 LOC646764 
4390661 0.009971 up DDX51 chr12 37059776 DDX51 
5360491 0.00533 down 
 
chr10 27878712 HS.61151 
4250181 9.36E-04 down EXOC5 chr14 82546833 EXOC5 
6650176 1.08E-05 up TRMT11 chr6 94420682 TRMT11 
6130382 4.56E-06 up PTER chr10 47933342 PTER 
4760079 1.73E-04 up ADARB1 chr21 75709170 ADARB1 
1010367 0.016954 up CSTF3 chr11 75709188 CSTF3 
10161 0.002524 down MOBKL2A chr19 40018625 MOBKL2A 
4120504 0.008054 down LOC643834 chr11 89033999 LOC643834 
130673 5.45E-10 down NHP2 chr5 53729323 NHP2 
1300519 0.003014 up ZNF597 chr16 22748966 ZNF597 
1570414 5.45E-06 down NAT5 chr20 89993684 NAT5 
4760630 0.002505 up RAB11FIP2 chr10 7662393 RAB11FIP2 
4150709 7.13E-04 up LOC651774 89062149 LOC651774 
7320437 2.41E-07 up DSCR3 chr21 5174424 DSCR3 
5340315 0.001115 down DEFB32 chr20 46409557 DEFB32 
5340382 0.001197 down BAT3 chr6 18375631 BAT3 
2190470 0.012785 up KLF10 chr8 5032176 KLF10 
3400379 1.89E-04 up STXBP6 chr14 46048194 STXBP6 
20435 0.00931 down LOC729279 169213739 LOC729279 
20010 4.14E-06 up CARS chr11 62240993 CARS 
2510689 6.72E-04 up ROGDI chr16 13375778 ROGDI 
1450026 0.006174 down LOC389101 113415004 LOC389101 
1430487 5.14E-09 up MGP chr12 49574513 MGP 
5130414 1.17E-06 down C9orf23 chr9 22325369 C9ORF23 
4250093 0.001689 up LCA5 chr6 32171218 LCA5 
2230743 0.015216 down LOC649578 89026013 LOC649578 
160639 1.86E-08 up EBAG9 chr8 37694064 EBAG9 
3800753 6.50E-06 down CDCA7L chr7 31542536 CDCA7L 
2970605 0.009297 up LOC100132098 chr19 169213500 LOC100132098 
1570221 0.007926 up C5orf34 chr5 38348407 C5ORF34 
4150204 9.58E-04 up PRRX2 chr9 38505203 PRRX2 
3190195 1.50E-04 down LOC646609 chr9 89029207 LOC646609 
6290114 0.012692 down SDPR chr2 66346738 SDPR 
5340324 0.006735 up FUT7 chr9 56090657 FUT7 
4850470 2.95E-07 down ITSN1 chr21 47717122 ITSN1 
3360553 0.011777 up RP5-1022P6.2 chr20 153218549 RP5-1022P6.2 
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2100519 0.006668 down IPP chr1 5174472 IPP 
6250450 0.003379 down LOC400558 169209573 LOC400558 
1850041 3.62E-04 down DPM2 chr9 24497593 DPM2 
6560672 3.00E-04 down HNRPR chr1 14141188 HNRPR 
6960241 0.011511 up PSAPL1 chr4 145977197 PSAPL1 
5420731 3.36E-04 down CNKSR3 chr6 74316005 CNKSR3 
4070632 0.012494 down 
 
chr3 14292080 HS.563147 
150180 0.013242 down MMP10 chr11 4505204 MMP10 
2070392 0.005635 down SLFN12 chr17 31542644 SLFN12 
1300402 0.008527 up TRMT2A chr22 51173877 TRMT2A 
7200601 4.32E-11 up MUC1 chr1 113206023 MUC1 
5260296 0.012736 up LOC100128905 chr2 169163414 LOC100128905 
5050047 0.001716 down KIAA1967 chr8 40548406 KIAA1967 
6840673 0.012241 down LOC100133288 chr8 169172702 LOC100133288 
520678 0.008923 up CD53 chr1 91106722 CD53 
7570338 0.005277 down LOC728138 chr16 169209809 LOC728138 
4010187 4.58E-07 up UGCGL2 chr13 11386200 UGCGL2 
6520661 1.78E-11 down C9orf46 chr9 142352128 C9ORF46 
5390288 5.03E-04 up C1GALT1C1 chrX 58532583 C1GALT1C1 
3780148 1.03E-06 up C7orf26 chr7 21362069 C7ORF26 
1940050 0.00225 down LOC388720 113412527 LOC388720 
7650192 5.02E-09 up LOC651102 89057454 LOC651102 
940288 2.37E-07 up BAZ1A chr14 32967604 BAZ1A 
5420687 2.92E-05 up DACT2 
 
141801653 DACT2 
610082 0.011357 up SKA2 chr17 154689645 SKA2 
540193 1.05E-04 down TMEM50A chr1 20357549 TMEM50A 
520189 1.63E-06 up HYOU1 chr11 13699861 HYOU1 
940497 0.005605 down GRK7 chr3 51896040 GRK7 
3310047 0.009964 down PKD1P1 
 
239745438 PKD1P1 
1940463 0.014108 down LOC729156 chr7 157671954 LOC729156 
6370273 9.28E-07 up CTPS chr1 4503132 CTPS 
6550594 5.86E-04 down LOC391157 chr1 113411635 LOC391157 
2190414 1.40E-09 up ACACA chr17 38679966 ACACA 
6180487 1.15E-06 down FOXRED2 chr22 34303916 FOXRED2 
2710438 0.001457 up LOC728711 169168299 LOC728711 
4640500 9.73E-12 up UCHL1 chr4 34147658 UCHL1 
610427 1.38E-04 up KLF8 chrX 89111942 KLF8 
3460537 0.001275 down LOC100132488 169162132 LOC100132488 
2900255 1.48E-05 up ZBTB45 chr19 21314759 ZBTB45 
1580220 0.003519 up LOC649466 88945886 LOC649466 
1740291 9.39E-05 down TMSB15A chrX 72255577 TMSB15A 
4810497 2.27E-05 down DMKN chr19 78486557 DMKN 
2600309 2.63E-06 up AADACL4 chr1 61966716 AADACL4 
5720541 0.004956 up LOC100128485 169206193 LOC100128485 
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510725 3.95E-04 down NDUFA10 chr2 33519462 NDUFA10 
430333 6.65E-09 up NLRX1 chr11 25777609 NLRX1 
7650286 1.52E-07 up EXPH5 chr11 21359817 EXPH5 
6550274 8.64E-06 down LOC649679 88981262 LOC649679 
2630133 0.009462 up LOC729389 169213728 LOC729389 
10433 0.005649 up ITGA10 chr1 38569397 ITGA10 
430192 9.25E-05 down PDSS1 chr10 50659085 PDSS1 
7040670 3.12E-08 down DHRS3 chr1 62988332 DHRS3 
4260138 0.017142 down LOC654116 89034481 LOC654116 
7210546 0.001736 up BHLHB9 chrX 39930462 BHLHB9 
3120521 5.54E-04 up NFATC4 chr14 37595561 NFATC4 
4060754 0.001138 up ZNF552 chr19 99028877 ZNF552 
6270131 0.016389 down LOC100129141 chr2 169163171 LOC100129141 
5570747 0.017686 up C21orf49 chr21 219277614 C21ORF49 
6280189 0.005298 up HPS4 chr22 23110969 HPS4 
3890167 0.003908 down SLC39A3 chr19 47080101 SLC39A3 
6510220 0.008568 down LOC650407 88999379 LOC650407 
6290021 9.03E-07 down PSMD7 chr16 34335279 PSMD7 
6250154 9.23E-04 up LZTFL1 chr3 56676319 LZTFL1 
2810767 0.010155 up EBI3 chr19 14577916 EBI3 
870669 9.66E-06 up LRRC56 chr11 142363978 LRRC56 
5490347 0.009744 up CCNL2 chr1 24475708 CCNL2 
2490259 0.0022 up PINK1 chr1 112382374 PINK1 
510451 0.01591 up TIRAP chr11 89111123 TIRAP 
2350730 2.98E-08 up CGA chr6 10800407 CGA 
7380338 5.78E-05 up UST chr6 5032218 UST 
3120136 2.21E-04 up NFAT5 chr16 27886525 NFAT5 
4050228 0.00411 up MEX3A chr1 147902745 MEX3A 
5360202 5.61E-04 up MRFAP1L1 chr4 44921607 MRFAP1L1 
4290358 0.003442 down CCT7 chr2 58331184 CCT7 
520497 0.00382 up LOC729786 chr15 113425046 LOC729786 
7150196 0.001204 up TMEM87A chr15 31377764 TMEM87A 
3170184 1.50E-10 down RPL36AL chr14 34335143 RPL36AL 
380762 4.70E-04 down LOC646300 113415240 LOC646300 
3940632 0.007287 down C8orf79 chr8 153251912 C8ORF79 
7570754 0.016603 up 
 
chr13 8905106 HS.539599 
1820682 0.013799 down RNASEL chr1 30795246 RNASEL 
5340528 0.008648 down 
 
chr16 1108803 HS.557218 
6580184 0.006146 down SERHL 
 
113429616 SERHL 
1110730 0.001148 up WWTR1 chr3 34147583 WWTR1 
4920286 0.003392 up C15orf44 
 
113425683 C15ORF44 
780762 8.60E-06 up CSNK1D chr17 20544143 CSNK1D 
540639 0.002492 up MIR197 
 
262206094 MIR197 
1580301 0.008457 down ATP10A chr15 157649070 ATP10A 
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6650639 0.003236 up VAMP1 chr12 40549445 VAMP1 
6520576 3.90E-06 down BOLA3 chr2 78486585 BOLA3 
5570114 5.24E-09 up GADD45G chr9 9790905 GADD45G 
5490139 6.13E-05 up HSPA13 chr21 48928055 HSPA13 
2850364 2.95E-04 up KIAA1333 chr14 33620748 KIAA1333 
2490128 0.017746 up SIK2 chr11 38569459 SIK2 
2650682 0.001963 down RBMX2 chrX 7706315 RBMX2 
460170 1.02E-05 down LOC728368 chr11 169202179 LOC728368 
4390646 1.94E-09 up ZHX2 chr8 63079684 ZHX2 
1170528 0.012861 down FANCB chrX 66528784 FANCB 
2230201 0.015463 up TARBP1 chr1 110825987 TARBP1 
6130138 7.47E-06 down POLR3C chr1 141801742 POLR3C 
2900184 0.016813 up LOC653163 chr9 89030014 LOC653163 
4860358 1.34E-04 down VBP1 chrX 66346740 VBP1 
1710139 0.008976 down LOC642362 chr11 89034189 LOC642362 
3520438 0.006134 down ARAP2 chr4 21264591 ARAP2 
2140288 2.71E-04 down FLJ22662 chr12 55743115 FLJ22662 
3140639 0.007504 down LOC133874 chr5 113416861 LOC133874 
1940167 1.24E-04 up PDPR 
 
113426487 PDPR 
7330364 0.002109 down LOC647065 chr2 113413275 LOC647065 
1940576 1.64E-12 up RPS6KB1 chr17 55925648 RPS6KB1 
1230047 7.05E-04 up CBS chr21 4557414 CBS 
840349 1.36E-04 up OVOL1 chr11 38570157 OVOL1 
4060131 0.005606 up C3orf58 chr3 34222231 C3ORF58 
110523 0.006601 down 
 
chr3 10302685 HS.188979 
780598 8.67E-05 up TBK1 chr12 19743810 TBK1 
4860500 0.001974 down LOC652968 chr22 83415180 LOC652968 
3440672 0.001161 up KIAA0261 chr10 42734324 KIAA0261 
7160612 7.51E-06 up USP36 chr17 35250685 USP36 
2000128 1.57E-04 up C4BPA chr1 62912459 C4BPA 
7550707 2.93E-05 up ING3 chr7 38201654 ING3 
460021 0.002601 up SLC39A7 chr6 117553618 SLC39A7 
2120082 0.005283 down LOC651302 113417962 LOC651302 
2900193 0.012448 up TAF5 chr10 50363367 TAF5 
2690270 6.61E-04 up SNIP1 chr1 21314719 SNIP1 
1780446 6.89E-05 up PCK2 chr14 66346720 PCK2 
1070280 0.005095 up 
 
chr21 6711912 HS.542575 
5570669 0.009916 up POFUT1 chr20 27436890 POFUT1 
2070477 0.006292 down C12orf71 chr12 122937208 C12ORF71 
510358 0.008557 down LOC651952 89067026 LOC651952 
7100639 4.06E-10 up ERRFI1 chr1 21314673 ERRFI1 
2970397 7.76E-07 down ZNF296 chr19 21687251 ZNF296 
3310451 0.014032 down PIGO chr9 38045916 PIGO 
4220246 6.63E-05 up CCL20 chr2 4759075 CCL20 
Continued 
178 
 
1780482 7.56E-05 up CACHD1 chr1 110578648 CACHD1 
2120689 1.84E-04 up UBXN6 chr19 13376853 UBXN6 
5390451 3.64E-10 up DKK3 chr11 66346687 DKK3 
270019 1.46E-04 up GOSR1 chr17 55774986 GOSR1 
5090424 2.29E-04 down RPS27 chr1 68160923 RPS27 
2140239 1.47E-11 down CMTM7 chr3 31657098 CMTM7 
5670296 1.67E-04 up UBTF chr17 115529450 UBTF 
2640341 7.98E-06 down FKBP5 chr6 17149847 FKBP5 
4830433 0.005753 up LARP6 chr15 37537709 LARP6 
3780156 0.002557 up AMH chr19 6138973 AMH 
1450634 2.89E-08 up TINAGL1 chr1 11545917 TINAGL1 
5310379 0.004393 up TMEM115 chr3 40795669 TMEM115 
1430152 2.15E-05 up SCML1 chrX 82830431 SCML1 
7570142 0.011886 down DGCR11 chr22 205830444 DGCR11 
6130343 0.010677 up MIR557 
 
262205768 MIR557 
1010674 4.01E-04 up LOC400352 169208770 LOC400352 
2000615 0.011791 down WWP1 chr8 33946331 WWP1 
5900593 3.04E-04 up THTPA chr14 54607163 THTPA 
160072 0.011453 up 
  
10373073 HS.574023 
2970402 4.92E-04 up TUBGCP6 chr22 56788363 TUBGCP6 
1070471 0.008473 down CLU chr8 42740906 CLU 
2490168 1.67E-08 up MAGEH1 chrX 18105051 MAGEH1 
5490131 1.92E-04 up NIPSNAP1 chr22 4505398 NIPSNAP1 
6510403 6.56E-05 up LGSN chr6 7705581 LGSN 
4050056 7.47E-07 down TBC1D16 chr17 33563375 TBC1D16 
4570730 0.01199 down LOC652797 89064519 LOC652797 
1740343 1.56E-08 up PCSK5 chr9 20336245 PCSK5 
2630554 0.007179 up JMY chr5 94721314 JMY 
6420674 5.18E-09 down LOC647954 113417184 LOC647954 
3780382 0.005964 up DKFZp761E198 chr11 149999370 DKFZP761E198 
3120681 0.001755 up AFM chr4 27754774 AFM 
1850437 3.71E-04 up UBR5 chr8 41352716 UBR5 
870402 9.00E-04 up MAGI1 chr3 74272283 MAGI1 
1450241 2.57E-07 up CLEC4GP1 chr19 89886424 CLEC4GP1 
5220528 0.006098 down LOC646627 chr1 88943942 LOC646627 
1570685 0.003351 up KIAA0415 chr7 82546846 KIAA0415 
6960445 0.013041 down LOC653104 chr8 89028013 LOC653104 
5270446 0.013446 down RBM41 chrX 38454187 RBM41 
2030672 0.006982 up LOC158160 chr10 72534773 LOC158160 
6290463 0.004669 up FALZ chr17 38788259 FALZ 
4880021 0.003245 down RBM12 chr20 33469952 RBM12 
2810138 0.008587 up PMEPA1 chr20 40317614 PMEPA1 
4060598 0.01285 down 
 
chr17 2140439 HS.98815 
5290037 0.001491 down HEATR2 chr7 31377743 HEATR2 
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4570672 0.014288 up TEKT2 chr1 16507949 TEKT2 
630474 6.62E-09 down ZP3 chr7 38327648 ZP3 
830274 0.002439 up CD55 chr1 40788009 CD55 
580433 7.00E-04 up DENND1A chr9 55749778 DENND1A 
3990278 1.10E-05 up SCGN chr6 59814903 SCGN 
4830747 8.60E-05 up ERI3 chr1 74136558 ERI3 
7380504 0.003195 up ZNF607 chr19 47271463 ZNF607 
430450 0.010878 down LOC649891 89042418 LOC649891 
3130541 0.013872 down CCNF chr16 4502620 CCNF 
6270468 0.014574 down LOC643000 chrX 89060141 LOC643000 
2690603 0.008168 up RNF5 chr6 34305290 RNF5 
6420743 1.26E-04 up DYSFIP1 chr17 116235449 DYSFIP1 
7000332 4.58E-07 up CCDC126 chr7 93277090 CCDC126 
3830577 0.001709 down LOC100133478 169215724 LOC100133478 
5420538 1.79E-05 up TP53INP1 chr8 20127661 TP53INP1 
270170 1.38E-05 up GLYATL2 chr11 31542212 GLYATL2 
5340615 0.008778 down TRPV4 chr12 22547179 TRPV4 
3130438 0.010258 up LOC100133167 chr22 169215504 LOC100133167 
2690639 0.013847 down AQR chr15 58374127 AQR 
540609 0.00115 down LOC653746 chr8 89028158 LOC653746 
3930577 0.001781 up HMGN2 chr1 148922918 HMGN2 
4180243 0.006362 down YIPF5 chr5 68226421 YIPF5 
4120192 0.010301 up CES3 chr16 38455414 CES3 
5670095 1.10E-09 down ZNF239 chr10 149999359 ZNF239 
290242 0.004851 down POTEC chr18 212549545 POTEC 
4730309 9.02E-08 up PCCA chr13 65506441 PCCA 
6220037 1.42E-04 up UTP23 chr8 14150117 UTP23 
2030537 0.014889 up 
 
chr5 3430558 HS.543983 
4120671 2.38E-04 down SSBP3 chr1 58218978 SSBP3 
4120750 1.36E-07 down OBFC1 chr10 34147613 OBFC1 
110056 1.67E-04 up NRP2 chr2 41872561 NRP2 
4180180 0.014362 up LOC100133950 169160865 LOC100133950 
6770639 1.38E-04 up NDEL1 chr17 71284428 NDEL1 
1740753 1.36E-05 down CBWD3 chr9 148727350 CBWD3 
7210594 1.79E-07 up ZNF650 chr2 40255162 ZNF650 
4810064 3.43E-04 up LOC730041 169218223 LOC730041 
3140110 1.05E-06 down C18orf10 chr18 68534956 C18ORF10 
3400400 0.002126 down LOC100131660 169204872 LOC100131660 
6900154 0.006386 up ZNF704 chr8 76253909 ZNF704 
6110561 0.006359 down MRPS27 chr5 16950608 MRPS27 
6980746 0.00417 down SSX3 chrX 28559008 SSX3 
1980706 0.005878 down ATP6V0D2 chr8 22749164 ATP6V0D2 
6650747 1.66E-07 up ZNF641 chr12 22748700 ZNF641 
5820091 4.38E-04 up LOC650612 88947033 LOC650612 
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4070059 0.00693 down LOC729197 chr15 113425458 LOC729197 
4860196 0.014239 up FLJ44124 chr7 89886184 FLJ44124 
7050180 2.73E-08 up SLC22A5 chr5 24497491 SLC22A5 
7000142 3.50E-06 up KIAA0430 chr16 85797659 KIAA0430 
3610424 0.006239 up TRIM67 chr1 134288905 TRIM67 
5900270 0.005496 up FOXD4L4 chr9 76880471 FOXD4L4 
670403 3.23E-06 down B4GALNT4 chr11 40789264 B4GALNT4 
630059 0.010897 down LOC648167 89038845 LOC648167 
6220451 1.14E-06 down SLC25A4 chr4 55749576 SLC25A4 
3130220 4.35E-04 up TMEM158 chr3 116805333 TMEM158 
1940026 0.008344 down LOC642797 chr12 89035773 LOC642797 
270670 0.012951 down LOC100133444 169217923 LOC100133444 
1170072 1.70E-06 up ZSWIM4 chr19 65301125 ZSWIM4 
20553 1.06E-05 down C1orf124 chr1 58331106 C1ORF124 
5670037 0.014606 down MUTYH chr1 115298649 MUTYH 
3780497 0.009768 down LOC100129465 chr10 169190996 LOC100129465 
3460309 6.01E-08 up ATF4 chr22 33469975 ATF4 
730725 9.82E-06 up AOF2 chr1 58761545 AOF2 
3360377 2.84E-06 down UTP14A chrX 21361347 UTP14A 
6980369 0.001303 down 
 
chr2 27878421 HS.131259 
1470521 1.55E-05 up NR2C1 chr12 73808083 NR2C1 
1580093 0.001128 up SCYL1 chr11 115430240 SCYL1 
540390 1.19E-04 up ALPK1 chr4 21361968 ALPK1 
7330446 0.001311 up LOC729764 chr5 113416915 LOC729764 
2100521 0.002569 up STARD8 chrX 31543658 STARD8 
2810739 0.016226 up PDE4B chr1 82799483 PDE4B 
3390392 0.006185 up SUGT1P 
 
89029227 SUGT1P 
3840193 3.50E-06 up KIAA0649 chr9 45387957 KIAA0649 
2470603 3.09E-07 up ARID4B chr1 118136292 ARID4B 
6450402 0.003296 up LOC643699 chr15 113425118 LOC643699 
5260343 7.67E-04 up SCG5 chr15 4506916 SCG5 
130070 0.001371 up IFT172 chr2 46358427 IFT172 
2260133 0.006305 up RPS6KA3 chrX 56243494 RPS6KA3 
7200608 6.26E-08 up HSPB1 chr7 4996892 HSPB1 
5570315 1.15E-04 up C2orf58 chr2 27734974 C2ORF58 
610592 5.63E-06 up ADCY1 chr7 31083192 ADCY1 
6100441 9.94E-09 down PRPF4 chr9 34222192 PRPF4 
7400402 0.003026 up HIST1H4D chr6 21071023 HIST1H4D 
6760026 0.002391 up LRRC57 chr15 23397553 LRRC57 
4280739 4.39E-09 down APCDD1 chr18 30387616 APCDD1 
2260070 5.54E-06 up MTERF chr7 68448540 MTERF 
4730019 0.015204 up EFNB1 chrX 31317225 EFNB1 
650301 1.72E-04 down SNRPF chr12 83776586 SNRPF 
1740091 0.001627 down LOC388458 chr18 113427693 LOC388458 
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6040148 0.016378 down PML 
 
89039091 PML 
1170468 0.008586 up UBE2MP1 chr16 84872128 UBE2MP1 
4180255 0.005662 down C1QTNF9B chr13 56847615 C1QTNF9B 
1070019 0.001327 up FBXO17 chr19 22325386 FBXO17 
1980202 0.002838 up CAPRIN2 chr12 50428932 CAPRIN2 
7610050 8.10E-04 up ABCC5 chr3 66529092 ABCC5 
2750139 1.47E-06 down RNF216L chr7 190194405 RNF216L 
4280327 7.74E-04 up C2orf82 chr2 46047466 C2ORF82 
4860553 1.67E-05 down INTS12 chr4 21361850 INTS12 
5220014 0.00341 up LOC96610 chr22 18426889 LOC96610 
3890397 1.61E-06 down C14orf112 chr14 142349815 C14ORF112 
2070605 0.001837 down ACAT1 chr11 31563501 ACAT1 
1710332 0.003893 down FAHD1 chr16 66348061 FAHD1 
6940619 0.001528 up Sep-02 chr2 56549635 Sep-02 
5360402 0.013099 up RTEL1 chr20 30089967 RTEL1 
5810121 0.004301 down LOC652786 89064437 LOC652786 
2650161 0.015031 down LOC644986 chr8 89028116 LOC644986 
2490452 9.26E-07 up GAA chr17 119393890 GAA 
2600487 0.008811 down 
 
chr13 24724856 HS.550139 
1340358 0.014793 up CREB1 chr2 22219459 CREB1 
6270347 1.55E-09 up TRAK1 chr3 111074531 TRAK1 
5690692 0.006578 up 
 
chr20 6398275 HS.542384 
5550553 0.008251 up DHRS13 chr17 146231949 DHRS13 
1090132 0.001036 up PARP10 
 
113420558 PARP10 
1820504 1.92E-08 down NME1 chr17 38045911 NME1 
3710598 0.004219 up PSTK chr10 23503260 PSTK 
7560019 0.003415 down MIR15A 
 
262205622 MIR15A 
6550026 1.65E-06 up TICAM2 chr5 48675828 TICAM2 
6860300 1.21E-04 up SMARCA4 chr19 21071055 SMARCA4 
5670475 8.81E-04 down GCHFR chr15 6382072 GCHFR 
4560202 0.003465 up AAA1 chr7 46402501 AAA1 
5340053 3.07E-06 up MAK10 chr9 39725954 MAK10 
4200270 0.010042 up TMUB2 chr17 115527089 TMUB2 
7000609 1.41E-06 up ARRDC2 chr19 18373304 ARRDC2 
7150671 0.004794 up ARL3 chr10 38569402 ARL3 
5260132 9.23E-04 up LOC100190938 chr17 213385284 LOC100190938 
870475 1.27E-08 up SYCP2 chr20 38373672 SYCP2 
290296 6.35E-06 up FAM113A chr20 21362095 FAM113A 
7610431 0.001262 down FLJ40330 chr2 113413041 FLJ40330 
7100300 0.003488 up ZNF200 chr16 37675269 ZNF200 
3990465 1.22E-06 down FASTKD3 chr5 40068496 FASTKD3 
7160730 0.010109 up NCRNA00120 chr6 84872053 NCRNA00120 
7510537 0.00104 down SCO2 chr22 4826991 SCO2 
6020482 5.45E-11 up KHDRBS3 chr8 5730072 KHDRBS3 
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3830070 0.015925 up 
 
chr7 34526302 HS.193767 
2510477 0.011417 down B3GALT6 chr1 116268096 B3GALT6 
6840100 1.07E-04 down C11orf51 chr11 7661621 C11ORF51 
4780193 0.012002 down POFUT2 chr21 116734661 POFUT2 
6380047 0.00327 down MIR586 
 
262205906 MIR586 
6480682 0.012575 up FSHB chr11 66528900 FSHB 
2970296 8.89E-10 down ALG8 chr11 91984777 ALG8 
2070470 7.56E-04 up C1orf21 chr1 58761542 C1ORF21 
3610427 0.002925 up LOC100128098 chr10 169191377 LOC100128098 
3390093 1.13E-05 down BOLA3 chr2 78486577 BOLA3 
2690040 0.01101 down ABHD12B chr14 32451491 ABHD12B 
1770630 3.86E-05 down ALOX12P2 chr17 117940057 ALOX12P2 
6130088 0.00251 up MED1 chr17 154813205 MED1 
510044 4.09E-06 up KLF4 chr9 34916057 KLF4 
7160167 9.10E-04 down ALKBH1 chr14 87298839 ALKBH1 
6290717 5.48E-04 down DMRTA1 chr9 46195736 DMRTA1 
6510598 1.35E-06 up NHLRC3 chr13 62821784 NHLRC3 
5340327 2.39E-04 up EIF4ENIF1 chr22 10947034 EIF4ENIF1 
5270747 3.41E-09 up HSDL1 chr16 24432036 HSDL1 
6650438 2.02E-05 up SYNGR1 chr22 39777617 SYNGR1 
2100224 3.99E-05 up RHBDD3 chr22 11072100 RHBDD3 
5310161 0.005654 up MTHFD2L chr4 62243411 MTHFD2L 
5720180 1.10E-06 up FZD2 chr17 5922012 FZD2 
110026 0.015352 down LOC286239 89030280 LOC286239 
2650021 6.15E-05 up NRP2 chr2 41872543 NRP2 
1570382 9.93E-04 up ADAMTS9 chr3 33624895 ADAMTS9 
6940719 1.14E-05 up PAPOLA chr14 47834324 PAPOLA 
620433 0.011961 down C1orf122 chr1 38348207 C1ORF122 
1190674 2.69E-04 down C19orf69 chr19 194473672 C19ORF69 
6060458 3.22E-05 up GFRA3 chr5 45593145 GFRA3 
2450020 6.61E-04 up SNORD56 chr20 84872023 SNORD56 
5270209 0.007488 up 
 
chr12 27830880 HS.436006 
4040674 0.008165 up UGT1A4 chr2 45827763 UGT1A4 
1070050 0.002206 up C9orf126 chr9 27735124 C9ORF126 
7160100 0.004027 up PPRC1 chr10 40807451 PPRC1 
1260544 3.15E-05 up AKIRIN1 chr1 13375790 AKIRIN1 
6100010 7.63E-04 up THEM4 chr1 76159292 THEM4 
6510754 6.11E-12 down ALDH1A1 chr9 25777722 ALDH1A1 
1410519 0.003505 up 
 
chr2 2185354 HS.66072 
4060095 0.01236 down CD84 chr1 4502686 CD84 
830446 7.86E-04 down RUNDC1 chr17 27436874 RUNDC1 
4920014 0.001667 up GIF chr11 32189397 GIF 
270630 0.006462 up LOC642213 89038794 LOC642213 
2760113 0.005586 up RANBP6 chr9 52486449 RANBP6 
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6770202 1.49E-06 up IPO11 chr5 39725949 IPO11 
4730427 0.014516 down MYLC2PL chr7 40286635 MYLC2PL 
780170 0.013616 up LOC100128505 169177891 LOC100128505 
3310487 0.011462 up RPL18A chr19 15431299 RPL18A 
5390041 4.41E-07 up TRIM3 chr11 32454738 TRIM3 
1990692 0.00753 down LOC100131895 169202635 LOC100131895 
3120520 1.07E-07 down GABARAPL2 chr16 27374999 GABARAPL2 
730291 6.76E-06 up OXR1 chr8 63055068 OXR1 
5860347 0.002367 up AKR1D1 chr7 66348134 AKR1D1 
5290075 0.002583 down GAS5 chr1 88943597 GAS5 
4230653 1.68E-06 up CCNC chr6 61676090 CCNC 
5570678 3.47E-09 down RPS27L chr15 76563938 RPS27L 
2340441 5.18E-05 up SLC22A18AS chr11 6005877 SLC22A18AS 
5490376 3.71E-05 down NCOR2 chr12 116256452 NCOR2 
840392 0.00106 up PCYOX1 chr2 33620750 PCYOX1 
5890735 0.004648 down SMURF2 chr17 56550041 SMURF2 
3870408 0.001584 up DUSP18 chr22 51093844 DUSP18 
50373 0.008038 up PKP3 
 
89034409 PKP3 
2060703 0.007976 down LOC643304 chr12 89035736 LOC643304 
2900270 0.005195 up LOC729090 chr5 169167519 LOC729090 
1570056 2.68E-08 up MYO5A chr15 115511013 MYO5A 
3420544 0.005806 down LOC653584 chr3 88965597 LOC653584 
1230746 1.69E-07 up ZCCHC6 chr9 58331271 ZCCHC6 
4640484 2.71E-05 up CNOT8 chr5 31542314 CNOT8 
4590608 1.53E-04 down POLD3 chr11 38492355 POLD3 
5270717 0.002061 up CCT3 chr1 58761483 CCT3 
6380112 0.006262 up GRAMD4 chr22 67782363 GRAMD4 
2760070 0.00274 down FLJ36492 chr17 50979285 FLJ36492 
1980138 7.77E-05 down MRRF chr9 40317613 MRRF 
4830551 0.009629 up HDX chrX 142357374 HDX 
4280209 0.013667 up LOC442546 chr7 169170379 LOC442546 
4290196 0.009606 up SCRIB chr8 115527071 SCRIB 
4050242 0.009557 down LOC642356 chr8 89028010 LOC642356 
150181 0.012188 down RUVBL1 
 
88971019 RUVBL1 
3850687 7.83E-04 up FICD chr12 42794619 FICD 
7330753 1.20E-07 down ACAT2 chr6 148539871 ACAT2 
770326 7.56E-06 down LDHA chr11 207028493 LDHA 
1050112 0.013148 down LOC643879 chr2 88953376 LOC643879 
3710253 1.96E-07 up CAPN12 chr19 46852396 CAPN12 
6040307 0.014748 up MORN3 chr12 50355989 MORN3 
2510088 0.012578 up GPR64 chrX 119943128 GPR64 
5670411 0.00747 down 
 
chr2 80804776 HS.580480 
2810437 0.001525 down LOC648834 89035927 LOC648834 
7650441 1.51E-07 down FGFBP1 chr4 49574208 FGFBP1 
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-1.166888 
 
LOC646198 646198 chrX 89059491 LOC646198 
1.105352 
 
KIAA1571 57683 
 
113414229 KIAA1571 
-1.1341 Hs.578698 
 
chr16 28444660 HS.578698 
1.038292 
 
CCDC18 343099 chr1 62243483 CCDC18 
1.104407 
 
TBC1D2 55357 chr9 62198224 TBC1D2 
-1.108194 
 
EPHA1 2041 chr7 56119206 EPHA1 
-1.10814 
 
HS6ST2 90161 chrX 116295255 HS6ST2 
1.100031 
 
YARS 8565 chr1 38202242 YARS 
1.046394 
 
RNF128 79589 chrX 37588872 RNF128 
-1.187303 
 
DCDC2B 149069 chr1 150456470 DCDC2B 
1.16733 
 
LOC652627 652627 
 
169218179 LOC652627 
-1.128098 Hs.98466 
  
chr16 15939282 HS.98466 
1.12353 Hs.187293 
 
chrX 11593467 HS.187293 
1.171721 
 
MSX2 4488 chr5 84452153 MSX2 
1.087886 
 
LOC650851 650851 
 
89042527 LOC650851 
1.109211 
 
ZC3H12A 80149 chr1 13376631 ZC3H12A 
1.087393 
 
LOC401357 401357 chr7 61966820 LOC401357 
-1.094295 
 
LOC641846 641846 
 
89027586 LOC641846 
1.084805 
 
LOC728728 728728 chr1 169162773 LOC728728 
1.091768 
 
LOC100134420 100134420 
 
169168352 LOC100134420 
-1.157601 
 
EGFLAM 133584 chr5 33469934 EGFLAM 
1.130594 
 
C2orf42 54980 chr2 8923527 C2ORF42 
-1.101714 
 
RBMY1E 378950 chrY 56090526 RBMY1E 
-1.236282 
 
LOC647012 647012 chr2 113413206 LOC647012 
1.10317 
 
LOC642325 642325 chr15 113425388 LOC642325 
-1.097124 
 
LOC644749 644749 chrX 89060510 LOC644749 
-1.101309 
 
LOC387703 387703 chr10 169188349 LOC387703 
-1.133106 
 
LOC100131774 100131774 
 
169169846 LOC100131774 
-1.08602 
 
LOC649060 649060 
 
89037132 LOC649060 
-1.078223 
 
ZNF713 349075 chr7 33438599 ZNF713 
1.174702 
 
ZNF658 26149 chr9 55769536 ZNF658 
-1.09019 
 
MITF 4286 chr3 38156696 MITF 
1.066027 
 
APP 351 chr21 41406053 APP 
-1.072007 
 
SPP2 6694 chr2 54262133 SPP2 
-1.160614 
 
SBDSP 155370 chr7 38348442 SBDSP 
1.135423 
 
FLJ13224 79857 chr12 113423275 FLJ13224 
1.223264 
 
ATP2B4 493 chr1 48255958 ATP2B4 
-1.095717 
 
LOC392335 392335 chr9 169177392 LOC392335 
1.082646 
 
SNX32 254122 chr11 72534837 SNX32 
-1.127806 Hs.211182 
 
chr9 27837068 HS.211182 
-1.059878 
 
LOC100129055 100129055 chr10 214831164 LOC100129055 
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3060008 5.18E-04 up C2CD4B chr15 157278360 C2CD4B 
6560091 1.70E-11 down TGFBR2 chr3 133908632 TGFBR2 
1780156 4.54E-04 up SAMD4B chr19 55742694 SAMD4B 
2370017 0.010312 up MCM8 chr20 33469925 MCM8 
7550192 2.06E-11 up SLC16A10 chr6 45433547 SLC16A10 
5080020 0.007012 up UBE2J1 chr6 37577121 UBE2J1 
2100450 0.010103 down LOC653651 chr10 89031348 LOC653651 
3780270 0.001178 up HBP1 chr7 47834345 HBP1 
6270307 2.61E-06 down LOC644934 chr15 113425249 LOC644934 
6400711 4.21E-04 up ZNF573 chr19 40789269 ZNF573 
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ProbeID Regulation Fold change Unigene_ID Symbol Entrez_Gene_ID Accession 
6380242 down -1.101846 
 
TNFSF11 8600 NM_033012.2 
2810327 up 1.1271994 
 
GIT2 9815 NM_014776.2 
5360398 down -1.161789 
 
ERI1 90459 NM_153332.3 
2690528 up 1.1861886 
 
SHMT1 6470 NM_004169.3 
110427 up 1.1791819 
 
TCEA1 6917 NM_201437.1 
6200615 down -1.138269 
 
SAPS2 9701 XM_942540.1 
3420279 up 1.091244 Hs.427229 
 
AI820955 
2940435 down -1.173766 
 
TFRC 7037 NM_003234.1 
3360592 up 1.1556085 
 
LOC388925 388925 XR_016133.2 
4390703 up 1.1696571 
 
PTPN1 5770 NM_002827.2 
7610403 up 1.1212988 
 
HAO1 54363 NM_017545.2 
4260382 down -1.166522 
 
LOC651609 651609 XM_940790.1 
2630619 down -1.198774 
 
RNF20 56254 NM_019592.5 
4590026 down -1.208029 
 
IMPDH2 3615 NM_000884.2 
6520026 down -1.211906 
 
NUCB1 4924 NM_006184.3 
3840372 down -1.152212 
 
LOC440225 440225 XR_042392.1 
2570091 down -1.144436 
 
PHF19 26147 NM_015651.1 
4260291 down -1.141839 
 
BEND4 389206 NM_207406.2 
620136 up 1.1948407 
 
LILRA5 353514 NM_181879.1 
2510324 up 1.1385332 
 
NUDT2 318 NM_147173.1 
1660403 down -1.095697 
 
FLJ41327 401045 NM_207485.1 
130554 up 1.0999346 
 
MIR620 693205 NR_030351.1 
3800487 up 1.1551031 
 
ZNFX1 57169 NM_021035.2 
4540682 down -1.146227 
 
PALM 5064 NM_002579.2 
940754 down -1.097704 
 
TMEM183A 92703 NM_138391.4 
110121 up 1.200783 
 
UBIAD1 29914 NM_013319.1 
3870184 up 1.2462937 
 
LOC441131 441131 XR_038026.1 
7000719 down -1.132033 
 
LOC650254 650254 XM_499385.2 
5310086 down -1.132955 
 
ZBED3 84327 NM_032367.2 
3870747 down -1.164346 
 
LOC645478 645478 XM_932922.2 
50470 down -1.154932 
 
PM20D2 135293 NM_001010853.1 
3850398 up 1.1297903 
 
STX2 2054 NM_194356.1 
5720053 up 1.1915785 
 
KRTHB6 3892 NM_002284.2 
6560445 up 1.1450862 
 
DNAJA3 9093 NM_005147.3 
130725 up 1.068769 
 
VWDE 221806 NM_001135924.1 
6290037 up 1.0788046 
 
LOC100130938 100130938 XM_001720237.1 
3870671 up 1.1964148 
 
SUPT7L 9913 NM_014860.1 
2350373 up 1.176096 
 
C1orf9 51430 NM_014283.2 
6770192 up 1.1502244 
 
LOC100134584 100134584 XM_001725215.1 
2480259 down -1.085064 
 
FLJ37201 283011 XR_000539.1 
2600608 down -1.199936 
 
LOC652436 652436 XM_941879.1 
6280201 down -1.15571 
 
PTPRK 5796 NM_002844.2 
2810181 up 1.1928123 
 
LOC645663 645663 XM_933036.1 
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6650026 up 1.138121 
 
ASTE1 28990 NM_014065.2 
3060278 up 1.165285 
 
MGC15763 92106 NM_138381.1 
3170632 down -1.090755 
 
LOC100132373 100132373 XR_038782.1 
1740674 down -1.173845 
 
TRAPPC3 27095 NM_014408.3 
6980368 down -1.13592 
 
LOC100131335 100131335 XM_001718069.1 
2140152 down -1.088221 Hs.130639 
 
BX109627 
240152 up 1.1372197 
 
MGC57346 401884 XM_377476.4 
2570189 up 1.1536074 
 
NTF4 4909 NM_006179.4 
240484 up 1.0792688 
 
ZNF182 7569 NM_001007088.1 
240392 down -1.076115 Hs.202577 
 
AK091904 
3290025 up 1.1511773 
 
LOC730074 730074 XM_001713717.1 
460259 up 1.1365315 
 
LAT 27040 NM_001014987.1 
6380747 up 1.2090231 
 
ANKRD32 84250 NM_032290.2 
6370315 up 1.143988 
 
HLA-DRB5 3127 NM_002125.3 
990671 down -1.139834 
 
TMEM150C 441027 NM_001080506.1 
4120278 up 1.2168293 
 
KIF23 9493 NM_004856.4 
1170437 up 1.185572 
 
FAM115C 285966 NM_001130026.1 
3360139 up 1.1297554 
 
NUDCD1 84955 NM_032869.2 
6980707 down -1.101264 Hs.566307 
 
AW296281 
3940136 down -1.190212 
 
NUDT15 55270 NM_018283.1 
4070064 down -1.227426 
 
LOC100133017 100133017 XM_001725861.1 
990711 up 1.0892527 
 
FAM45A 404636 NM_207009.2 
6980097 up 1.1785063 
 
NANP 140838 NM_152667.1 
6840315 down -1.164836 
 
LOC644968 644968 XM_928045.1 
1030022 up 1.0780691 
 
PDCD11 22984 NM_014976.1 
5220445 up 1.158647 
 
QKI 9444 NM_006775.1 
4890112 up 1.2324053 
 
ZNRD1 30834 NM_014596.4 
3890215 up 1.2472177 
 
KIAA0258 9827 XM_941746.1 
3460762 up 1.0891758 
 
LOC653441 653441 XM_934161.1 
4390014 up 1.1294407 
 
C1orf58 148362 NM_144695.2 
4120451 down -1.172609 
 
LOC654032 654032 XM_939494.1 
7330750 up 1.0786141 
 
ZNF491 126069 NM_152356.3 
4250091 down -1.160961 Hs.543683 
 
AI494041 
2100050 up 1.1440773 
 
IGHMBP2 3508 NM_002180.2 
4010195 up 1.125784 
 
COL6A2 1292 NM_058175.2 
730259 down -1.141625 
 
CACNA1H 8912 NM_001005407.1 
160343 up 1.1662397 
 
ALDH4A1 8659 NM_003748.2 
2680044 up 1.0811857 
 
RAB27A 5873 NM_183236.1 
6270754 up 1.14812 
 
LHX3 8022 NM_014564.2 
6220246 down -1.111788 
 
LOC647726 647726 XM_936788.1 
4230356 up 1.1693654 
 
C17orf56 146705 NM_144679.1 
6250553 down -1.156608 
 
ITFG3 83986 NM_032039.1 
270068 up 1.0794486 
 
SMOX 54498 NM_175842.1 
4850538 up 1.1937208 
 
PAOX 196743 NM_207128.1 
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510274 up 1.1062914 
 
LOC401010 401010 NR_002826.1 
6180600 up 1.1627448 
 
NLRP7 199713 NM_139176.2 
6510437 up 1.172108 
 
HNRNPM 4670 NM_005968.3 
6250180 up 1.2303317 
 
HMG20A 10363 NM_018200.2 
580670 up 1.1504056 
 
CCM2 83605 NM_031443.3 
5670594 up 1.1357732 
 
NMB 4828 NM_021077.3 
940148 down -1.168866 
 
ABTB2 25841 NM_145804.1 
1470181 down -1.203757 
 
KIAA1712 80817 NM_030633.1 
3830678 down -1.06753 
 
CD207 50489 NM_015717.2 
5560273 down -1.081719 
 
BTBD9 114781 NM_052893.1 
6020280 up 1.1831449 
 
NRAS 4893 NM_002524.2 
2630370 up 1.1182835 
 
MAD1L1 8379 NM_001013836.1 
6020612 down -1.140802 
 
FOXN2 3344 NM_002158.3 
670367 up 1.1702397 
 
RAB5A 5868 NM_004162.3 
4260075 up 1.1414013 
 
LSM3 27258 NM_014463.1 
4570735 down -1.141777 
 
ARG99 83857 NM_031920.2 
1820739 down -1.128086 
 
CCRK 23552 NM_012119.3 
6270619 up 1.1851883 
 
ZNF689 115509 NM_138447.1 
2970100 up 1.2290854 
 
LOC652773 652773 XM_942415.1 
70070 down -1.223366 
 
GRINA 2907 NM_000837.1 
2360446 up 1.1962687 
 
OSBPL3 26031 NM_145321.1 
4640706 down -1.199041 Hs.579522 
 
CR744191 
7210465 down -1.087286 Hs.543364 
 
AI392610 
4640722 down -1.108859 
 
LOC653581 653581 XM_932712.1 
1940082 up 1.1404402 Hs.40289 
  
BX538337 
3610594 up 1.0752829 
 
LOC401602 401602 XR_038621.1 
6200215 up 1.1300117 
 
TTC13 79573 NM_024525.2 
1990687 up 1.1811662 
 
LOC285307 285307 XM_211837.2 
3130445 up 1.1414944 Hs.536451 
 
BX105743 
3830739 up 1.1539812 
 
TCEAL1 9338 NM_001006640.1 
1090072 down -1.10742 
 
KIAA0494 9813 NM_014774.1 
3710719 up 1.1377243 
 
MRPL45 84311 NM_032351.3 
3830112 down -1.130088 
 
LOC644150 644150 XM_933686.1 
6960026 down -1.232799 
 
STXBP2 6813 NM_006949.1 
6220048 up 1.118372 
 
LOC392501 392501 XR_016267.2 
3610019 down -1.101024 
 
DSEL 92126 NM_032160.2 
7160474 down -1.146197 
 
HLA-DQB1 3119 NM_002123.2 
1820154 up 1.1883807 Hs.334093 
 
BG184196 
5360463 down -1.1561 
 
LOC651991 651991 XM_945086.1 
2810746 down -1.163429 
 
DNAJB2 3300 NM_006736.5 
3290671 down -1.112728 
 
LOC647042 647042 XM_294765.7 
4290270 up 1.1540604 
 
LOC645445 645445 XM_932902.1 
730605 up 1.1977056 
 
MRPS22 56945 NM_020191.2 
2060220 up 1.1460649 
 
FAM174A 345757 NM_198507.1 
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1090753 down -1.358616 
 
OAZ2 4947 NM_002537.2 
4150392 up 1.1726096 
 
NR6A1 2649 NM_001489.3 
7050010 up 1.1139034 
 
BNC2 54796 NM_017637.5 
4210408 down -1.150428 
 
GPR157 80045 NM_024980.4 
270341 up 1.2323076 
 
NUDT9 53343 NM_198038.1 
5960162 down -1.15478 
 
ATP6V1G3 127124 NM_133262.2 
4670020 up 1.1310441 
 
NIPA2 81614 NM_030922.5 
2360189 up 1.1435916 
 
AFF4 27125 NM_014423.3 
4610411 up 1.1183329 
 
MTERFD1 51001 NM_015942.3 
7320717 up 1.1143837 
 
GALNT4 8693 NM_003774.3 
4290041 down -1.090744 Hs.146614 
 
DB032405 
3930228 down -1.101705 
 
LOC730274 730274 XM_001125976.1 
4810372 down -1.094232 Hs.87066 
  
BF448257 
5080561 down -1.156813 
 
BARD1 580 NM_000465.1 
7150326 up 1.0703942 
 
ZNF253 56242 NM_021047.2 
1690647 down -1.194795 
 
WASF1 8936 NM_001024936.1 
2140082 down -1.169753 
 
PALMD 54873 NM_017734.3 
2680750 down -1.114575 
 
PTK2 5747 NM_153831.2 
6620669 down -1.114098 
 
C3orf23 285343 NM_173826.3 
3830072 up 1.0999687 
 
HIF3A 64344 NM_022462.3 
2230343 up 1.23422 
 
RABIF 5877 NM_002871.3 
50176 up 1.0749401 
 
TMEM16B 57101 NM_020373.1 
1010246 up 1.4021088 
 
IFI6 2537 NM_022872.2 
2510463 up 1.1417383 
 
METTL13 51603 NM_001007239.1 
7160523 down -1.165254 
 
LOC650439 650439 XM_944199.1 
5700484 down -1.08405 
 
RHBG 57127 NM_020407.2 
2140370 up 1.0898942 
 
RPS29 6235 NM_001030001.1 
1850184 up 1.1209373 
 
PMS2CL 441194 NR_002217.1 
1660341 down -1.191054 
 
FLJ39632 642477 XR_015133.1 
5810068 down -1.112694 
 
SIPA1 6494 NM_006747.2 
3190592 up 1.173245 
 
KIAA1644 85352 XM_936510.2 
780204 down -1.170127 
 
ZNF669 79862 NM_024804.1 
3310039 down -1.135884 
 
KIAA0754 643314 NM_015038.1 
1450408 up 1.161646 
 
SIX1 6495 NM_005982.2 
1780440 up 1.067443 
 
CD79A 973 NM_001783.3 
6760008 down -1.211301 
 
DBN1 1627 NM_004395.2 
4830706 down -1.130678 Hs.561633 
 
BM674971 
1570300 up 1.1124007 
 
SPATA13 221178 NM_153023.1 
5690400 down -1.30657 
 
GSTTP2 653399 NR_003082.1 
5720474 up 1.1827844 
 
TMCO6 55374 NM_018502.3 
6510661 down -1.221892 
 
SS18L1 26039 NM_198935.1 
20056 up 1.0747428 
 
TPT1 7178 NM_003295.1 
1230382 down -1.129323 
 
LOC644285 644285 XM_929631.1 
2900129 up 1.1805732 
 
FTO 79068 NM_001080432.1 
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4060035 up 1.1900021 
 
WDR20 91833 NM_181308.1 
2340193 down -1.165052 
 
KRT80 144501 NM_182507.2 
5420475 down -1.127245 
 
LOC100128056 100128056 XM_001722552.1 
6520440 down -1.149656 
 
KIF1A 547 NM_004321.4 
2060400 up 1.1352553 
 
NKTR 4820 NM_001012651.1 
510112 up 1.1547036 
 
PTAFR 5724 NM_000952.3 
1470170 up 1.1055858 
 
C18orf8 29919 NM_013326.3 
1820187 down -1.11035 
 
TMX3 54495 NM_019022.3 
630524 up 1.1387056 
 
PCTK2 5128 NM_002595.2 
2260349 down -1.447008 
 
MIR1974 100302207 NR_031738.1 
4560110 up 1.1937718 
 
ARMET 7873 NM_006010.2 
2260181 down -1.173932 
 
SLC38A4 55089 NM_018018.2 
290154 down -1.123759 
 
LOC127406 127406 XM_497679.2 
7320291 up 1.1901416 
 
IQCK 124152 NM_153208.1 
770717 up 1.0971276 
 
LOC646079 646079 XM_929039.2 
4150291 up 1.1540513 
 
LOC643466 643466 XM_926789.1 
780435 down -1.180221 
 
LSAMP 4045 NM_002338.2 
1850348 up 1.1251006 
 
ERCC4 2072 NM_005236.1 
2190156 up 1.200798 
 
ASB7 140460 NM_198243.1 
4010386 up 1.127643 
 
PGBD1 84547 NM_032507.2 
2060095 up 1.1251669 
 
SNRK 54861 NM_017719.3 
5960438 down -1.164907 
 
MASP1 5648 NM_139125.2 
450021 up 1.1029086 
 
LOC338797 338797 NM_001025466.1 
4120187 down -1.084005 
 
EFNA3 1944 NM_004952.3 
5690017 down -1.086775 
 
LOC100132288 100132288 NM_001033515.1 
6660736 up 1.1210369 Hs.577713 
 
BI830379 
1980424 up 1.2212617 
 
LOC647349 647349 XR_019572.1 
160364 down -1.165164 
 
ZNF282 8427 NM_003575.2 
2810487 up 1.1136636 
 
OTUB2 78990 NM_023112.2 
990719 down -1.171091 Hs.579530 
 
CD522953 
1580731 up 1.1475848 
 
LOC441896 441896 XR_038885.1 
7320246 up 1.0889354 
 
HEMGN 55363 NM_197978.1 
5890491 down -1.133837 Hs.542687 
 
AK125234 
1580079 up 1.153013 
 
LOC648665 648665 XR_042292.1 
4150673 down -1.093552 
 
LOC646617 646617 XM_929557.1 
20239 down -1.153654 
 
REPS2 9185 NM_004726.2 
380594 up 1.1134462 
 
ZFYVE21 79038 NM_024071.2 
6110768 down -1.229162 
 
ZNF334 55713 NM_199441.1 
7400468 down -1.147194 
 
AP1G2 8906 NM_003917.2 
6020504 down -1.141693 
 
DSCR5 51227 NM_153681.1 
4390326 up 1.1470286 
 
SDR42E1 93517 NM_145168.2 
4830653 down -1.122231 Hs.551358 
 
BF057027 
5260100 down -1.109773 
 
LOC100128548 100128548 XR_037705.1 
4490358 up 1.175183 
 
KIF12 113220 NM_138424.1 
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3780435 up 1.1220481 
 
GART 2618 NM_175085.1 
6400088 up 1.2453427 
 
C6orf148 80759 NM_030568.2 
4230626 down -1.185336 
 
PRKCD 5580 NM_006254.3 
7050138 up 1.1063979 
 
RQCD1 9125 NM_005444.1 
4480112 down -1.201179 
 
PGM5 5239 NM_021965.3 
2030253 up 1.1219461 
 
THSD1P 374500 NR_002816.1 
630332 down -1.205303 
 
ZNF773 374928 NM_198542.1 
4920768 up 1.1533679 
 
LOC647691 647691 XM_936748.1 
2710114 down -1.142388 
 
GNB1 2782 NM_002074.2 
2570300 up 1.1195511 
 
IFI44 10561 NM_006417.3 
4280292 up 1.1600114 
 
RNF126 55658 NM_194460.1 
4120523 up 1.1541446 
 
LOC100131673 100131673 XM_001724387.1 
1470397 down -1.164193 
 
C8orf33 65265 NM_023080.1 
540301 down -1.160606 
 
WHSC1 7468 NM_133330.1 
6400646 up 1.1914828 
 
CCDC85B 11007 NM_006848.2 
3450020 up 1.1057111 
 
PTK7 5754 NM_152882.2 
4250497 down -1.167817 
 
ABCC13 150000 NM_138726.2 
3840593 up 1.116043 
 
SP110 3431 NM_004510.2 
290372 down -1.271676 Hs.125395 
 
BX110351 
4490156 down -1.14282 
 
LOC390367 390367 XM_374352.3 
4480091 up 1.1935943 
 
ASB9 140462 NM_024087.1 
5050403 up 1.0921485 
 
TDH 157739 NR_001578.1 
6940524 down -1.130081 
 
EXD1 161829 NM_152596.2 
5890768 down -1.118049 
 
NFIC 4782 NM_005597.2 
1400037 down -1.143737 
 
OXCT2 64064 NM_022120.1 
4920364 up 1.1595012 
 
LOC728654 728654 XM_001128037.1 
360192 up 1.2140545 
 
INSIG1 3638 NM_198336.1 
6280577 down -1.183386 
 
LOC284620 284620 XR_039089.1 
7610129 up 1.1245514 
 
RAD51C 5889 NM_058216.1 
160424 down -1.12283 
 
SCARNA6 677772 NR_003006.1 
1980039 up 1.1396345 
 
NEIL3 55247 NM_018248.1 
5260477 down -1.204522 
 
LOC100133163 100133163 XM_001726385.1 
1510468 up 1.1456934 
 
GRPEL1 80273 NM_025196.2 
2450338 up 1.1336782 
 
TUSC1 286319 NM_001004125.2 
1980563 down -1.165844 
 
FANCA 2175 NM_001018112.1 
1450072 up 1.1505334 
 
PIGF 5281 NM_002643.3 
6180088 up 1.1098685 
 
ATP6V0E2 155066 NM_145230.2 
730035 up 1.1653159 
 
RAP1GDS1 5910 NM_021159.3 
2070386 down -1.122579 
 
GABRA5 2558 NM_000810.2 
4260066 down -1.17216 
 
LOC646111 646111 XM_929073.1 
4830577 up 1.241573 
 
MRPS16 51021 NM_016065.3 
5910215 up 1.2241374 
 
RAD51C 5889 NM_002876.2 
2000291 up 1.2037286 
 
PCGF3 10336 NM_006315.4 
1780035 down -1.170406 
 
SNORD19 692089 NR_003047.1 
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150386 up 1.0920098 
 
LOC642624 642624 XM_926095.1 
2120717 down -1.121327 
 
BMP10 27302 NM_014482.1 
2900246 up 1.1266797 
 
TRIOBP 11078 NM_138632.2 
1090546 up 1.1745024 
 
PPTC7 160760 NM_139283.1 
4860747 up 1.0886035 
 
LOC654342 654342 XM_946374.1 
4390195 up 1.1022699 
 
HMGN1 3150 NM_004965.6 
2230204 up 1.1496263 
 
OAS2 4939 NM_001032731.1 
1470176 up 1.1264374 
 
SYT17 51760 NM_016524.2 
6620315 down -1.132426 
 
COQ6 51004 NM_182476.1 
2370301 down -1.161003 
 
PELI3 246330 NM_145065.1 
3800692 up 1.2002835 
 
LOC652683 652683 XM_942283.2 
2230059 up 1.1651405 
 
NAT12 122830 NM_001011713.1 
770040 up 1.1363423 
 
CBWD7 728013 XM_001717050.1 
7510170 down -1.273866 
 
CD79A 973 NM_021601.3 
1110280 down -1.167376 
 
MAP6 4135 NM_207577.1 
1260056 down -1.127988 
 
LOC643265 643265 XM_926627.1 
4730634 up 1.1757776 
 
SLC31A2 1318 NM_001860.2 
7330114 up 1.1184865 
 
ZNF366 167465 NM_152625.1 
160162 down -1.156233 
 
LOC652721 652721 XM_942346.2 
1820717 down -1.146642 
 
LOC100129767 100129767 XR_039365.1 
2320603 down -1.199532 
 
FLJ40113 374650 NR_003246.1 
3130300 up 1.1497453 
 
NRN1 51299 NM_016588.2 
7210209 up 1.0830995 
 
CENTD2 116985 NM_001040118.1 
5720086 down -1.125677 Hs.137466 
 
AL137470 
4250184 down -1.091055 
 
LOC653184 653184 XM_927570.1 
6840184 up 1.3923239 
 
GRN 2896 NM_002087.2 
5560398 up 1.1731099 
 
DEGS1 8560 NM_003676.2 
3120400 up 1.2459776 
 
KANK2 25959 NM_015493.4 
2230113 up 1.1942986 
 
TANK 10010 NM_004180.2 
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down -1.13842 
 
LOC646198 646198 89059491 LOC646198 
up 1.115448 
 
KIAA1571 57683 113414229 KIAA1571 
up 1.129676 Hs.578698 
 
28444660 HS.578698 
down -1.051351 
 
CCDC18 343099 62243483 CCDC18 
down -1.096435 
 
TBC1D2 55357 62198224 TBC1D2 
down -1.12665 
 
EPHA1 2041 56119206 EPHA1 
down -1.09942 
 
HS6ST2 90161 116295255 HS6ST2 
up 1.068824 
 
YARS 8565 38202242 YARS 
down -1.063068 
 
RNF128 79589 37588872 RNF128 
up 1.215158 
 
DCDC2B 149069 150456470 DCDC2B 
up 1.171807 
 
LOC652627 652627 169218179 LOC652627 
up 1.129679 Hs.98466 
  
15939282 HS.98466 
up 1.156498 Hs.187293 
 
11593467 HS.187293 
up 1.119788 
 
MSX2 4488 84452153 MSX2 
up 1.082557 
 
LOC650851 650851 89042527 LOC650851 
up 1.099799 
 
ZC3H12A 80149 13376631 ZC3H12A 
down -1.08052 
 
LOC401357 401357 61966820 LOC401357 
down -1.068555 
 
LOC641846 641846 89027586 LOC641846 
down -1.118542 
 
LOC728728 728728 169162773 LOC728728 
up 1.080354 
 
LOC100134420 100134420 169168352 LOC100134420 
down -1.173822 
 
EGFLAM 133584 33469934 EGFLAM 
up 1.101918 
 
C2orf42 54980 8923527 C2ORF42 
down -1.120504 
 
RBMY1E 378950 56090526 RBMY1E 
up 1.21002 
 
LOC647012 647012 113413206 LOC647012 
down -1.104548 
 
LOC642325 642325 113425388 LOC642325 
up 1.073368 
 
LOC644749 644749 89060510 LOC644749 
down -1.17688 
 
LOC387703 387703 169188349 LOC387703 
down -1.10599 
 
LOC100131774 100131774 169169846 LOC100131774 
down -1.075613 
 
LOC649060 649060 89037132 LOC649060 
up 1.082465 
 
ZNF713 349075 33438599 ZNF713 
up 1.123446 
 
ZNF658 26149 55769536 ZNF658 
up 1.092025 
 
MITF 4286 38156696 MITF 
down -1.121361 
 
APP 351 41406053 APP 
down -1.073675 
 
SPP2 6694 54262133 SPP2 
up 1.171518 
 
SBDSP 155370 38348442 SBDSP 
down -1.143442 
 
FLJ13224 79857 113423275 FLJ13224 
up 1.161505 
 
ATP2B4 493 48255958 ATP2B4 
down -1.065657 
 
LOC392335 392335 169177392 LOC392335 
up 1.081459 
 
SNX32 254122 72534837 SNX32 
down -1.136309 Hs.211182 
 
27837068 HS.211182 
up 1.064002 
 
LOC100129055 100129055 214831164 LOC100129055 
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ProbeID Regulation Symbol Entrez_Gene_ID 
3930132 up TUBA3D 113457 
5960328 down LOC644844 644844 
150706 up UGP2 7360 
5560747 up LOC100133803 100133803 
770743 down MIR1978 100302173 
10176 up TAF15 8148 
7320722 up LOC727984 727984 
5260035 down LGALS14 56891 
2690561 up RPLP1 6176 
70286 up LOC441743 441743 
6840072 down PTEN 5728 
2760564 up LOC389322 389322 
620047 up BNIP3L 665 
5290220 up LOC100129599 100129599 
1660477 down CALM1 801 
5860689 down PRODH 5625 
830593 up VIM 7431 
7050019 up VIM 7431 
6650603 up LOC100131905 100131905 
7040286 down ACSL5 51703 
5360156 down IFITM1 8519 
3310050 down GNRH2 2797 
780309 down CIDEC 63924 
4880678 down GNRH2 2797 
7100424 down N-PAC 84656 
4570044 up ODAM 54959 
4150014 down CEACAM1 634 
5700753 down CEACAM1 634 
4050070 up UBE2E1 7324 
3060408 up LOC645231 645231 
5960324 up ARL6IP1 23204 
3060477 down RPL8 6132 
3930370 up LOC100131672 100131672 
6960411 down RCN2 5955 
730626 down LOC285074 285074 
2810093 down LOC285074 285074 
2030736 down SEPHS2 22928 
3140521 down SCARNA14 692149 
2190128 down RAB32 10981 
2060674 up CA2 760 
870630 up CA2 760 
240576 down C5orf28 64417 
4670487 down SIVA 10572 
4260397 up LOC727821 727821 
5340129 down AKR1C2 1646 
5490341 up CLEC2D 29121 
290600 up ZNF738 148203 
6250408 up RPL12P6 440176 
5090278 down GPX2 2877 
5360347 down NQO1 1728 
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650519 down TMBIM6 7009 
270609 up ANXA2P1 303 
4640445 up AIDA 64853 
4480128 up LOC100134273 100134273 
990768 down OAS3 4940 
1980176 down LOC644799 644799 
520240 up SERPINI1 5274 
4070037 down TMED10 10972 
6450524 up LOC653737 653737 
3780056 down GGCT 79017 
7400377 down CEACAM6 4680 
3890541 down ITGA2 3673 
2760452 down RPS29 6235 
6370703 down UGT1A6 54578 
2230008 up FGG 2266 
2100196 down ISG15 9636 
5670497 down LOC644363 644363 
6840014 up TULP3 7289 
5130255 up FGA 2243 
2850703 up FGA 2243 
4860463 up TAF15 8148 
4260338 up LOC647307 647307 
6200068 up CYP51A1 1595 
160615 up GGH 8836 
5260176 down GSTA1 2938 
1090561 down GSTA1 2938 
7210259 down ANAPC1 64682 
830039 down ERGIC1 57222 
6290537 up HRSP12 10247 
1660181 down LOC440145 440145 
6520273 up LOC646527 646527 
130228 down HDHD1A 8226 
1690066 down MX1 4599 
3450735 down UGT1A6 54578 
4200152 down IFRD2 7866 
6860593 down 
  
6760017 up YY1 7528 
5260047 up FABP5 2171 
650685 up LOC390735 390735 
2750670 down SCARNA18 677765 
2340577 down AQP10 89872 
2070437 up LOC653631 653631 
6620368 down NAT13 80218 
4210041 down UQCRQ 27089 
830682 up LOC387934 387934 
3290435 down TFDP1 7027 
6370538 down WBSCR22 114049 
6960735 up UQCRH 7388 
1340192 down REEP1 65055 
1260129 down TMED10P 286102 
3990170 down IFI27 3429 
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3140202 down MYPOP 339344 
2750088 up LOC730996 730996 
2970577 up LOC730996 730996 
2120021 up COL3A1 1281 
5820601 down CCND1 595 
780041 down LAMP2 3920 
3120743 down LAMP2 3920 
4640086 down FOXQ1 94234 
3400215 down B3GNT1 11041 
3170594 down MAL2 114569 
2000148 down IFIT1 3434 
3940358 down OSBPL8 114882 
6770202 down IPO11 51194 
4010086 down OKL38 29948 
2060280 up LOC646966 646966 
3180025 up FGG 2266 
1470435 up LOC642738 642738 
6250672 up CCNO 10309 
5360307 up LOC644937 644937 
1260341 down IL13RA1 3597 
1710142 up RGS4 5999 
7400072 up FGA 2243 
4900343 down MORF4L1 10933 
7000224 down SIRT1 23411 
1240440 down TXNIP 10628 
840554 down RYBP 23429 
620615 down NDUFA7 4701 
4070075 up OSTCL 202459 
1820253 down PRKRIR 5612 
2360594 down TPT1 7178 
4220259 up CTSZ 1522 
110181 up KIAA1199 57214 
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ENSMUSG00000000275 ENSMUSG00000006782 ENSMUSG00000020029 
ENSMUSG00000000278 ENSMUSG00000006932 ENSMUSG00000020034 
ENSMUSG00000000296 ENSMUSG00000007476 ENSMUSG00000020038 
ENSMUSG00000000303 ENSMUSG00000007564 ENSMUSG00000020044 
ENSMUSG00000000326 ENSMUSG00000007613 ENSMUSG00000020048 
ENSMUSG00000000374 ENSMUSG00000007617 ENSMUSG00000020051 
ENSMUSG00000000420 ENSMUSG00000007656 ENSMUSG00000020076 
ENSMUSG00000000440 ENSMUSG00000007659 ENSMUSG00000020078 
ENSMUSG00000000530 ENSMUSG00000007739 ENSMUSG00000020085 
ENSMUSG00000000531 ENSMUSG00000007815 ENSMUSG00000020089 
ENSMUSG00000000532 ENSMUSG00000008035 ENSMUSG00000020091 
ENSMUSG00000000562 ENSMUSG00000008090 ENSMUSG00000020097 
ENSMUSG00000000581 ENSMUSG00000008301 ENSMUSG00000020098 
ENSMUSG00000000594 ENSMUSG00000008348 ENSMUSG00000020102 
ENSMUSG00000000686 ENSMUSG00000008398 ENSMUSG00000020108 
ENSMUSG00000000708 ENSMUSG00000008976 ENSMUSG00000020114 
ENSMUSG00000000711 ENSMUSG00000009013 ENSMUSG00000020122 
ENSMUSG00000000751 ENSMUSG00000009079 ENSMUSG00000020123 
ENSMUSG00000000753 ENSMUSG00000009097 ENSMUSG00000020130 
ENSMUSG00000000787 ENSMUSG00000009112 ENSMUSG00000020131 
ENSMUSG00000000792 ENSMUSG00000009378 ENSMUSG00000020149 
ENSMUSG00000000817 ENSMUSG00000009549 ENSMUSG00000020163 
ENSMUSG00000000826 ENSMUSG00000009575 ENSMUSG00000020173 
ENSMUSG00000000861 ENSMUSG00000009646 ENSMUSG00000020176 
ENSMUSG00000000876 ENSMUSG00000009739 ENSMUSG00000020182 
ENSMUSG00000000901 ENSMUSG00000009828 ENSMUSG00000020190 
ENSMUSG00000001014 ENSMUSG00000009927 ENSMUSG00000020205 
ENSMUSG00000001016 ENSMUSG00000010097 ENSMUSG00000020211 
ENSMUSG00000001029 ENSMUSG00000010358 ENSMUSG00000020241 
ENSMUSG00000001095 ENSMUSG00000010376 ENSMUSG00000020250 
ENSMUSG00000001119 ENSMUSG00000010435 ENSMUSG00000020260 
ENSMUSG00000001123 ENSMUSG00000010517 ENSMUSG00000020262 
ENSMUSG00000001128 ENSMUSG00000010660 ENSMUSG00000020265 
ENSMUSG00000001131 ENSMUSG00000010830 ENSMUSG00000020271 
ENSMUSG00000001225 ENSMUSG00000011148 ENSMUSG00000020277 
ENSMUSG00000001240 ENSMUSG00000011179 ENSMUSG00000020288 
ENSMUSG00000001247 ENSMUSG00000011257 ENSMUSG00000020290 
ENSMUSG00000001249 ENSMUSG00000011305 ENSMUSG00000020300 
ENSMUSG00000001270 ENSMUSG00000011958 ENSMUSG00000020309 
ENSMUSG00000001323 ENSMUSG00000012123 ENSMUSG00000020330 
ENSMUSG00000001366 ENSMUSG00000012422 ENSMUSG00000020361 
ENSMUSG00000001403 ENSMUSG00000012443 ENSMUSG00000020380 
ENSMUSG00000001416 ENSMUSG00000012705 ENSMUSG00000020381 
ENSMUSG00000001435 ENSMUSG00000012848 ENSMUSG00000020385 
ENSMUSG00000001467 ENSMUSG00000013275 ENSMUSG00000020400 
ENSMUSG00000001472 ENSMUSG00000013593 ENSMUSG00000020402 
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ENSMUSG00000001506 ENSMUSG00000013663 ENSMUSG00000020405 
ENSMUSG00000001517 ENSMUSG00000013698 ENSMUSG00000020427 
ENSMUSG00000001524 ENSMUSG00000013822 ENSMUSG00000020432 
ENSMUSG00000001525 ENSMUSG00000013973 ENSMUSG00000020458 
ENSMUSG00000001542 ENSMUSG00000014077 ENSMUSG00000020459 
ENSMUSG00000001576 ENSMUSG00000014177 ENSMUSG00000020463 
ENSMUSG00000001604 ENSMUSG00000014195 ENSMUSG00000020484 
ENSMUSG00000001627 ENSMUSG00000014226 ENSMUSG00000020486 
ENSMUSG00000001663 ENSMUSG00000014313 ENSMUSG00000020514 
ENSMUSG00000001670 ENSMUSG00000014503 ENSMUSG00000020534 
ENSMUSG00000001729 ENSMUSG00000014542 ENSMUSG00000020538 
ENSMUSG00000001774 ENSMUSG00000014551 ENSMUSG00000020541 
ENSMUSG00000001794 ENSMUSG00000014599 ENSMUSG00000020570 
ENSMUSG00000001829 ENSMUSG00000014606 ENSMUSG00000020571 
ENSMUSG00000001891 ENSMUSG00000014725 ENSMUSG00000020572 
ENSMUSG00000001930 ENSMUSG00000014748 ENSMUSG00000020585 
ENSMUSG00000001942 ENSMUSG00000014771 ENSMUSG00000020591 
ENSMUSG00000001962 ENSMUSG00000014773 ENSMUSG00000020593 
ENSMUSG00000002017 ENSMUSG00000014859 ENSMUSG00000020599 
ENSMUSG00000002031 ENSMUSG00000014905 ENSMUSG00000020609 
ENSMUSG00000002032 ENSMUSG00000014956 ENSMUSG00000020610 
ENSMUSG00000002055 ENSMUSG00000015002 ENSMUSG00000020611 
ENSMUSG00000002129 ENSMUSG00000015053 ENSMUSG00000020614 
ENSMUSG00000002147 ENSMUSG00000015083 ENSMUSG00000020629 
ENSMUSG00000002204 ENSMUSG00000015112 ENSMUSG00000020641 
ENSMUSG00000002222 ENSMUSG00000015143 ENSMUSG00000020644 
ENSMUSG00000002227 ENSMUSG00000015217 ENSMUSG00000020647 
ENSMUSG00000002265 ENSMUSG00000015243 ENSMUSG00000020650 
ENSMUSG00000002274 ENSMUSG00000015289 ENSMUSG00000020664 
ENSMUSG00000002319 ENSMUSG00000015290 ENSMUSG00000020681 
ENSMUSG00000002324 ENSMUSG00000015291 ENSMUSG00000020715 
ENSMUSG00000002329 ENSMUSG00000015312 ENSMUSG00000020719 
ENSMUSG00000002455 ENSMUSG00000015357 ENSMUSG00000020733 
ENSMUSG00000002524 ENSMUSG00000015363 ENSMUSG00000020766 
ENSMUSG00000002550 ENSMUSG00000015437 ENSMUSG00000020775 
ENSMUSG00000002580 ENSMUSG00000015522 ENSMUSG00000020787 
ENSMUSG00000002603 ENSMUSG00000015568 ENSMUSG00000020790 
ENSMUSG00000002661 ENSMUSG00000015647 ENSMUSG00000020831 
ENSMUSG00000002733 ENSMUSG00000015653 ENSMUSG00000020846 
ENSMUSG00000002741 ENSMUSG00000015745 ENSMUSG00000020849 
ENSMUSG00000002831 ENSMUSG00000015749 ENSMUSG00000020873 
ENSMUSG00000002845 ENSMUSG00000015750 ENSMUSG00000020889 
ENSMUSG00000002885 ENSMUSG00000015804 ENSMUSG00000020893 
ENSMUSG00000002910 ENSMUSG00000015846 ENSMUSG00000020897 
ENSMUSG00000002944 ENSMUSG00000015852 ENSMUSG00000020900 
ENSMUSG00000002948 ENSMUSG00000015932 ENSMUSG00000020902 
ENSMUSG00000002949 ENSMUSG00000015947 ENSMUSG00000020914 
ENSMUSG00000002957 ENSMUSG00000015970 ENSMUSG00000020917 
ENSMUSG00000002963 ENSMUSG00000016087 ENSMUSG00000020918 
ENSMUSG00000002996 ENSMUSG00000016150 ENSMUSG00000020926 
ENSMUSG00000003032 ENSMUSG00000016194 ENSMUSG00000020950 
ENSMUSG00000003099 ENSMUSG00000016256 ENSMUSG00000020954 
ENSMUSG00000003123 ENSMUSG00000016257 ENSMUSG00000020962 
ENSMUSG00000003135 ENSMUSG00000016308 ENSMUSG00000020986 
ENSMUSG00000003153 ENSMUSG00000016319 ENSMUSG00000020994 
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ENSMUSG00000003161 ENSMUSG00000016534 ENSMUSG00000021000 
ENSMUSG00000003228 ENSMUSG00000016541 ENSMUSG00000021012 
ENSMUSG00000003299 ENSMUSG00000016626 ENSMUSG00000021025 
ENSMUSG00000003379 ENSMUSG00000017119 ENSMUSG00000021037 
ENSMUSG00000003380 ENSMUSG00000017188 ENSMUSG00000021051 
ENSMUSG00000003402 ENSMUSG00000017264 ENSMUSG00000021054 
ENSMUSG00000003426 ENSMUSG00000017428 ENSMUSG00000021065 
ENSMUSG00000003477 ENSMUSG00000017493 ENSMUSG00000021069 
ENSMUSG00000003526 ENSMUSG00000017588 ENSMUSG00000021072 
ENSMUSG00000003528 ENSMUSG00000017652 ENSMUSG00000021096 
ENSMUSG00000003531 ENSMUSG00000017686 ENSMUSG00000021114 
ENSMUSG00000003534 ENSMUSG00000017707 ENSMUSG00000021127 
ENSMUSG00000003541 ENSMUSG00000017716 ENSMUSG00000021135 
ENSMUSG00000003545 ENSMUSG00000017737 ENSMUSG00000021149 
ENSMUSG00000003617 ENSMUSG00000017754 ENSMUSG00000021178 
ENSMUSG00000003721 ENSMUSG00000017756 ENSMUSG00000021185 
ENSMUSG00000003759 ENSMUSG00000017950 ENSMUSG00000021196 
ENSMUSG00000003779 ENSMUSG00000017969 ENSMUSG00000021200 
ENSMUSG00000003813 ENSMUSG00000018001 ENSMUSG00000021203 
ENSMUSG00000003814 ENSMUSG00000018102 ENSMUSG00000021214 
ENSMUSG00000003923 ENSMUSG00000018167 ENSMUSG00000021218 
ENSMUSG00000003948 ENSMUSG00000018287 ENSMUSG00000021226 
ENSMUSG00000003949 ENSMUSG00000018334 ENSMUSG00000021228 
ENSMUSG00000004035 ENSMUSG00000018339 ENSMUSG00000021236 
ENSMUSG00000004038 ENSMUSG00000018340 ENSMUSG00000021238 
ENSMUSG00000004070 ENSMUSG00000018362 ENSMUSG00000021242 
ENSMUSG00000004071 ENSMUSG00000018379 ENSMUSG00000021248 
ENSMUSG00000004098 ENSMUSG00000018395 ENSMUSG00000021253 
ENSMUSG00000004127 ENSMUSG00000018401 ENSMUSG00000021265 
ENSMUSG00000004221 ENSMUSG00000018417 ENSMUSG00000021270 
ENSMUSG00000004264 ENSMUSG00000018428 ENSMUSG00000021273 
ENSMUSG00000004285 ENSMUSG00000018442 ENSMUSG00000021277 
ENSMUSG00000004319 ENSMUSG00000018446 ENSMUSG00000021281 
ENSMUSG00000004347 ENSMUSG00000018459 ENSMUSG00000021282 
ENSMUSG00000004446 ENSMUSG00000018470 ENSMUSG00000021286 
ENSMUSG00000004460 ENSMUSG00000018548 ENSMUSG00000021288 
ENSMUSG00000004558 ENSMUSG00000018566 ENSMUSG00000021322 
ENSMUSG00000004610 ENSMUSG00000018567 ENSMUSG00000021327 
ENSMUSG00000004633 ENSMUSG00000018585 ENSMUSG00000021338 
ENSMUSG00000004667 ENSMUSG00000018593 ENSMUSG00000021340 
ENSMUSG00000004798 ENSMUSG00000018604 ENSMUSG00000021360 
ENSMUSG00000004846 ENSMUSG00000018669 ENSMUSG00000021361 
ENSMUSG00000004891 ENSMUSG00000018736 ENSMUSG00000021364 
ENSMUSG00000004931 ENSMUSG00000018752 ENSMUSG00000021365 
ENSMUSG00000004980 ENSMUSG00000018796 ENSMUSG00000021368 
ENSMUSG00000005089 ENSMUSG00000018819 ENSMUSG00000021376 
ENSMUSG00000005161 ENSMUSG00000018821 ENSMUSG00000021390 
ENSMUSG00000005220 ENSMUSG00000018846 ENSMUSG00000021411 
ENSMUSG00000005251 ENSMUSG00000018882 ENSMUSG00000021417 
ENSMUSG00000005268 ENSMUSG00000018900 ENSMUSG00000021427 
ENSMUSG00000005312 ENSMUSG00000018906 ENSMUSG00000021453 
ENSMUSG00000005320 ENSMUSG00000018907 ENSMUSG00000021456 
ENSMUSG00000005355 ENSMUSG00000018930 ENSMUSG00000021477 
ENSMUSG00000005362 ENSMUSG00000018965 ENSMUSG00000021493 
ENSMUSG00000005373 ENSMUSG00000018995 ENSMUSG00000021495 
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ENSMUSG00000005374 ENSMUSG00000019039 ENSMUSG00000021500 
ENSMUSG00000005410 ENSMUSG00000019054 ENSMUSG00000021518 
ENSMUSG00000005447 ENSMUSG00000019066 ENSMUSG00000021520 
ENSMUSG00000005481 ENSMUSG00000019122 ENSMUSG00000021537 
ENSMUSG00000005483 ENSMUSG00000019132 ENSMUSG00000021549 
ENSMUSG00000005514 ENSMUSG00000019179 ENSMUSG00000021556 
ENSMUSG00000005610 ENSMUSG00000019189 ENSMUSG00000021576 
ENSMUSG00000005615 ENSMUSG00000019232 ENSMUSG00000021577 
ENSMUSG00000005683 ENSMUSG00000019256 ENSMUSG00000021583 
ENSMUSG00000005800 ENSMUSG00000019278 ENSMUSG00000021585 
ENSMUSG00000005803 ENSMUSG00000019302 ENSMUSG00000021587 
ENSMUSG00000005836 ENSMUSG00000019433 ENSMUSG00000021591 
ENSMUSG00000005871 ENSMUSG00000019471 ENSMUSG00000021594 
ENSMUSG00000005873 ENSMUSG00000019478 ENSMUSG00000021595 
ENSMUSG00000005892 ENSMUSG00000019494 ENSMUSG00000021607 
ENSMUSG00000005973 ENSMUSG00000019558 ENSMUSG00000021620 
ENSMUSG00000006024 ENSMUSG00000019577 ENSMUSG00000021660 
ENSMUSG00000006057 ENSMUSG00000019579 ENSMUSG00000021662 
ENSMUSG00000006205 ENSMUSG00000019590 ENSMUSG00000021670 
ENSMUSG00000006299 ENSMUSG00000019774 ENSMUSG00000021676 
ENSMUSG00000006301 ENSMUSG00000019791 ENSMUSG00000021706 
ENSMUSG00000006315 ENSMUSG00000019794 ENSMUSG00000021707 
ENSMUSG00000006335 ENSMUSG00000019802 ENSMUSG00000021709 
ENSMUSG00000006356 ENSMUSG00000019804 ENSMUSG00000021710 
ENSMUSG00000006369 ENSMUSG00000019820 ENSMUSG00000021737 
ENSMUSG00000006390 ENSMUSG00000019849 ENSMUSG00000021745 
ENSMUSG00000006392 ENSMUSG00000019851 ENSMUSG00000021748 
ENSMUSG00000006442 ENSMUSG00000019857 ENSMUSG00000021750 
ENSMUSG00000006458 ENSMUSG00000019873 ENSMUSG00000021751 
ENSMUSG00000006494 ENSMUSG00000019889 ENSMUSG00000021756 
ENSMUSG00000006517 ENSMUSG00000019916 ENSMUSG00000021764 
ENSMUSG00000006529 ENSMUSG00000019923 ENSMUSG00000021775 
ENSMUSG00000036368 ENSMUSG00000019942 ENSMUSG00000021794 
ENSMUSG00000036371 ENSMUSG00000019948 ENSMUSG00000021822 
ENSMUSG00000036427 ENSMUSG00000019960 ENSMUSG00000021823 
ENSMUSG00000036432 ENSMUSG00000019961 ENSMUSG00000021830 
ENSMUSG00000036478 ENSMUSG00000019966 ENSMUSG00000021832 
ENSMUSG00000036503 ENSMUSG00000037062 ENSMUSG00000037608 
ENSMUSG00000036570 ENSMUSG00000037071 ENSMUSG00000037652 
ENSMUSG00000036580 ENSMUSG00000037095 ENSMUSG00000037664 
ENSMUSG00000036585 ENSMUSG00000037119 ENSMUSG00000037674 
ENSMUSG00000036591 ENSMUSG00000037149 ENSMUSG00000037697 
ENSMUSG00000036594 ENSMUSG00000037161 ENSMUSG00000037706 
ENSMUSG00000036606 ENSMUSG00000037166 ENSMUSG00000037710 
ENSMUSG00000036620 ENSMUSG00000037172 ENSMUSG00000037712 
ENSMUSG00000036639 ENSMUSG00000037197 ENSMUSG00000037722 
ENSMUSG00000036667 ENSMUSG00000037206 ENSMUSG00000037736 
ENSMUSG00000036751 ENSMUSG00000037235 ENSMUSG00000037780 
ENSMUSG00000036752 ENSMUSG00000037236 ENSMUSG00000037798 
ENSMUSG00000036769 ENSMUSG00000037242 ENSMUSG00000037808 
ENSMUSG00000036775 ENSMUSG00000037260 ENSMUSG00000037818 
ENSMUSG00000036777 ENSMUSG00000037266 ENSMUSG00000037820 
ENSMUSG00000036825 ENSMUSG00000037278 ENSMUSG00000037847 
ENSMUSG00000036833 ENSMUSG00000037326 ENSMUSG00000037852 
ENSMUSG00000036840 ENSMUSG00000037348 ENSMUSG00000037894 
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ENSMUSG00000036867 ENSMUSG00000037362 ENSMUSG00000037916 
ENSMUSG00000036875 ENSMUSG00000037370 ENSMUSG00000037921 
ENSMUSG00000036879 ENSMUSG00000037379 ENSMUSG00000037926 
ENSMUSG00000036887 ENSMUSG00000037393 ENSMUSG00000037933 
ENSMUSG00000036896 ENSMUSG00000037419 ENSMUSG00000037935 
ENSMUSG00000036905 ENSMUSG00000037440 ENSMUSG00000037936 
ENSMUSG00000036918 ENSMUSG00000037465 ENSMUSG00000037960 
ENSMUSG00000036932 ENSMUSG00000037493 ENSMUSG00000037962 
ENSMUSG00000036957 ENSMUSG00000037514 ENSMUSG00000037984 
ENSMUSG00000036990 ENSMUSG00000037573 ENSMUSG00000037989 
ENSMUSG00000037003 ENSMUSG00000037580 ENSMUSG00000038068 
ENSMUSG00000037017 ENSMUSG00000037581 ENSMUSG00000038086 
ENSMUSG00000037025 ENSMUSG00000037601 ENSMUSG00000038092 
ENSMUSG00000041815 ENSMUSG00000042797 ENSMUSG00000044749 
ENSMUSG00000041827 ENSMUSG00000042826 ENSMUSG00000044783 
ENSMUSG00000041836 ENSMUSG00000042834 ENSMUSG00000044813 
ENSMUSG00000041957 ENSMUSG00000042978 ENSMUSG00000044864 
ENSMUSG00000041959 ENSMUSG00000043013 ENSMUSG00000044876 
ENSMUSG00000041975 ENSMUSG00000043068 ENSMUSG00000044894 
ENSMUSG00000041984 ENSMUSG00000043122 ENSMUSG00000044986 
ENSMUSG00000042032 ENSMUSG00000043207 ENSMUSG00000045038 
ENSMUSG00000042043 ENSMUSG00000043259 ENSMUSG00000045160 
ENSMUSG00000042118 ENSMUSG00000043300 ENSMUSG00000045193 
ENSMUSG00000042195 ENSMUSG00000043613 ENSMUSG00000045211 
ENSMUSG00000042198 ENSMUSG00000043668 ENSMUSG00000045382 
ENSMUSG00000042213 ENSMUSG00000043681 ENSMUSG00000045438 
ENSMUSG00000042246 ENSMUSG00000043760 
ENSMUSG00000045455|ENSMU
SG00000048007 
ENSMUSG00000042248 ENSMUSG00000043909 ENSMUSG00000045471 
ENSMUSG00000042275 ENSMUSG00000043962 ENSMUSG00000045534 
ENSMUSG00000042279 ENSMUSG00000044018 ENSMUSG00000045569 
ENSMUSG00000042289 ENSMUSG00000044026 ENSMUSG00000045658 
ENSMUSG00000042323 ENSMUSG00000044037 ENSMUSG00000045664 
ENSMUSG00000042363 ENSMUSG00000044167 ENSMUSG00000045730 
ENSMUSG00000042396 ENSMUSG00000044221 ENSMUSG00000045868 
ENSMUSG00000042406 ENSMUSG00000044258 ENSMUSG00000045917 
ENSMUSG00000042451 ENSMUSG00000044309 ENSMUSG00000045954 
ENSMUSG00000042506 ENSMUSG00000044320 ENSMUSG00000045962 
ENSMUSG00000042510 ENSMUSG00000044338 ENSMUSG00000045969 
ENSMUSG00000042520 ENSMUSG00000044350 ENSMUSG00000045973 
ENSMUSG00000042622 ENSMUSG00000044393 ENSMUSG00000045983 
ENSMUSG00000042650 ENSMUSG00000044461 ENSMUSG00000046027 
ENSMUSG00000042682 ENSMUSG00000044573 ENSMUSG00000046032 
ENSMUSG00000042712 ENSMUSG00000044600 ENSMUSG00000046062 
ENSMUSG00000042747 ENSMUSG00000044674 ENSMUSG00000046093 
ENSMUSG00000055717 ENSMUSG00000055782 ENSMUSG00000055866 
ENSMUSG00000055737 ENSMUSG00000055835 ENSMUSG00000055912 
ENSMUSG00000056116 ENSMUSG00000057228 ENSMUSG00000058793 
ENSMUSG00000056201 ENSMUSG00000057230 ENSMUSG00000058794 
ENSMUSG00000056211 ENSMUSG00000057322 ENSMUSG00000058799 
ENSMUSG00000056228 ENSMUSG00000057367 ENSMUSG00000059005 
ENSMUSG00000056313 ENSMUSG00000057409 ENSMUSG00000059039 
ENSMUSG00000056426 ENSMUSG00000057457 
ENSMUSG00000059040|ENSMU
SG00000063524 
ENSMUSG00000056429 ENSMUSG00000057722 ENSMUSG00000059060 
ENSMUSG00000056501 ENSMUSG00000057738 ENSMUSG00000059070 
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ENSMUSG00000056515 ENSMUSG00000057789 ENSMUSG00000059201 
ENSMUSG00000056537 ENSMUSG00000057880 ENSMUSG00000059208 
ENSMUSG00000056553 ENSMUSG00000057933 ENSMUSG00000059218 
ENSMUSG00000056612 ENSMUSG00000058153 ENSMUSG00000059263 
ENSMUSG00000056666 ENSMUSG00000058207 ENSMUSG00000059434 
ENSMUSG00000056708 ENSMUSG00000058230 ENSMUSG00000059436 
ENSMUSG00000056749 ENSMUSG00000058297 ENSMUSG00000059447 
ENSMUSG00000056917 ENSMUSG00000058454 ENSMUSG00000059518 
ENSMUSG00000056973 ENSMUSG00000058488 ENSMUSG00000059734 
ENSMUSG00000056999 ENSMUSG00000058523 ENSMUSG00000059796 
ENSMUSG00000057074 ENSMUSG00000058672 ENSMUSG00000059811 
ENSMUSG00000057113 ENSMUSG00000058706 ENSMUSG00000059824 
ENSMUSG00000057193 ENSMUSG00000058729 ENSMUSG00000059895 
ENSMUSG00000073489 ENSMUSG00000074207 ENSMUSG00000074698 
ENSMUSG00000073676 ENSMUSG00000074264 ENSMUSG00000074743 
ENSMUSG00000073832|ENSMU
SG00000073839 ENSMUSG00000074340 ENSMUSG00000075273 
ENSMUSG00000073838 ENSMUSG00000074604 ENSMUSG00000075602 
ENSMUSG00000073888 ENSMUSG00000074656 ENSMUSG00000075705 
ENSMUSG00000073987 ENSMUSG00000074682 ENSMUSG00000076431 
ENSMUSG00000021871 ENSMUSG00000024143 ENSMUSG00000026150 
ENSMUSG00000021877 ENSMUSG00000024145 ENSMUSG00000026179 
ENSMUSG00000021884 ENSMUSG00000024150 ENSMUSG00000026185 
ENSMUSG00000021892 ENSMUSG00000024164 ENSMUSG00000026201 
ENSMUSG00000021903 ENSMUSG00000024190 ENSMUSG00000026202 
ENSMUSG00000021910 ENSMUSG00000024194 ENSMUSG00000026203 
ENSMUSG00000021929 ENSMUSG00000024208 ENSMUSG00000026205 
ENSMUSG00000021930 ENSMUSG00000024212 ENSMUSG00000026223 
ENSMUSG00000021938 ENSMUSG00000024222 ENSMUSG00000026229 
ENSMUSG00000021939 ENSMUSG00000024231 ENSMUSG00000026234 
ENSMUSG00000021944 ENSMUSG00000024236 ENSMUSG00000026245 
ENSMUSG00000021945 ENSMUSG00000024241 ENSMUSG00000026248 
ENSMUSG00000021947 ENSMUSG00000024245 ENSMUSG00000026255 
ENSMUSG00000021948 ENSMUSG00000024247 ENSMUSG00000026259 
ENSMUSG00000021950 ENSMUSG00000024254 ENSMUSG00000026272 
ENSMUSG00000021951 ENSMUSG00000024269 ENSMUSG00000026275 
ENSMUSG00000021957 ENSMUSG00000024271 ENSMUSG00000026278 
ENSMUSG00000021969 ENSMUSG00000024277 ENSMUSG00000026285 
ENSMUSG00000021987 ENSMUSG00000024283 ENSMUSG00000026289 
ENSMUSG00000021994 ENSMUSG00000024292 ENSMUSG00000026308 
ENSMUSG00000021998 ENSMUSG00000024298 ENSMUSG00000026317 
ENSMUSG00000022003 ENSMUSG00000024304 ENSMUSG00000026319 
ENSMUSG00000022010 ENSMUSG00000024308 ENSMUSG00000026353 
ENSMUSG00000022013 ENSMUSG00000024331 ENSMUSG00000026360 
ENSMUSG00000022018 ENSMUSG00000024337 ENSMUSG00000026361 
ENSMUSG00000022033 ENSMUSG00000024346 ENSMUSG00000026365 
ENSMUSG00000022034 ENSMUSG00000024354 ENSMUSG00000026368 
ENSMUSG00000022037 ENSMUSG00000024359 ENSMUSG00000026380 
ENSMUSG00000022040 ENSMUSG00000024360 ENSMUSG00000026385 
ENSMUSG00000022048 ENSMUSG00000024372 ENSMUSG00000026390 
ENSMUSG00000022051 ENSMUSG00000024386 ENSMUSG00000026393 
ENSMUSG00000022053 ENSMUSG00000024392 ENSMUSG00000026405 
ENSMUSG00000022056 ENSMUSG00000024404 ENSMUSG00000026407 
ENSMUSG00000022090 ENSMUSG00000024413 ENSMUSG00000026409 
ENSMUSG00000022096 ENSMUSG00000024424 ENSMUSG00000026421 
203 
 
ENSMUSG00000022098 ENSMUSG00000024425 ENSMUSG00000026434 
ENSMUSG00000022102 ENSMUSG00000024426 ENSMUSG00000026437 
ENSMUSG00000022119 ENSMUSG00000024431 ENSMUSG00000026456 
ENSMUSG00000022125 ENSMUSG00000024448 ENSMUSG00000026473 
ENSMUSG00000022129 ENSMUSG00000024487 ENSMUSG00000026475 
ENSMUSG00000022149 ENSMUSG00000024498 ENSMUSG00000026489 
ENSMUSG00000022151 ENSMUSG00000024507 ENSMUSG00000026492 
ENSMUSG00000022181 ENSMUSG00000024526 ENSMUSG00000026496 
ENSMUSG00000022186 ENSMUSG00000024538 ENSMUSG00000026509 
ENSMUSG00000022193 ENSMUSG00000024580 ENSMUSG00000026526 
ENSMUSG00000022194 ENSMUSG00000024587 ENSMUSG00000026531 
ENSMUSG00000022198 ENSMUSG00000024588 ENSMUSG00000026535 
ENSMUSG00000022200 ENSMUSG00000024589 ENSMUSG00000026554 
ENSMUSG00000022215 ENSMUSG00000024590 ENSMUSG00000026568 
ENSMUSG00000022219 ENSMUSG00000024597 ENSMUSG00000026576 
ENSMUSG00000022225 ENSMUSG00000024601 ENSMUSG00000026586 
ENSMUSG00000022241 ENSMUSG00000024610 ENSMUSG00000026605 
ENSMUSG00000022246 ENSMUSG00000024617 ENSMUSG00000026608 
ENSMUSG00000022247 ENSMUSG00000024644 ENSMUSG00000026617 
ENSMUSG00000022253 ENSMUSG00000024660 ENSMUSG00000026622 
ENSMUSG00000022257 ENSMUSG00000024665 ENSMUSG00000026623 
ENSMUSG00000022261 ENSMUSG00000024695 ENSMUSG00000026628 
ENSMUSG00000022265 ENSMUSG00000024713 ENSMUSG00000026638 
ENSMUSG00000022270 ENSMUSG00000024727 ENSMUSG00000026639 
ENSMUSG00000022299 ENSMUSG00000024747 ENSMUSG00000026640 
ENSMUSG00000022314 ENSMUSG00000024750 ENSMUSG00000026655 
ENSMUSG00000022322 ENSMUSG00000024778 ENSMUSG00000026659 
ENSMUSG00000022323 ENSMUSG00000024782 ENSMUSG00000026663 
ENSMUSG00000022336 ENSMUSG00000024805 ENSMUSG00000026669 
ENSMUSG00000022338 ENSMUSG00000024807 ENSMUSG00000026670 
ENSMUSG00000022353 ENSMUSG00000024827 ENSMUSG00000026687 
ENSMUSG00000022358 ENSMUSG00000024835 ENSMUSG00000026691 
ENSMUSG00000022370 ENSMUSG00000024847 ENSMUSG00000026696 
ENSMUSG00000022383 ENSMUSG00000024856 ENSMUSG00000026721 
ENSMUSG00000022389 ENSMUSG00000024892 ENSMUSG00000026726 
ENSMUSG00000022403 ENSMUSG00000024896 ENSMUSG00000026728 
ENSMUSG00000022415 ENSMUSG00000024899 ENSMUSG00000026730 
ENSMUSG00000022419 ENSMUSG00000024900 ENSMUSG00000026749 
ENSMUSG00000022420 ENSMUSG00000024902 ENSMUSG00000026751 
ENSMUSG00000022425 ENSMUSG00000024921 ENSMUSG00000026755 
ENSMUSG00000022427 ENSMUSG00000024924 ENSMUSG00000026773 
ENSMUSG00000022433 ENSMUSG00000024940 ENSMUSG00000026775 
ENSMUSG00000022437 ENSMUSG00000024942 ENSMUSG00000026781 
ENSMUSG00000022440 ENSMUSG00000024955 ENSMUSG00000026790 
ENSMUSG00000022442 ENSMUSG00000024959 ENSMUSG00000026814 
ENSMUSG00000022443 ENSMUSG00000024975 ENSMUSG00000026818 
ENSMUSG00000022445 ENSMUSG00000024981 ENSMUSG00000026822 
ENSMUSG00000022450 ENSMUSG00000024985 ENSMUSG00000026827 
ENSMUSG00000022462 ENSMUSG00000024986 ENSMUSG00000026832 
ENSMUSG00000022464 ENSMUSG00000024991 ENSMUSG00000026839 
ENSMUSG00000022477 ENSMUSG00000024997 ENSMUSG00000026842 
ENSMUSG00000022496 ENSMUSG00000025002 ENSMUSG00000026848 
ENSMUSG00000022500 ENSMUSG00000025003 ENSMUSG00000026853 
ENSMUSG00000022505 ENSMUSG00000025004 ENSMUSG00000026864 
ENSMUSG00000022508 ENSMUSG00000025006 ENSMUSG00000026866 
204 
 
ENSMUSG00000022512 ENSMUSG00000025016 ENSMUSG00000026870 
ENSMUSG00000022514 ENSMUSG00000025035 ENSMUSG00000026874 
ENSMUSG00000022528 ENSMUSG00000025037 ENSMUSG00000026879 
ENSMUSG00000022548 ENSMUSG00000025059 ENSMUSG00000026896 
ENSMUSG00000022550 ENSMUSG00000025068 ENSMUSG00000026914 
ENSMUSG00000022555 ENSMUSG00000025075 ENSMUSG00000026922 
ENSMUSG00000022556 ENSMUSG00000025076 ENSMUSG00000026924 
ENSMUSG00000022564 ENSMUSG00000025077 ENSMUSG00000026942 
ENSMUSG00000022565 ENSMUSG00000025078 ENSMUSG00000026961 
ENSMUSG00000022579 ENSMUSG00000025085 ENSMUSG00000026966 
ENSMUSG00000022587 ENSMUSG00000025089 ENSMUSG00000026986 
ENSMUSG00000022594 ENSMUSG00000025129 ENSMUSG00000026988 
ENSMUSG00000022602 ENSMUSG00000025138 ENSMUSG00000026991 
ENSMUSG00000022615 ENSMUSG00000025139 ENSMUSG00000027016 
ENSMUSG00000022622 ENSMUSG00000025150 ENSMUSG00000027048 
ENSMUSG00000022634 ENSMUSG00000025153 ENSMUSG00000027067 
ENSMUSG00000022656 ENSMUSG00000025162 ENSMUSG00000027075 
ENSMUSG00000022664 ENSMUSG00000025165 ENSMUSG00000027088 
ENSMUSG00000022672 ENSMUSG00000025170 ENSMUSG00000027099 
ENSMUSG00000022673 ENSMUSG00000025176 ENSMUSG00000027104 
ENSMUSG00000022686 ENSMUSG00000025178 ENSMUSG00000027108 
ENSMUSG00000022708 ENSMUSG00000025190 ENSMUSG00000027111 
ENSMUSG00000022742 ENSMUSG00000025194 ENSMUSG00000027133 
ENSMUSG00000022747 ENSMUSG00000025199 ENSMUSG00000027164 
ENSMUSG00000022752 ENSMUSG00000025203 ENSMUSG00000027170 
ENSMUSG00000022757 ENSMUSG00000025204 ENSMUSG00000027177 
ENSMUSG00000022769 ENSMUSG00000025207 ENSMUSG00000027180 
ENSMUSG00000022771 ENSMUSG00000025217 ENSMUSG00000027184 
ENSMUSG00000022773 ENSMUSG00000025220 ENSMUSG00000027195 
ENSMUSG00000022774 ENSMUSG00000025221 ENSMUSG00000027199 
ENSMUSG00000022791 ENSMUSG00000025225 ENSMUSG00000027204 
ENSMUSG00000022797 ENSMUSG00000025227 ENSMUSG00000027206 
ENSMUSG00000022809 ENSMUSG00000025260 ENSMUSG00000027210 
ENSMUSG00000022814 ENSMUSG00000025270 ENSMUSG00000027223 
ENSMUSG00000022816 ENSMUSG00000025271 ENSMUSG00000027227 
ENSMUSG00000022817 ENSMUSG00000025272 ENSMUSG00000027238 
ENSMUSG00000022843 ENSMUSG00000025277 ENSMUSG00000027248 
ENSMUSG00000022853 ENSMUSG00000025283 ENSMUSG00000027253 
ENSMUSG00000022863 ENSMUSG00000025323 ENSMUSG00000027274 
ENSMUSG00000022878 ENSMUSG00000025337 ENSMUSG00000027282 
ENSMUSG00000022884 ENSMUSG00000025353 ENSMUSG00000027288 
ENSMUSG00000022895 ENSMUSG00000025357 ENSMUSG00000027296 
ENSMUSG00000022899 ENSMUSG00000025364 ENSMUSG00000027315 
ENSMUSG00000022906 ENSMUSG00000025372 ENSMUSG00000027326 
ENSMUSG00000022948 ENSMUSG00000025395 ENSMUSG00000027349 
ENSMUSG00000022951 ENSMUSG00000025401 ENSMUSG00000027358 
ENSMUSG00000022956 ENSMUSG00000025402 ENSMUSG00000027365 
ENSMUSG00000022957 ENSMUSG00000025405 ENSMUSG00000027367 
ENSMUSG00000022961 ENSMUSG00000025408 ENSMUSG00000027371 
ENSMUSG00000022972 ENSMUSG00000025428 ENSMUSG00000027378 
ENSMUSG00000022992 ENSMUSG00000025477 ENSMUSG00000027379 
ENSMUSG00000022994 ENSMUSG00000025479 ENSMUSG00000027381 
ENSMUSG00000022995 ENSMUSG00000025486 ENSMUSG00000027386 
ENSMUSG00000023004 ENSMUSG00000025487 ENSMUSG00000027397 
ENSMUSG00000023015 ENSMUSG00000025488 ENSMUSG00000027405 
205 
 
ENSMUSG00000023018 ENSMUSG00000025492 ENSMUSG00000027408 
ENSMUSG00000023022 ENSMUSG00000025497 ENSMUSG00000027422 
ENSMUSG00000023031 ENSMUSG00000025503 ENSMUSG00000027423 
ENSMUSG00000023034 ENSMUSG00000025504 ENSMUSG00000027429 
ENSMUSG00000023043 ENSMUSG00000025510 ENSMUSG00000027452 
ENSMUSG00000023044 ENSMUSG00000025511 ENSMUSG00000027465 
ENSMUSG00000023045 ENSMUSG00000025532 ENSMUSG00000027469 
ENSMUSG00000023046 ENSMUSG00000025533 ENSMUSG00000027472 
ENSMUSG00000023048 ENSMUSG00000025544 ENSMUSG00000027479 
ENSMUSG00000023067 ENSMUSG00000025586 ENSMUSG00000027485 
ENSMUSG00000023073 ENSMUSG00000025646 ENSMUSG00000027490 
ENSMUSG00000023075 ENSMUSG00000025651 ENSMUSG00000027496 
ENSMUSG00000023087 ENSMUSG00000025702 ENSMUSG00000027499 
ENSMUSG00000023092 ENSMUSG00000025728 ENSMUSG00000027531 
ENSMUSG00000023122 ENSMUSG00000025731 ENSMUSG00000027533 
ENSMUSG00000023132 ENSMUSG00000025732 ENSMUSG00000027551 
ENSMUSG00000023150 ENSMUSG00000025743 ENSMUSG00000027552 
ENSMUSG00000023224 ENSMUSG00000025757 ENSMUSG00000027559 
ENSMUSG00000023243 ENSMUSG00000025780 ENSMUSG00000027562 
ENSMUSG00000023272 ENSMUSG00000025781 ENSMUSG00000027566 
ENSMUSG00000023307 ENSMUSG00000025791 ENSMUSG00000027580 
ENSMUSG00000023452 ENSMUSG00000025809 ENSMUSG00000027597 
ENSMUSG00000023791 ENSMUSG00000025812 ENSMUSG00000027599 
ENSMUSG00000023809 ENSMUSG00000025823 ENSMUSG00000027601 
ENSMUSG00000023829 ENSMUSG00000025858 ENSMUSG00000027610 
ENSMUSG00000023832 ENSMUSG00000025860 ENSMUSG00000027613 
ENSMUSG00000023846 ENSMUSG00000025862 ENSMUSG00000027620 
ENSMUSG00000023905 ENSMUSG00000025887 ENSMUSG00000027637 
ENSMUSG00000023935 ENSMUSG00000025888 ENSMUSG00000027667 
ENSMUSG00000023944 ENSMUSG00000025903 ENSMUSG00000027668 
ENSMUSG00000023951 ENSMUSG00000025907 ENSMUSG00000027673 
ENSMUSG00000023963 ENSMUSG00000025921 ENSMUSG00000027690 
ENSMUSG00000023967 ENSMUSG00000025934 ENSMUSG00000027698 
ENSMUSG00000024002 ENSMUSG00000025950 ENSMUSG00000027699 
ENSMUSG00000024014 ENSMUSG00000025964 ENSMUSG00000027706 
ENSMUSG00000024038 ENSMUSG00000025968 ENSMUSG00000027715 
ENSMUSG00000024039 ENSMUSG00000025981 ENSMUSG00000027746 
ENSMUSG00000024045 ENSMUSG00000025982 ENSMUSG00000027763 
ENSMUSG00000024052 ENSMUSG00000025991 ENSMUSG00000027770 
ENSMUSG00000024063 ENSMUSG00000026003 ENSMUSG00000027782 
ENSMUSG00000024066 ENSMUSG00000026004 ENSMUSG00000027792 
ENSMUSG00000024070 ENSMUSG00000026012 ENSMUSG00000027801 
ENSMUSG00000024072 ENSMUSG00000026024 ENSMUSG00000027803 
ENSMUSG00000024073 ENSMUSG00000026028 ENSMUSG00000027805 
ENSMUSG00000024085 ENSMUSG00000026029 ENSMUSG00000027810 
ENSMUSG00000024087 ENSMUSG00000026031 ENSMUSG00000027822 
ENSMUSG00000024097 ENSMUSG00000026042 ENSMUSG00000027834 
ENSMUSG00000024104 ENSMUSG00000026043 ENSMUSG00000027835 
ENSMUSG00000024107 ENSMUSG00000026047 ENSMUSG00000027852 
ENSMUSG00000024121 ENSMUSG00000026062 ENSMUSG00000027869 
ENSMUSG00000024124 ENSMUSG00000026064 ENSMUSG00000027870 
ENSMUSG00000024131 ENSMUSG00000026070 ENSMUSG00000027879 
ENSMUSG00000024132 ENSMUSG00000026072 ENSMUSG00000027884 
ENSMUSG00000024134 ENSMUSG00000026077 ENSMUSG00000027900 
ENSMUSG00000024140 ENSMUSG00000026090 ENSMUSG00000027944 
206 
 
ENSMUSG00000026109 ENSMUSG00000026104 ENSMUSG00000027947 
ENSMUSG00000038143 ENSMUSG00000038776 ENSMUSG00000039361 
ENSMUSG00000038145 ENSMUSG00000038805 ENSMUSG00000039375 
ENSMUSG00000038250 ENSMUSG00000038845 ENSMUSG00000039382 
ENSMUSG00000038252 ENSMUSG00000038848 ENSMUSG00000039384 
ENSMUSG00000038312 ENSMUSG00000038859 ENSMUSG00000039405 
ENSMUSG00000038332 ENSMUSG00000038871 ENSMUSG00000039410 
ENSMUSG00000038344 ENSMUSG00000038884 ENSMUSG00000039456 
ENSMUSG00000038366 ENSMUSG00000038893 ENSMUSG00000039461 
ENSMUSG00000038374 ENSMUSG00000038965 ENSMUSG00000039474 
ENSMUSG00000038375 ENSMUSG00000039062 ENSMUSG00000039485 
ENSMUSG00000038393 ENSMUSG00000039068 ENSMUSG00000039519 
ENSMUSG00000038418 ENSMUSG00000039089 ENSMUSG00000039601 
ENSMUSG00000038422 ENSMUSG00000039096 ENSMUSG00000039615 
ENSMUSG00000038503 ENSMUSG00000039109 ENSMUSG00000039620 
ENSMUSG00000038526 ENSMUSG00000039114 ENSMUSG00000039629 
ENSMUSG00000038539 ENSMUSG00000039145 ENSMUSG00000039630 
ENSMUSG00000038569 ENSMUSG00000039157 ENSMUSG00000039640 
ENSMUSG00000038582 ENSMUSG00000039159 ENSMUSG00000039648 
ENSMUSG00000038599 ENSMUSG00000039195 ENSMUSG00000039671 
ENSMUSG00000038619 ENSMUSG00000039197 ENSMUSG00000039682 
ENSMUSG00000038641 ENSMUSG00000039217 ENSMUSG00000039798 
ENSMUSG00000038642 ENSMUSG00000039218 ENSMUSG00000039831 
ENSMUSG00000038650 ENSMUSG00000039221 ENSMUSG00000039840 
ENSMUSG00000038671 ENSMUSG00000039233 ENSMUSG00000039899 
ENSMUSG00000038695 ENSMUSG00000039239 ENSMUSG00000039910 
ENSMUSG00000038700 ENSMUSG00000039242 ENSMUSG00000039914 
ENSMUSG00000038712 ENSMUSG00000039246 ENSMUSG00000039952 
ENSMUSG00000038717 ENSMUSG00000039275 ENSMUSG00000039956 
ENSMUSG00000038718 ENSMUSG00000039304 ENSMUSG00000039960 
ENSMUSG00000038745 ENSMUSG00000039316 ENSMUSG00000039982 
ENSMUSG00000038754 ENSMUSG00000039323 ENSMUSG00000039989 
ENSMUSG00000046160 ENSMUSG00000047843 ENSMUSG00000049404 
ENSMUSG00000046179 ENSMUSG00000047866 ENSMUSG00000049470 
ENSMUSG00000046230 ENSMUSG00000047879 ENSMUSG00000049511 
ENSMUSG00000046324 ENSMUSG00000047921 ENSMUSG00000049580 
ENSMUSG00000046447 ENSMUSG00000047945 ENSMUSG00000049588 
ENSMUSG00000046470 ENSMUSG00000047963 ENSMUSG00000049647 
ENSMUSG00000046519 ENSMUSG00000048126 ENSMUSG00000049723 
ENSMUSG00000046546 ENSMUSG00000048138 ENSMUSG00000049775 
ENSMUSG00000046562 ENSMUSG00000048285 ENSMUSG00000049892 
ENSMUSG00000046668 ENSMUSG00000048307 ENSMUSG00000049932 
ENSMUSG00000046718 ENSMUSG00000048332 ENSMUSG00000050017 
ENSMUSG00000046722 ENSMUSG00000048376 ENSMUSG00000050043 
ENSMUSG00000046818 ENSMUSG00000048482 ENSMUSG00000050069 
ENSMUSG00000046876 ENSMUSG00000048490 ENSMUSG00000050071 
ENSMUSG00000046879 ENSMUSG00000048537 ENSMUSG00000050103 
ENSMUSG00000047067 ENSMUSG00000048546 ENSMUSG00000050213 
ENSMUSG00000047112 ENSMUSG00000048572 ENSMUSG00000050234 
ENSMUSG00000047139 ENSMUSG00000048578 ENSMUSG00000050295 
ENSMUSG00000047155 ENSMUSG00000048703 ENSMUSG00000050370 
ENSMUSG00000047230 ENSMUSG00000048756 ENSMUSG00000050423 
ENSMUSG00000047250 ENSMUSG00000048769 ENSMUSG00000050440 
ENSMUSG00000047363 ENSMUSG00000048772 ENSMUSG00000050445 
ENSMUSG00000047368 ENSMUSG00000048782 ENSMUSG00000050520 
207 
 
ENSMUSG00000047514 ENSMUSG00000048834 ENSMUSG00000050541 
ENSMUSG00000047554 ENSMUSG00000048856 ENSMUSG00000050565 
ENSMUSG00000047617 ENSMUSG00000048905 ENSMUSG00000050612 
ENSMUSG00000047638 ENSMUSG00000048910 ENSMUSG00000050627 
ENSMUSG00000047714 ENSMUSG00000048911 ENSMUSG00000050737 
ENSMUSG00000047731 ENSMUSG00000049044 ENSMUSG00000050761 
ENSMUSG00000047797 ENSMUSG00000049354 ENSMUSG00000050912 
ENSMUSG00000047822 ENSMUSG00000049387 ENSMUSG00000050953 
ENSMUSG00000055923 ENSMUSG00000056050 ENSMUSG00000056071 
ENSMUSG00000055980 ENSMUSG00000056054 ENSMUSG00000056091 
ENSMUSG00000059908 ENSMUSG00000061393 ENSMUSG00000062908 
ENSMUSG00000060002 ENSMUSG00000061540 ENSMUSG00000062929 
ENSMUSG00000060126 ENSMUSG00000061780 ENSMUSG00000062937 
ENSMUSG00000060261 ENSMUSG00000061877 ENSMUSG00000062960 
ENSMUSG00000060376 ENSMUSG00000061906 ENSMUSG00000063015 
ENSMUSG00000060548 ENSMUSG00000061911 ENSMUSG00000063077 
ENSMUSG00000060560 ENSMUSG00000061947 ENSMUSG00000063229 
ENSMUSG00000060586 ENSMUSG00000061959 ENSMUSG00000063273 
ENSMUSG00000060657 ENSMUSG00000061981 ENSMUSG00000063275 
ENSMUSG00000060733 ENSMUSG00000062014 ENSMUSG00000063354 
ENSMUSG00000060739 ENSMUSG00000062352 ENSMUSG00000063406 
ENSMUSG00000060807 ENSMUSG00000062380 ENSMUSG00000063415 
ENSMUSG00000060862 ENSMUSG00000062397 ENSMUSG00000063522 
ENSMUSG00000060882 ENSMUSG00000062410 ENSMUSG00000063558 
ENSMUSG00000060904 ENSMUSG00000062515 ENSMUSG00000063659 
ENSMUSG00000060961 ENSMUSG00000062563 ENSMUSG00000063683 
ENSMUSG00000061032 ENSMUSG00000062604 ENSMUSG00000063694 
ENSMUSG00000061046 ENSMUSG00000062783 ENSMUSG00000063713 
ENSMUSG00000061130 ENSMUSG00000062797 ENSMUSG00000063727 
ENSMUSG00000061132 ENSMUSG00000062822 ENSMUSG00000063730 
ENSMUSG00000061353 ENSMUSG00000062901 ENSMUSG00000063931 
ENSMUSG00000076441 ENSMUSG00000078453 ENSMUSG00000079111 
ENSMUSG00000076615 ENSMUSG00000078566 ENSMUSG00000079316 
ENSMUSG00000076722 ENSMUSG00000078652 ENSMUSG00000079363 
ENSMUSG00000078302 ENSMUSG00000078922 ENSMUSG00000079488 
ENSMUSG00000078429 ENSMUSG00000079017 ENSMUSG00000079523 
ENSMUSG00000078440 ENSMUSG00000079057 
 ENSMUSG00000027952 ENSMUSG00000030042 ENSMUSG00000032079 
ENSMUSG00000027954 ENSMUSG00000030057 ENSMUSG00000032085 
ENSMUSG00000027962 ENSMUSG00000030062 ENSMUSG00000032092 
ENSMUSG00000027968 ENSMUSG00000030077 ENSMUSG00000032094 
ENSMUSG00000027978 ENSMUSG00000030087 ENSMUSG00000032114 
ENSMUSG00000027993 ENSMUSG00000030088 ENSMUSG00000032116 
ENSMUSG00000027997 ENSMUSG00000030089 ENSMUSG00000032121 
ENSMUSG00000027999 ENSMUSG00000030094 ENSMUSG00000032171 
ENSMUSG00000028005 ENSMUSG00000030096 ENSMUSG00000032174 
ENSMUSG00000028011 ENSMUSG00000030101 ENSMUSG00000032187 
ENSMUSG00000028024 ENSMUSG00000030103 ENSMUSG00000032193 
ENSMUSG00000028029 ENSMUSG00000030104 ENSMUSG00000032207 
ENSMUSG00000028032 ENSMUSG00000030105 ENSMUSG00000032216 
ENSMUSG00000028034 ENSMUSG00000030107 ENSMUSG00000032228 
ENSMUSG00000028035 ENSMUSG00000030108 ENSMUSG00000032238 
ENSMUSG00000028044 ENSMUSG00000030109 ENSMUSG00000032243 
ENSMUSG00000028049 ENSMUSG00000030110 ENSMUSG00000032249 
ENSMUSG00000028053 ENSMUSG00000030127 ENSMUSG00000032271 
208 
 
ENSMUSG00000028070 ENSMUSG00000030131 ENSMUSG00000032279 
ENSMUSG00000028088 ENSMUSG00000030137 ENSMUSG00000032290 
ENSMUSG00000028098 ENSMUSG00000030138 ENSMUSG00000032294 
ENSMUSG00000028104 ENSMUSG00000030161 ENSMUSG00000032320 
ENSMUSG00000028107 ENSMUSG00000030162 ENSMUSG00000032323 
ENSMUSG00000028124 ENSMUSG00000030168 ENSMUSG00000032328 
ENSMUSG00000028127 ENSMUSG00000030208 ENSMUSG00000032330 
ENSMUSG00000028128 ENSMUSG00000030214 ENSMUSG00000032336 
ENSMUSG00000028132 ENSMUSG00000030220 ENSMUSG00000032348 
ENSMUSG00000028150 ENSMUSG00000030232 ENSMUSG00000032349 
ENSMUSG00000028161 ENSMUSG00000030236 ENSMUSG00000032353 
ENSMUSG00000028163 ENSMUSG00000030237 ENSMUSG00000032359 
ENSMUSG00000028182 ENSMUSG00000030244 ENSMUSG00000032366 
ENSMUSG00000028187 ENSMUSG00000030257 ENSMUSG00000032372 
ENSMUSG00000028191 ENSMUSG00000030268 ENSMUSG00000032376 
ENSMUSG00000028195 ENSMUSG00000030278 ENSMUSG00000032380 
ENSMUSG00000028199 ENSMUSG00000030291 ENSMUSG00000032381 
ENSMUSG00000028211 ENSMUSG00000030337 ENSMUSG00000032402 
ENSMUSG00000028248 ENSMUSG00000030339 ENSMUSG00000032411 
ENSMUSG00000028251 ENSMUSG00000030341 ENSMUSG00000032418 
ENSMUSG00000028255 ENSMUSG00000030352 ENSMUSG00000032431 
ENSMUSG00000028261 ENSMUSG00000030357 ENSMUSG00000032434 
ENSMUSG00000028270 ENSMUSG00000030364 ENSMUSG00000032437 
ENSMUSG00000028273 ENSMUSG00000030403 ENSMUSG00000032449 
ENSMUSG00000028291 ENSMUSG00000030421 ENSMUSG00000032480 
ENSMUSG00000028307 ENSMUSG00000030470 ENSMUSG00000032492 
ENSMUSG00000028312 ENSMUSG00000030483 ENSMUSG00000032504 
ENSMUSG00000028339 ENSMUSG00000030495 ENSMUSG00000032548 
ENSMUSG00000028394 ENSMUSG00000030513 ENSMUSG00000032555 
ENSMUSG00000028398 ENSMUSG00000030530 ENSMUSG00000032557 
ENSMUSG00000028399 ENSMUSG00000030545 ENSMUSG00000032558 
ENSMUSG00000028405 ENSMUSG00000030551 ENSMUSG00000032575 
ENSMUSG00000028410 ENSMUSG00000030555 ENSMUSG00000032580 
ENSMUSG00000028420 ENSMUSG00000030556 ENSMUSG00000032602 
ENSMUSG00000028426 ENSMUSG00000030579 ENSMUSG00000032698 
ENSMUSG00000028454 ENSMUSG00000030590 ENSMUSG00000032705 
ENSMUSG00000028464 ENSMUSG00000030629 ENSMUSG00000032725 
ENSMUSG00000028470 ENSMUSG00000030643 ENSMUSG00000032740 
ENSMUSG00000028479 ENSMUSG00000030647 ENSMUSG00000032757 
ENSMUSG00000028480 ENSMUSG00000030653 ENSMUSG00000032763 
ENSMUSG00000028494 ENSMUSG00000030674 ENSMUSG00000032766 
ENSMUSG00000028496 ENSMUSG00000030677 ENSMUSG00000032777 
ENSMUSG00000028527 ENSMUSG00000030680 ENSMUSG00000032786 
ENSMUSG00000028530 ENSMUSG00000030703 ENSMUSG00000032816 
ENSMUSG00000028536 ENSMUSG00000030711 ENSMUSG00000032827 
ENSMUSG00000028556 ENSMUSG00000030733 ENSMUSG00000032860 
ENSMUSG00000028584 ENSMUSG00000030737 ENSMUSG00000032902 
ENSMUSG00000028599 ENSMUSG00000030738 ENSMUSG00000032942 
ENSMUSG00000028607 ENSMUSG00000030741 ENSMUSG00000032946 
ENSMUSG00000028612 ENSMUSG00000030747 ENSMUSG00000032966 
ENSMUSG00000028639 ENSMUSG00000030761 ENSMUSG00000032978 
ENSMUSG00000028646 ENSMUSG00000030762 ENSMUSG00000033022 
ENSMUSG00000028655 ENSMUSG00000030772 ENSMUSG00000033024 
ENSMUSG00000028671 ENSMUSG00000030779 ENSMUSG00000033059 
ENSMUSG00000028676 ENSMUSG00000030789 ENSMUSG00000033060 
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ENSMUSG00000028680 ENSMUSG00000030800 ENSMUSG00000033065 
ENSMUSG00000028691 ENSMUSG00000030805 ENSMUSG00000033096 
ENSMUSG00000028706 ENSMUSG00000030824 ENSMUSG00000033105 
ENSMUSG00000028713 ENSMUSG00000030842 ENSMUSG00000033107 
ENSMUSG00000028715 ENSMUSG00000030846 ENSMUSG00000033161 
ENSMUSG00000028757 ENSMUSG00000030852 ENSMUSG00000033174 
ENSMUSG00000028776 ENSMUSG00000030862 ENSMUSG00000033186 
ENSMUSG00000028788 ENSMUSG00000030867 ENSMUSG00000033187 
ENSMUSG00000028792 ENSMUSG00000030869 ENSMUSG00000033228 
ENSMUSG00000028820 ENSMUSG00000030870 ENSMUSG00000033294 
ENSMUSG00000028832 ENSMUSG00000030880 ENSMUSG00000033295 
ENSMUSG00000028851 ENSMUSG00000030895 ENSMUSG00000033308 
ENSMUSG00000028862 ENSMUSG00000030905 ENSMUSG00000033318 
ENSMUSG00000028869 ENSMUSG00000030909 ENSMUSG00000033355 
ENSMUSG00000028883 ENSMUSG00000030963 ENSMUSG00000033379 
ENSMUSG00000028894 ENSMUSG00000030967 ENSMUSG00000033400 
ENSMUSG00000028902 ENSMUSG00000030978 ENSMUSG00000033416 
ENSMUSG00000028914 ENSMUSG00000030990 ENSMUSG00000033436 
ENSMUSG00000028919 ENSMUSG00000030994 ENSMUSG00000033446 
ENSMUSG00000028931 ENSMUSG00000031007 ENSMUSG00000033491 
ENSMUSG00000028937 ENSMUSG00000031010 ENSMUSG00000033499 
ENSMUSG00000028954 ENSMUSG00000031016 ENSMUSG00000033538 
ENSMUSG00000028955 ENSMUSG00000031024 ENSMUSG00000033540 
ENSMUSG00000028957 ENSMUSG00000031065 ENSMUSG00000033545 
ENSMUSG00000028959 ENSMUSG00000031068 ENSMUSG00000033610 
ENSMUSG00000028967 ENSMUSG00000031077 ENSMUSG00000033629 
ENSMUSG00000028969 ENSMUSG00000031078 ENSMUSG00000033658 
ENSMUSG00000028970 ENSMUSG00000031095 ENSMUSG00000033715 
ENSMUSG00000028971 ENSMUSG00000031119 ENSMUSG00000033730 
ENSMUSG00000028974 ENSMUSG00000031134 ENSMUSG00000033735 
ENSMUSG00000028976 ENSMUSG00000031149 ENSMUSG00000033770 
ENSMUSG00000028980 ENSMUSG00000031154 ENSMUSG00000033863 
ENSMUSG00000028982 ENSMUSG00000031157 ENSMUSG00000033880 
ENSMUSG00000028991 ENSMUSG00000031167 ENSMUSG00000033917 
ENSMUSG00000028998 ENSMUSG00000031168 ENSMUSG00000033940 
ENSMUSG00000029009 ENSMUSG00000031209 ENSMUSG00000033965 
ENSMUSG00000029019 ENSMUSG00000031229 ENSMUSG00000033985 
ENSMUSG00000029030 ENSMUSG00000031246 ENSMUSG00000034022 
ENSMUSG00000029050 ENSMUSG00000031250 ENSMUSG00000034024 
ENSMUSG00000029059 ENSMUSG00000031274 ENSMUSG00000034039 
ENSMUSG00000029064 ENSMUSG00000031297 ENSMUSG00000034120 
ENSMUSG00000029068 ENSMUSG00000031299 ENSMUSG00000034157 
ENSMUSG00000029084 ENSMUSG00000031311 ENSMUSG00000034161 
ENSMUSG00000029103 ENSMUSG00000031349 ENSMUSG00000034163 
ENSMUSG00000029106 ENSMUSG00000031357 ENSMUSG00000034220 
ENSMUSG00000029108 ENSMUSG00000031360 ENSMUSG00000034254 
ENSMUSG00000029110 ENSMUSG00000031370 ENSMUSG00000034265 
ENSMUSG00000029111 ENSMUSG00000031382 ENSMUSG00000034278 
ENSMUSG00000029131 ENSMUSG00000031386 ENSMUSG00000034285 
ENSMUSG00000029136 ENSMUSG00000031392 ENSMUSG00000034308 
ENSMUSG00000029145 ENSMUSG00000031399 ENSMUSG00000034311 
ENSMUSG00000029147 ENSMUSG00000031422 ENSMUSG00000034317 
ENSMUSG00000029167 ENSMUSG00000031425 ENSMUSG00000034349 
ENSMUSG00000029169 ENSMUSG00000031431 ENSMUSG00000034353 
ENSMUSG00000029173 ENSMUSG00000031438 ENSMUSG00000034435 
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ENSMUSG00000029176 ENSMUSG00000031441 ENSMUSG00000034438 
ENSMUSG00000029177 ENSMUSG00000031442 ENSMUSG00000034459 
ENSMUSG00000029178 ENSMUSG00000031446 ENSMUSG00000034484 
ENSMUSG00000029188 ENSMUSG00000031453 ENSMUSG00000034486 
ENSMUSG00000029191 ENSMUSG00000031458 ENSMUSG00000034528 
ENSMUSG00000029198 ENSMUSG00000031461 ENSMUSG00000034563 
ENSMUSG00000029217 ENSMUSG00000031482 ENSMUSG00000034566 
ENSMUSG00000029229 ENSMUSG00000031489 ENSMUSG00000034570 
ENSMUSG00000029231 ENSMUSG00000031490 ENSMUSG00000034579 
ENSMUSG00000029234 ENSMUSG00000031502 ENSMUSG00000034584 
ENSMUSG00000029238 ENSMUSG00000031520 ENSMUSG00000034614 
ENSMUSG00000029247 ENSMUSG00000031529 ENSMUSG00000034620 
ENSMUSG00000029249 ENSMUSG00000031536 ENSMUSG00000034647 
ENSMUSG00000029253 ENSMUSG00000031537 ENSMUSG00000034648 
ENSMUSG00000029267 ENSMUSG00000031538 ENSMUSG00000034659 
ENSMUSG00000029269 ENSMUSG00000031543 ENSMUSG00000034663 
ENSMUSG00000029270 ENSMUSG00000031553 ENSMUSG00000034667 
ENSMUSG00000029273 ENSMUSG00000031555 ENSMUSG00000034681 
ENSMUSG00000029275 ENSMUSG00000031561 ENSMUSG00000034707 
ENSMUSG00000029283 ENSMUSG00000031568 ENSMUSG00000034708 
ENSMUSG00000029287 ENSMUSG00000031578 ENSMUSG00000034724 
ENSMUSG00000029304 ENSMUSG00000031584 ENSMUSG00000034744 
ENSMUSG00000029314 ENSMUSG00000031586 ENSMUSG00000034785 
ENSMUSG00000029321 ENSMUSG00000031591 ENSMUSG00000034801 
ENSMUSG00000029328 ENSMUSG00000031596 ENSMUSG00000034868 
ENSMUSG00000029330 ENSMUSG00000031613 ENSMUSG00000034875 
ENSMUSG00000029359 ENSMUSG00000031628 ENSMUSG00000034880 
ENSMUSG00000029380 ENSMUSG00000031654 ENSMUSG00000034903 
ENSMUSG00000029385 ENSMUSG00000031660 ENSMUSG00000034906 
ENSMUSG00000029390 ENSMUSG00000031673 ENSMUSG00000034917 
ENSMUSG00000029405 ENSMUSG00000031696 ENSMUSG00000034928 
ENSMUSG00000029426 ENSMUSG00000031700 ENSMUSG00000034932 
ENSMUSG00000029430 ENSMUSG00000031701 ENSMUSG00000034936 
ENSMUSG00000029440 ENSMUSG00000031714 ENSMUSG00000034981 
ENSMUSG00000029452 ENSMUSG00000031725 ENSMUSG00000034993 
ENSMUSG00000029455 ENSMUSG00000031731 ENSMUSG00000034994 
ENSMUSG00000029467 ENSMUSG00000031734 ENSMUSG00000035000 
ENSMUSG00000029513 ENSMUSG00000031762 ENSMUSG00000035104 
ENSMUSG00000029538 ENSMUSG00000031765 ENSMUSG00000035105 
ENSMUSG00000029545 ENSMUSG00000031767 ENSMUSG00000035133 
ENSMUSG00000029550 ENSMUSG00000031770 ENSMUSG00000035150 
ENSMUSG00000029571 ENSMUSG00000031774 ENSMUSG00000035212 
ENSMUSG00000029575 ENSMUSG00000031778 ENSMUSG00000035237 
ENSMUSG00000029580 ENSMUSG00000031782 ENSMUSG00000035248 
ENSMUSG00000029581 ENSMUSG00000031790 ENSMUSG00000035268 
ENSMUSG00000029597 ENSMUSG00000031799 ENSMUSG00000035351 
ENSMUSG00000029608 ENSMUSG00000031808 ENSMUSG00000035372 
ENSMUSG00000029616 ENSMUSG00000031811 ENSMUSG00000035373 
ENSMUSG00000029617 ENSMUSG00000031819 ENSMUSG00000035376 
ENSMUSG00000029629 ENSMUSG00000031838 ENSMUSG00000035383 
ENSMUSG00000029630 ENSMUSG00000031840 ENSMUSG00000035385 
ENSMUSG00000029635 ENSMUSG00000031844 ENSMUSG00000035443 
ENSMUSG00000029650 ENSMUSG00000031851 ENSMUSG00000035451 
ENSMUSG00000029651 ENSMUSG00000031858 ENSMUSG00000035458 
ENSMUSG00000029656 ENSMUSG00000031880 ENSMUSG00000035469 
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ENSMUSG00000029657 ENSMUSG00000031884 ENSMUSG00000035473 
ENSMUSG00000029661 ENSMUSG00000031891 ENSMUSG00000035493 
ENSMUSG00000029664 ENSMUSG00000031921 ENSMUSG00000035505 
ENSMUSG00000029669 ENSMUSG00000031924 ENSMUSG00000035530 
ENSMUSG00000029710 ENSMUSG00000031930 ENSMUSG00000035547 
ENSMUSG00000029718 ENSMUSG00000031960 ENSMUSG00000035561 
ENSMUSG00000029720 ENSMUSG00000031967 ENSMUSG00000035585 
ENSMUSG00000029723 ENSMUSG00000031970 ENSMUSG00000035637 
ENSMUSG00000029727 ENSMUSG00000031980 ENSMUSG00000035649 
ENSMUSG00000029730 ENSMUSG00000031987 ENSMUSG00000035683 
ENSMUSG00000029763 ENSMUSG00000031996 ENSMUSG00000035686 
ENSMUSG00000029771 ENSMUSG00000031997 ENSMUSG00000035692 
ENSMUSG00000029772 ENSMUSG00000032000 ENSMUSG00000035769 
ENSMUSG00000029781 ENSMUSG00000032010 ENSMUSG00000035828 
ENSMUSG00000029802 ENSMUSG00000032018 ENSMUSG00000035878 
ENSMUSG00000029833 ENSMUSG00000032026 ENSMUSG00000035896 
ENSMUSG00000029836|ENSMU
SG00000059647 ENSMUSG00000032035 ENSMUSG00000035901 
ENSMUSG00000029840 ENSMUSG00000032038 ENSMUSG00000035992 
ENSMUSG00000029922 ENSMUSG00000032041 ENSMUSG00000036019 
ENSMUSG00000029999 ENSMUSG00000032047 ENSMUSG00000036053 
ENSMUSG00000030008 ENSMUSG00000032051 ENSMUSG00000036073 
ENSMUSG00000036292 ENSMUSG00000032060 ENSMUSG00000036078 
ENSMUSG00000036295 ENSMUSG00000032066 ENSMUSG00000036083 
ENSMUSG00000036309 ENSMUSG00000032067 ENSMUSG00000036110 
ENSMUSG00000036241 ENSMUSG00000032076 ENSMUSG00000036120 
ENSMUSG00000036199 ENSMUSG00000036144 ENSMUSG00000036123 
ENSMUSG00000036216 ENSMUSG00000036181 ENSMUSG00000039994 
ENSMUSG00000040006 ENSMUSG00000040562 ENSMUSG00000041020 
ENSMUSG00000040010 ENSMUSG00000040565 ENSMUSG00000041028 
ENSMUSG00000040093 ENSMUSG00000040584 ENSMUSG00000041058 
ENSMUSG00000040127 ENSMUSG00000040600 ENSMUSG00000041119 
ENSMUSG00000040158 ENSMUSG00000040652 ENSMUSG00000041132 
ENSMUSG00000040170 ENSMUSG00000040659 ENSMUSG00000041220 
ENSMUSG00000040181 ENSMUSG00000040660 ENSMUSG00000041261 
ENSMUSG00000040204 ENSMUSG00000040666 ENSMUSG00000041263 
ENSMUSG00000040213 ENSMUSG00000040694 ENSMUSG00000041333 
ENSMUSG00000040242 ENSMUSG00000040701 ENSMUSG00000041378 
ENSMUSG00000040249 ENSMUSG00000040706 ENSMUSG00000041390 
ENSMUSG00000040282 ENSMUSG00000040715 ENSMUSG00000041417 
ENSMUSG00000040325 ENSMUSG00000040746 ENSMUSG00000041426 
ENSMUSG00000040328 ENSMUSG00000040759 ENSMUSG00000041431 
ENSMUSG00000040413 ENSMUSG00000040843 ENSMUSG00000041459 
ENSMUSG00000040446 ENSMUSG00000040857 ENSMUSG00000041483 
ENSMUSG00000040447 ENSMUSG00000040891 ENSMUSG00000041488 
ENSMUSG00000040479 ENSMUSG00000040935 ENSMUSG00000041540 
ENSMUSG00000040505 ENSMUSG00000040940 ENSMUSG00000041559 
ENSMUSG00000040521 ENSMUSG00000040963 ENSMUSG00000041567 
ENSMUSG00000040548 ENSMUSG00000040997 ENSMUSG00000041571 
ENSMUSG00000040550 ENSMUSG00000040998 ENSMUSG00000041625 
ENSMUSG00000041733 ENSMUSG00000041773 ENSMUSG00000041638 
ENSMUSG00000041750 ENSMUSG00000041774 ENSMUSG00000041654 
ENSMUSG00000051113 ENSMUSG00000052837 ENSMUSG00000053931 
ENSMUSG00000051236 ENSMUSG00000052974 ENSMUSG00000053935 
ENSMUSG00000051314 ENSMUSG00000052997 ENSMUSG00000054072 
212 
 
ENSMUSG00000051391 ENSMUSG00000053044 ENSMUSG00000054128 
ENSMUSG00000051469 ENSMUSG00000053093 ENSMUSG00000054206 
ENSMUSG00000051483 ENSMUSG00000053113 ENSMUSG00000054280 
ENSMUSG00000051592 ENSMUSG00000053175 ENSMUSG00000054309 
ENSMUSG00000051671 ENSMUSG00000053205 ENSMUSG00000054364 
ENSMUSG00000051768 ENSMUSG00000053279 ENSMUSG00000054422 
ENSMUSG00000051802 ENSMUSG00000053289 ENSMUSG00000054435 
ENSMUSG00000051817 ENSMUSG00000053302 ENSMUSG00000054545 
ENSMUSG00000051864 ENSMUSG00000053303 ENSMUSG00000054619 
ENSMUSG00000051910 ENSMUSG00000053317 ENSMUSG00000054717 
ENSMUSG00000052040 ENSMUSG00000053329 ENSMUSG00000054757 
ENSMUSG00000052102 ENSMUSG00000053460 ENSMUSG00000054889 
ENSMUSG00000052117 ENSMUSG00000053477 ENSMUSG00000054942 
ENSMUSG00000052146 ENSMUSG00000053483 ENSMUSG00000055053 
ENSMUSG00000052151 ENSMUSG00000053510 ENSMUSG00000055065 
ENSMUSG00000052160 ENSMUSG00000053559 ENSMUSG00000055116 
ENSMUSG00000052293 ENSMUSG00000053581 ENSMUSG00000055128 
ENSMUSG00000052392 ENSMUSG00000053600 ENSMUSG00000055148 
ENSMUSG00000052516 ENSMUSG00000053644 ENSMUSG00000055172 
ENSMUSG00000052520 ENSMUSG00000053654 ENSMUSG00000055296 
ENSMUSG00000052566 ENSMUSG00000053768 ENSMUSG00000055301 
ENSMUSG00000052593 ENSMUSG00000053799 ENSMUSG00000055401 
ENSMUSG00000052684 ENSMUSG00000053819 ENSMUSG00000055436 
ENSMUSG00000052712 ENSMUSG00000053846 ENSMUSG00000055491 
ENSMUSG00000052751 ENSMUSG00000053862 ENSMUSG00000055531 
ENSMUSG00000052798 ENSMUSG00000053870 ENSMUSG00000055612 
ENSMUSG00000052819 ENSMUSG00000053898 ENSMUSG00000055675 
ENSMUSG00000052833 ENSMUSG00000053916 ENSMUSG00000055692 
ENSMUSG00000064023 ENSMUSG00000067847 ENSMUSG00000069919 
ENSMUSG00000064145 ENSMUSG00000067889 ENSMUSG00000069922 
ENSMUSG00000064215 ENSMUSG00000068086 ENSMUSG00000070436 
ENSMUSG00000064225 ENSMUSG00000068205 ENSMUSG00000070561 
ENSMUSG00000064254 ENSMUSG00000068220 ENSMUSG00000070702 
ENSMUSG00000064294 ENSMUSG00000068328 ENSMUSG00000070730 
ENSMUSG00000064326 ENSMUSG00000068329 ENSMUSG00000070953 
ENSMUSG00000066026 ENSMUSG00000068335 ENSMUSG00000071177 
ENSMUSG00000066036 ENSMUSG00000068391 ENSMUSG00000071369 
ENSMUSG00000066072 ENSMUSG00000068614 ENSMUSG00000071650 
ENSMUSG00000066149 ENSMUSG00000068742 ENSMUSG00000071655 
ENSMUSG00000066232 ENSMUSG00000068874 ENSMUSG00000071713 
ENSMUSG00000066324 ENSMUSG00000069020 ENSMUSG00000072082 
ENSMUSG00000066516 ENSMUSG00000069089 ENSMUSG00000072235 
ENSMUSG00000066637 ENSMUSG00000069456 ENSMUSG00000072620 
ENSMUSG00000066860 ENSMUSG00000069515 ENSMUSG00000072849 
ENSMUSG00000067279 ENSMUSG00000069601 ENSMUSG00000072949 
ENSMUSG00000067283 ENSMUSG00000069662 ENSMUSG00000073057 
ENSMUSG00000067338 ENSMUSG00000069668 ENSMUSG00000073126 
ENSMUSG00000067653 ENSMUSG00000069743 ENSMUSG00000073418 
ENSMUSG00000067713 ENSMUSG00000069899 ENSMUSG00000073421 
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ENSMUSG00000001056 ENSMUSG00000032041 
ENSMUSG00000001416 ENSMUSG00000032047 
ENSMUSG00000002910 ENSMUSG00000032109 
ENSMUSG00000002996 ENSMUSG00000032115 
ENSMUSG00000003032 ENSMUSG00000032187 
ENSMUSG00000003038 ENSMUSG00000032258 
ENSMUSG00000003206 ENSMUSG00000032440 
ENSMUSG00000003348 ENSMUSG00000032536 
ENSMUSG00000003545 ENSMUSG00000032932 
ENSMUSG00000003847 ENSMUSG00000033423 
ENSMUSG00000004948 ENSMUSG00000033624 
ENSMUSG00000005897 ENSMUSG00000033808 
ENSMUSG00000010045 ENSMUSG00000033909 
ENSMUSG00000010392 ENSMUSG00000034175 
ENSMUSG00000010755 ENSMUSG00000034189 
ENSMUSG00000014158 ENSMUSG00000034285 
ENSMUSG00000015202 ENSMUSG00000034551 
ENSMUSG00000015478 ENSMUSG00000034584 
ENSMUSG00000018160 ENSMUSG00000034593 
ENSMUSG00000018363 ENSMUSG00000034757 
ENSMUSG00000018736 ENSMUSG00000034839 
ENSMUSG00000018900 ENSMUSG00000035007 
ENSMUSG00000019792 ENSMUSG00000035021 
ENSMUSG00000019838 ENSMUSG00000035248 
ENSMUSG00000020018 ENSMUSG00000035262 
ENSMUSG00000020115 ENSMUSG00000035392 
ENSMUSG00000020260 ENSMUSG00000035671 
ENSMUSG00000020262 ENSMUSG00000035704 
ENSMUSG00000020431 ENSMUSG00000035900 
ENSMUSG00000020454 ENSMUSG00000036587 
ENSMUSG00000020515 ENSMUSG00000036781 
ENSMUSG00000020516 ENSMUSG00000036986 
ENSMUSG00000020532 ENSMUSG00000036989 
ENSMUSG00000020834 ENSMUSG00000037112 
ENSMUSG00000020923 ENSMUSG00000037465 
ENSMUSG00000021111 ENSMUSG00000037487 
ENSMUSG00000021175 ENSMUSG00000037513 
ENSMUSG00000021337 ENSMUSG00000037601 
ENSMUSG00000021453 ENSMUSG00000037773 
ENSMUSG00000021690 ENSMUSG00000037999 
ENSMUSG00000022037 ENSMUSG00000038147 
ENSMUSG00000022307 ENSMUSG00000038400 
ENSMUSG00000022313 ENSMUSG00000038564 
ENSMUSG00000022332 ENSMUSG00000038637 
ENSMUSG00000022339 ENSMUSG00000038641 
ENSMUSG00000022415 ENSMUSG00000038685 
ENSMUSG00000022540 ENSMUSG00000039067 
ENSMUSG00000022568 ENSMUSG00000039219 
ENSMUSG00000022721 ENSMUSG00000039476 
ENSMUSG00000022822 ENSMUSG00000039976 
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ENSMUSG00000022898 ENSMUSG00000040383 
ENSMUSG00000022957 ENSMUSG00000040429 
ENSMUSG00000023075 ENSMUSG00000040618 
ENSMUSG00000023236 ENSMUSG00000040747 
ENSMUSG00000023832 ENSMUSG00000041058 
ENSMUSG00000024039 ENSMUSG00000041632 
ENSMUSG00000024222 ENSMUSG00000041649 
ENSMUSG00000024327 ENSMUSG00000041650 
ENSMUSG00000024366 ENSMUSG00000042035 
ENSMUSG00000024487 ENSMUSG00000042328 
ENSMUSG00000024682 ENSMUSG00000042406 
ENSMUSG00000024713 ENSMUSG00000042590 
ENSMUSG00000024922 ENSMUSG00000042694 
ENSMUSG00000024941 ENSMUSG00000042784 
ENSMUSG00000025035 ENSMUSG00000042997 
ENSMUSG00000025049 ENSMUSG00000043430 
ENSMUSG00000025129 ENSMUSG00000043753 
ENSMUSG00000025162 ENSMUSG00000045095 
ENSMUSG00000025245 ENSMUSG00000045160 
ENSMUSG00000025324 ENSMUSG00000045316 
ENSMUSG00000025395 ENSMUSG00000045691 
ENSMUSG00000025579 ENSMUSG00000045954 
ENSMUSG00000025958 ENSMUSG00000046020 
ENSMUSG00000025969 ENSMUSG00000046314 
ENSMUSG00000026166 ENSMUSG00000046814 
ENSMUSG00000026260 ENSMUSG00000046822 
ENSMUSG00000026399 ENSMUSG00000047205 
ENSMUSG00000026730 ENSMUSG00000047562 
ENSMUSG00000026810 ENSMUSG00000047712 
ENSMUSG00000027120 ENSMUSG00000047757 
ENSMUSG00000027176 ENSMUSG00000048373 
ENSMUSG00000027353 ENSMUSG00000048826 
ENSMUSG00000027803 ENSMUSG00000048970 
ENSMUSG00000028016 ENSMUSG00000050213 
ENSMUSG00000028099 ENSMUSG00000050217 
ENSMUSG00000028238 ENSMUSG00000050288 
ENSMUSG00000028252 ENSMUSG00000050786 
ENSMUSG00000028277 ENSMUSG00000050796 
ENSMUSG00000028298 ENSMUSG00000051786 
ENSMUSG00000028454 ENSMUSG00000053279 
ENSMUSG00000028525 ENSMUSG00000053334 
ENSMUSG00000028532 ENSMUSG00000054065 
ENSMUSG00000028633 ENSMUSG00000054083 
ENSMUSG00000028687 ENSMUSG00000054871 
ENSMUSG00000028756 ENSMUSG00000055125 
ENSMUSG00000028776 ENSMUSG00000055491 
ENSMUSG00000028822 ENSMUSG00000055629 
ENSMUSG00000028967 ENSMUSG00000056130 
ENSMUSG00000029068 ENSMUSG00000058586 
ENSMUSG00000029369 ENSMUSG00000060445 
ENSMUSG00000029477 ENSMUSG00000060726 
ENSMUSG00000029478 ENSMUSG00000060962 
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ENSMUSG00000029504 ENSMUSG00000061244 
ENSMUSG00000029670 ENSMUSG00000061482 
ENSMUSG00000029998 ENSMUSG00000061887 
ENSMUSG00000030007 ENSMUSG00000063229 
ENSMUSG00000030079 ENSMUSG00000063268 
ENSMUSG00000030218 ENSMUSG00000063785 
ENSMUSG00000030309 ENSMUSG00000066026 
ENSMUSG00000030337 ENSMUSG00000066148 
ENSMUSG00000030598 ENSMUSG00000066800 
ENSMUSG00000030726 ENSMUSG00000071757 
ENSMUSG00000030772 ENSMUSG00000071847 
ENSMUSG00000030935 ENSMUSG00000072082 
ENSMUSG00000031107 ENSMUSG00000072964 
ENSMUSG00000031197 ENSMUSG00000074909 
ENSMUSG00000031216 ENSMUSG00000021469 
ENSMUSG00000031217 ENSMUSG00000022892 
ENSMUSG00000031298 ENSMUSG00000026295 
ENSMUSG00000031309 ENSMUSG00000026463 
ENSMUSG00000031433 ENSMUSG00000028811 
ENSMUSG00000031633 ENSMUSG00000029859 
ENSMUSG00000031950 ENSMUSG00000031438 
ENSMUSG00000042961 ENSMUSG00000035158 
ENSMUSG00000056531 ENSMUSG00000039813 
ENSMUSG00000062184 ENSMUSG00000042677 
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II.   genes converted into ensemble identifier in MCF-7 cells 
 
ENSMUSG00000000378 ENSMUSG00000038633 
ENSMUSG00000001417 ENSMUSG00000038702 
ENSMUSG00000003379 ENSMUSG00000038736 
ENSMUSG00000004069 ENSMUSG00000039086 
ENSMUSG00000004328 ENSMUSG00000039114 
ENSMUSG00000004626 ENSMUSG00000039347 
ENSMUSG00000006850 ENSMUSG00000039396 
ENSMUSG00000007646 ENSMUSG00000039501 
ENSMUSG00000014602 ENSMUSG00000040681 
ENSMUSG00000017831 ENSMUSG00000040701 
ENSMUSG00000018882 ENSMUSG00000040855 
ENSMUSG00000019831 ENSMUSG00000041731 
ENSMUSG00000019889 ENSMUSG00000041890 
ENSMUSG00000020241 ENSMUSG00000041995 
ENSMUSG00000020534 ENSMUSG00000042229 
ENSMUSG00000021203 ENSMUSG00000042305 
ENSMUSG00000021235 ENSMUSG00000045294 
ENSMUSG00000021286 ENSMUSG00000047719 
ENSMUSG00000021519 ENSMUSG00000047875 
ENSMUSG00000021597 ENSMUSG00000048647 
ENSMUSG00000021948 ENSMUSG00000049470 
ENSMUSG00000021953 ENSMUSG00000049536 
ENSMUSG00000022015 ENSMUSG00000049960 
ENSMUSG00000022464 ENSMUSG00000050640 
ENSMUSG00000022545 ENSMUSG00000051367 
ENSMUSG00000022564 ENSMUSG00000053916 
ENSMUSG00000022607 ENSMUSG00000054000 
ENSMUSG00000022797 ENSMUSG00000055053 
ENSMUSG00000022887 ENSMUSG00000055078 
ENSMUSG00000022962 ENSMUSG00000056529 
ENSMUSG00000023972 ENSMUSG00000056917 
ENSMUSG00000024112 ENSMUSG00000057406 
ENSMUSG00000024145 ENSMUSG00000058420 
ENSMUSG00000024187 ENSMUSG00000059208 
ENSMUSG00000024614 ENSMUSG00000060126 
ENSMUSG00000024831 ENSMUSG00000061080 
ENSMUSG00000024901 ENSMUSG00000062867 
ENSMUSG00000024993 ENSMUSG00000063972 
ENSMUSG00000025047 ENSMUSG00000064289 
ENSMUSG00000025723 ENSMUSG00000066152 
ENSMUSG00000026174 ENSMUSG00000070034 
ENSMUSG00000026196 ENSMUSG00000021469 
ENSMUSG00000026203 ENSMUSG00000022892 
ENSMUSG00000026394 ENSMUSG00000026295 
ENSMUSG00000026694 ENSMUSG00000026463 
ENSMUSG00000026873 ENSMUSG00000028811 
ENSMUSG00000026934 ENSMUSG00000029859 
ENSMUSG00000027261 ENSMUSG00000031438 
ENSMUSG00000027333 ENSMUSG00000035158 
ENSMUSG00000027852 ENSMUSG00000039813 
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ENSMUSG00000028037 ENSMUSG00000042677 
ENSMUSG00000028039 ENSMUSG00000042961 
ENSMUSG00000028149 ENSMUSG00000056531 
ENSMUSG00000028309 ENSMUSG00000062184 
ENSMUSG00000028332 ENSMUSG00000032724 
ENSMUSG00000028443 ENSMUSG00000032815 
ENSMUSG00000028487 ENSMUSG00000033088 
ENSMUSG00000028847 ENSMUSG00000033377 
ENSMUSG00000029064 ENSMUSG00000033405 
ENSMUSG00000029198 ENSMUSG00000033623 
ENSMUSG00000029310 ENSMUSG00000033813 
ENSMUSG00000029428 ENSMUSG00000034192 
ENSMUSG00000029554 ENSMUSG00000034308 
ENSMUSG00000029822 ENSMUSG00000034675 
ENSMUSG00000029851 ENSMUSG00000034708 
ENSMUSG00000030046 ENSMUSG00000034783 
ENSMUSG00000030452 ENSMUSG00000034998 
ENSMUSG00000030509 ENSMUSG00000035890 
ENSMUSG00000030742 ENSMUSG00000036315 
ENSMUSG00000030824 ENSMUSG00000037185 
ENSMUSG00000031384 ENSMUSG00000038145 
ENSMUSG00000031527 ENSMUSG00000038582 
ENSMUSG00000032194 ENSMUSG00000032459 
ENSMUSG00000032202 ENSMUSG00000032525 
ENSMUSG00000032254 ENSMUSG00000032567 
ENSMUSG00000032329 ENSMUSG00000032690 
 
